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Four aryl- and ferrocenyl-derived thiosemicarbazone ligands have been synthesized and 
characterized using NMR, infrared (IR) spectroscopy and mass spectrometry. These ligands 
were used towards the synthesis of three series of mono- and multinuclear complexes, in 
which the thiosemicarbazone ligands chelate in either a bidentate (N,S) or tridentate (C,N,S) 
mode.     
 
The first series focuses on aryl-derived cyclopalladated thiosemicarbazone complexes. Two 
[C,N,S] tetranuclear complexes were prepared by reacting the thiosemicarbazone ligands with 
K2[PdCl4]/Na2[PdCl4], and were used in subsequent reactions with P- and N-donor ligands. 
Three mononuclear complexes containing P-donor ligands, and one mononuclear and two 
binuclear complexes containing N-donor ligands were synthesized. These complexes were 
characterized using NMR and IR spectroscopies, and mass spectrometry. The complexes 
containing the P-donor ligands were synthesized more readily than those containing the N-
donor ligands, where reactions occurred more sluggishly and required harsher conditions. 
Further to their spectroscopic and analytical characterization,  molecular structures of two 
mononuclear cyclopalladated complexes, containing P-donor ligands, have been solved using 
single-crystal X-ray diffraction, and the palladium atoms were found to have slightly distorted 
square-planar geometries.     
 
A second series based on N,S-chelated ferrocenylthiosemicarbazone ruthenium(II) complexes 
was also synthesized. Three ruthenium(II)-arene dimers (Ar = p-
i
PrC6H4CH3, 
C6H5O(CH2)2OH, C6H6) were reacted with ferrocenyl-derived thiosemicarbazones to prepare 
three binuclear and two tetranuclear ruthenium(II)-arene complexes. These complexes were 
characterized using NMR and IR spectroscopies, and mass spectrometry.   
 
The third series centres around the synthesis of ferrocenyl-derived [N,S] palladium(II) 
complexes. This series proceeds via a binuclear chloro-bridged complex, prepared by reacting 
the monomeric ferrocenyl-derived thiosemicarbazone with K2[PdCl4]. Subsequent reactions 
were carried out using the binuclear chloro-bridged complex to prepare heterobimetallic 
complexes containing P-donor ligands. Two binuclear complexes, two tetranuclear complexes 
and one pentanuclear complex were synthesized and characterized using NMR and IR 












containing the water-soluble P-donor ligand 1,3,5-triaza-7-phosphaadamantane, was solved 
using single-crystal X-ray diffraction.  
 
Selected ligands and metal complexes were evaluated for antiplasmodial activity against 
Plasmodium falciparum. The ligands and complexes exhibited moderate inhibitory effects. In 
certain cases, an enhancement of activity was observed for the complexes relative to that of 
the free ligand. 
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The role of thiosemicarbazones and its metal complexes as biological agents. 
 
1. Introduction   
Malaria is one of the leading parasitic diseases in the world, and the second major infectious 
disease in Africa. It is estimated that in 2010, there were 216 million clinical cases, which led 
to nearly 655 000 deaths.
1
 The disease affects mainly the tropical and subtropical regions, 
where Africa is the most affected with 81% of the cases, as illustrated in Fig. 1.1. 
 
There are five species affecting humans, namely Plasmodium falciparum, P. vivax, P. 
malariae, P. ovale and P. knowlesi. However, P. knowlesi has only recently been affecting 
humans, as it is originally an ape strain. P. falciparum is the most prevalent and deadly 
species.
2








1.1. Defence mechanism of the malaria parasite 
After infection, the red blood cell cytoplasm is ingested and transported to the digestive 
vacuole of the parasite (Fig. 1.2.a.). The haemoglobin is digested by cysteine proteases 



















 to generate short peptides (Fig. 1.2.c.). After being transported out of the digestive 
vacuole (Fig. 1.2.d.), the peptides are converted to amino acids.
8
 Upon the degradation of 
haemoglobin (Fig. 1.2.d.), free haem (Fe(III)PPIX) is released. The iron in the haem is then 
oxidised, from Fe(II) to Fe(III), by molecular dioxygen to produce reactive oxygen species, 
namely hydroxyl radicals (Fig. 1.2.f.). The hydroxyl radicals produced are known to be 
disruptive to lipid membranes; leading to the death of the parasites.
9
 However, the parasite 
does have a defence mechanism to protect itself against the cytotoxicity of α-haematin. In an 
aqueous environment, haem dimerizes (Fig. 1.2.g.) and is transported to a lipid body (Fig. 





RBC - red blood cell 
C - cytosome  
Pf - parasite 
TV - transport vesicle 
DV - digestive vacuole 
Hb - haemoglobin  
LB - lipid body 
 




Alpha-haematin dimers, linked via hydrogen bonds between the iron in the haem and the 
propionic acid side chain of the adjacent haem, are able to form chains. The chains, which 
exist due to the hydrogen bonded propionic acid side chains, form low solubility haemozoin 




Therefore, a number of antimalarial drug candidates are designed with the intent of either 
inhibiting the above mentioned proteases or preventing the conversion of α-haematin to 
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1.2. Drugs administered for the treatment of malaria 
1.2.1. The use of quinoline-based compounds as antimalarial agents 
Antimalarial drugs synthesized with a quinoline base became a popular choice with the 
success of quinine, I (Fig. 1.3). Quinine has a variety of medical uses, including anti-
inflammatory effects, and it was the first effective antimalarial treatment. The use of quinine 
as an antimalarial treatment originated in the 17
th




















Chloroquine, II (Fig. 1.3), was one of the most widely used antimalarial drugs, due to its low 
cost. Studies have shown that the mode of action of chloroquine involves binding to the α-
haematin through π - π complexation in an attempt to inhibit the parasites’ defence 
mechanism by slowing the rate of conversion to haemozoin.
12
 An accumulation of α-





With the development of resistance to chloroquine, drugs such as mefloquine (III) and 
piperaquine (IV, Fig. 1.4) were developed for areas affected by chloroquine-resistant strains.  
The mode of action of mefloquine is not known but it is believed to play a role in the 
transport of the parasites’ nutrient source to the food vacuole.
13
 When piperaquine is used in 
conjunction with chloroquine, it is believed that the bulky structure of piperaquine may act by 
preventing an efflux of chloroquine out of the digestive vacuole, by blocking the membrane 
transporters. However, the drugs started losing effectiveness as the parasite developed 
resistance.
14-17 










































This has led to the synthesis of compounds such as trioxaquine (PA1103/SAR116242), V 
(Fig. 1.4) by Cosledan et al., which has a dual mode of action.
18
 The compound contains a 
1,2,4-trioxane motif, along with the attached cyclohexyl ring, is required for haem 
alkylation.
18
 The 7-chloro-4-aminoquinoline base allows for haem stacking, which prevents 
haemozoin formation while the stability of the compound is enhanced by the linker 
cyclohexyl ring. Trioxaquine exhibited the best activity against D6 (CQS) and FcM29 (CQR) 
malaria strains in vitro with IC50 values of 7 nM and 10 nM respectively.
18
 In vivo studies 
carried out on mice infected with rodent strains P. vinckei petteri (CQS strain) and P. vinckei 
vinckei (CQR strain) demonstrated that the antimalarial activity was similar. Therefore, due 
to the high antimalarial activity of compound V, as well as the low toxicity of the compound, 
trioxaquine was entered into clinical trials.
18
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1.2.2. The use of artemisinin-derivatives, antifolates and cysteine protease inhibitors as 
antimalarial agents  
There have been successful antimalarial drugs which do not contain a quinoline base. 
Artemisinin, VI, (Fig. 1.5) is an antimalarial drug used against chloroquine-resistant strains 
of P. falciparum. The drug has a 1,2,4-trioxane core that contains a peroxide bond whose 










            VI 




Artemisinin exhibits antimalarial activity against chloroquine-sensitive (D10) and 
chloroquine-resistant K1 strains, with IC50 values 0.013 µM and 0.011 µM respectively. 
These IC50 values are lower than those observed for chloroquine at 0.03 µM and 0.66 µM for 
D10 and K1 respectively.
20
 However, in an attempt to slow down the emergence of resistance 
artemisinin-based combination therapies (ACTs) were developed. 
 
ACTs, in which two antimalarial drugs are used in combination to overcome drug resistance, 
are being used worldwide to combat resistant strains. One such combination is marketed as 
Coartem
TM
, artemether/lumefantrine (Fig. 1.6), where artemisinin derivatives are fast acting 
drugs with a short half-life (artemether (VII), t1/2 = ~ 4hr), which kills off parasitaemia very 
quickly.
21
 These fast acting drugs are used in combination with a drug which has a longer 
half-life. Lumefantrine (VIII), has a half-life of approximately 4.5 days, and thus remains in 
the body long after artemether, to remove any remaining parasites.
22-23
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Another target for antimalarial agents is the folic acid cycle. The folic acid cycle involves the 
transfer of one-carbon units during the synthesis of DNA components such as amino acids, 
nucleotides and other biomolecules. Therefore antifolates inhibit enzymes, such as 
dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), which are involved 




Proguanil, IX (Fig. 1.7) an antifolate discovered in 1945, functions as a prodrug (i.e. a drug 
administered in its inactive form which activates upon metabolism) with its active form being 
chlorcycloguanil (X). Chlorcycloguanil, an inhibitor of DHFR, attracted attention after 
exhibiting better activity against avian malaria than quinine.
25-26
 Due to the activity exhibited 
by chlorcycloguanil, prodrug derivatives such as chlorproguanil (XI), clociguanil (XII) and 
the dihydrotriazine BRL 6231 (XIII), were synthesized. An increase in activity has been 
observed upon chlorination of the aryl group or an increase in the length of the linker chain.
27
    
 
However, the most widely used antimalarial antifolate would be pyrimethamine (XIV), 
which is used in combination with sulfadoxine (XV).
28
 Pyrimethamine, inhibits DHFR 
whereas sulfadoxine inhibits DHPS. However, as mutations in DHFR and DHPS genes 












































































Figure 1.7: The antimalarial compounds proguanil (IX), chlorcycloguanil (X), chlorproguanil (XI), clociguanil 




As previously mentioned, cysteine proteases play a role in the degradation of haemoglobin.
31
 
Inhibition of these proteases has also been a target of interest.
31
 Peptide structures such as 
fluoromethyl ketones (XVI) and vinyl sulfones (XVII), as well as nonpeptide structures such 
as isoquinolines (XVIII) and chalcones (XVIX) have been tested as protease inhibitors (Fig. 
1.8).
31-35
 The fluoromethyl ketone, Z-Phe-Arg-CH2F, and the vinyl sulfone, Mu-Phe-
homoPhe-VSPh, exhibited good activity when tested against the cysteine protease FP-2. The 
fluoromethyl ketone exhibited activity with values of IC50 values of 0.36 nM and 64 nM 
against FP-2 and cultured malaria parasites respectively.
32
 The vinyl sulfone was active 
against the P. falciparum and vinckei FP-2 cysteine proteases with IC50 values of 0.08 μM 

























































Figure 1.8: Cysteine protease inhibitors fluoromethyl ketone (XVI, Z-Phe-Arg-CH2F); isoquinolines (XVII); 




Biological agents containing particular moieties such as quinoline or trioxane still exhibit 
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1.3. Thiosemicarbazones  





Thiosemicarbazones are Schiff base compounds, which are formed by the condensation 
reaction occurring between a carbonyl and an amine group. Therefore, the thiosemicarbazone 









R1, R2, R3, R4 = H, alkyl, aryl or heteroaromatic group 
Figure 1.9: The general structure of a thiosemicarbazone compound 
 
Thiosemicarbazone systems contain donor atoms such as nitrogen, sulfur and oxygen which 
allow for chelation to various metals depending on the softness [Pd(II), Pt(II)] or hardness 













 have been displayed by thiosemicarbazones. In most cases, it is believed 
that these compounds act through the entrapment of metal ions essential for cell function, or 




1.3.1. The application of thiosemicarbazones as biological agents 
There has been significant interest in the use of thiosemicarbazones as antimalarial drug 
candidates, and thus various research projects have been pursued.
52-54
 In a study by 
Greenbaum et al., a series of thiosemicarbazone derivatives, which contained aromatic rings 
onto which various substituents were incorporated, were tested against the W2 (CQR) 
strain.
52
 The compounds which were prepared by reacting 2-acetylpyridine or 2,6-
diacetylpyridine with a thiosemicarbazide, with either a NH2 or SMe group attached to the 
thione carbon, were most active. Compound XX (Fig. 1.10) is one of the compounds which 



































In a separate study by de Oliveira et al., thiosemicarbazones were synthesized using naturally 
occurring aldehydes and ketones.
53
 Compound XXI (Fig. 1.10), which was synthesized from 
6,6-dimethylnorpin-2-ene-2-carboxaldehyde, exhibited the lowest IC50 value (7.2 μM) 




Phenolic Mannich bases of benzaldehyde and thiosemicarbazone derivatives were 
synthesized by Chipeleme et al. as a potential inhibitors of the cysteine protease falcipain-2, 
and tested against a chloroquine-resistant strain of P. falciparum.
54
 Of the thiosemicarbazone-
containing Mannich base compounds, compound XXII (Fig. 1.11) showed the best overall 
inhibition of falcipain-2 (IC50 value = 2.25 µM) and antiplasmodial activity against W2 (IC50 
value = 3.75 µM).
54
 The presence of the quinoline suggests that the activity is related to 
haem-binding, and the ability of the compound to chelate to iron in the cell.
54
   
 
Chiyanzu et al. have also investigated potential cysteine protease inhibitors in the form of 
thiosemicarbazone derivative of isatins.
56
 The compounds were evaluated against three 
parasitic cysteine proteases cruzain, falcipain-2 and rhodesain. The thiosemicarbazone 
containing compound XXIII (Fig. 1.11) exhibited good activity (IC50 = 10.5, 9.4 and 3 μM 
respectively) against all three proteases.
56











































Figure 1.11: Thiosemicarbazone-containing compounds which exhibits inhibitory activity against the cysteine 




The first reported success of thiosemicarbazones having antitumour activity dates back to 
1956 with the synthesis of pyridine-2-carboxaldehyde thiosemicarbazone, XXIV (Fig. 1.12), 
by Brockman et al.
47
 This compound was tested in vivo on mice infected with L1210 
leukaemia, where it exhibited anti-leukemic properties, by means of prolonging the lifespan 
of the mice.
47
   
 
Due to the activity observed for pyridine-2-carboxaldehyde thiosemicarbazone, various α-N-
heterocyclic thiosemicarbazone derivatives with a N,N,S-chelating nature (XXV and XXVI) 
were synthesized and studied (Fig. 1.12). These compounds were shown to be active 
antineoplastic agents.
48,55,58-59
    
 
Triapine, XXVII (Fig. 1.12), is one of the α-N-heterocyclic thiosemicarbazone derivatives 
which exhibited the most potent activity, and is currently undergoing phase II clinical 
trials.
60-62
 Triapine exhibited activity against hydroxyurea-resistant leukaemia cell, human 
KB nasopharyngeal carcinoma, murine M109 lung carcinoma and human A2780 ovarian 















































Figure 1.12: The α-N-heterocyclic thiosemicarbazone derivatives pyridine-2-carboxaldehyde thiosemicarbazone 
(XXIV), 5-hydroxypyridine-2-carboxaldehyde thiosemicarbazone (XXV), isoquinoline-1-carboxaldehyde 
thiosemicarbazone (XXVI) and Triapine (XXVII).
47,58-60
   
 
Various studies into the mode of action of these α-N-heterocyclic thiosemicarbazones 
revealed that ribonucleotide reductase (RNR) was the target of these compounds.
64-65
 The 
iron required to maintain the tyrosyl radical of the RNR as well as intracellular iron is 




1.4. The application of metals in the medical field    
Throughout history, metals have been recognized for their medicinal properties. However, the 
role of metals as medicinal agents became more prominent as researchers began to 
understand how biological systems worked, and how metals fit into these systems. A variety 
of gold salts, such as [KAu(CN)2] (tuberculosis)
68
 and gold phosphine (rheumatoid 
arthritis),
69
 antimony compounds (leishmaniasis)
21
 and lanthanum carbonate (end stage renal 
disease)
21
 have been used in the medical field.  
 
Interest in transition metal complexes as biological agents began with the use of cisplatin 
[cis-diamminedichloridoplatinum(II)], XXVIII (Fig. 1.13). Cisplatin, is a drug whose anti-
cancer activity was only discovered in 1969 by Rosenberg, despite initially being synthesized 
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1.4.1. The use of transition metal complexes as antimalarial agents 
The use of metal complexes as antimalarial agents has become prevalent in research. A trend 
is observed whereby upon complexation, an enhancement of activity is generally observed.
72-
74
 A large number of research projects attempt to use known antimalarial drugs, which are 
losing their effectiveness, and complex them with various metals to determine if there is an 
enhancement of activity.
75-78
 Therefore, complexation of chloroquine has been of significant 
interest in various research projects, where the metal coordinates to either the quinoline 
nitrogen or the amine nitrogen.  
 
One of the first organometallic complex evaluated as an antimalarial agent was 
RhCl(COD)CQ (XXIX) which was synthesized by Sánchez-Delgado et al. (Fig. 1.14).
79, 80
 In 
addition to the rhodium complex, a binuclear ruthenium(II)-chloroquine complex (XXXI) 
was also synthesized by Sánchez-Delgado and co-workers (Fig 1.14).
79
 In the case of the 
rhodium complex, the chloroquine binds to the metal via the quinoline nitrogen, whilst in 
XXXI, the ruthenium is coordinated to both chloroquines, through the quinoline N of one 




Compounds XXIX and XXXI exhibited in vitro and in vivo activity against the rodent strain 
P. berghei. However, compound XXXI exhibited better activity than XXIX, as well as 
chloroquine diphosphate, with IC50 = 18 ± 7 nM (in vitro) and a 94 % reduction of 
parasitaemia (in vivo). Therefore, XXXI was also evaluated against two chloroquine-resistant 
strains FcB1 and FcB2 (IC50 = 10.5 ± 6.5 and 46.5 ± 9.0 nM respectively).79 The structure 
and basicity of the complex, as well as the presence of the Ru(II), contributed to the enhanced 
activity of the complex.
79















































Figure 1.14: The mononuclear rhodium complex RhCl(COD)CQ (XXIX), the mononuclear ruthenium complex 
[Ru(η
6




Due to the low toxicity exhibited by ruthenium complexes, further research has gone into the 
synthesis of ruthenium-chloroquine complexes.
81,82
 The arene ring is present in order to 
stabilize the metal, as well as possibly altering the lipophilicity of chloroquine, thus retaining 
the complex within the active site. The ruthenium(II)-complexes were tested in vitro, and 
showed significant activity against the resistant strains, with compound XXX (Fig. 1.14) 
showing the highest activity.
81
 Compound XXX exhibited IC50 values (234 nM for Dd2) 




In a study conducted by Ajibade et al., the Mn(II), Co(II), Pt(II) and Cu(II) ions were 
coordinated to pyridyl derivatives, such as chloroquine, to yield various complexes.
75
 
Platinum was complexed to chloroquine, compound XXXII (Fig. 1.15), in an attempt to use 
chloroquine as an antimalarial agent against the K1 (CQR) strain.
75
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complexes synthesized showed cytotoxic activity against the chloroquine-resistant strain, 
where the Mn(II) and Pt(II) complexes showed the most enhanced activity with IC50 values 
1.13 and 0.16 μM respectively.
75 
   
 
Due to the medicinal purposes of gold, Au(III)-chloroquine complexes were synthesized by 
Navarro et al. and their antiplasmodial activity was evaluated (Fig. 1.15).
76
 With the 
coordination of Au(III) to chloroquine, there is a change in the electronic properties of the 7-
chloro-4-aminoquinoline base. The complex [Au(PPh3)(CQ)]PF6, XXXIII, showed good 
activity against P. falciparum chloroquine-resistant strains FcB1 and FcB2, with IC50 values 
of 5 nM and 23 nM respectively,
76
 which was significantly lower than CQDP (47 ± 2.3 nM 
for FcB1
79
 and 104.5 ± 9.2 nM for FcB2
79






























Due to the activity displayed by compound XXXIII, various derivatives of these Au(III)-
chloroquine complexes were synthesized. [Au(PEt3)(CQ)]PF6 showed the highest activity 
against the chloroquine-resistant strain FcB1 with an IC50 value of 10 nM when compared to 




Ferroquine, XXXIV (Fig. 1.16), an aminoquinoline derivative with a ferrocenyl moiety 
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than chloroquine, but has also displayed activity against chloroquine-resistant strains.
84
  
Ferroquine and its derivatives are currently in clinical trials.
9


















Trioxaferroquine, which contain a 1,2,4-trioxane motif, a ferrocenyl moiety and 7-chloro-4-
aminoquinoline, were synthesized by Bellot et al.
37
 The trioxaferroquines and 
trioxaferrocenes, compounds which lack the 7-chloro-4-aminoquinoline, were tested against 
the chloroquine-resistant P. falciparum strains FcB1 and FcM29.
37
 All the trioxaferroquines 
displayed activity similar to that of artemisinin and ferroquine, whilst they were more active 
than chloroquine. The activity of the trioxaferroquines was significantly higher than the 
trioxaferrocenes, which suggests that in this instance the quinoline is required for activity. 
Compound XXXV (Fig. 1.16), showed the highest activity with IC50 values 20 nM and 17 
nM against the strains FcB1 and FcM29 respectively.
37
    
 
Research into transition metal complexes as antimalarial agents is scarce. However, aside 
from quinoline-based complexes, the search for thiosemicarbazone complexes as antimalarial 




1.5. Transition metal complexes prepared from thiosemicarbazones  
1.5.1. Complexation of thiosemicarbazone ligands 
The interest in thiosemicarbazone complexes originates from the enhanced activity exhibited 
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With the discovery of cisplatin and its activity, research into platinum(II)-based complexes 
became a regular occurrence. However, as toxicity problems became associated with 
platinum(II)-based complexes, research was directed at the use of other metals.
86
 Platinum 
and palladium ions resemble each other in a given oxidation state, and thus palladium 
complexes were synthesized to determine if they were biologically active. Palladium can 
exist in the oxidation states Pd(0), Pd(II) and Pd(IV). However, the Pd(II) state is more stable 




Ruthenium is able to access the oxidation state Ru(II), Ru(III) and Ru(IV) under 
physiological conditions. Ruthenium(II) complexes are generally more biologically active 
and lower in toxicity due to their ability to mimic iron. Iron(II) is able to bind to biological 
molecules and be excreted. Thus, ruthenium is able to reduce its concentration in the body in 
a similar manner as Fe(II), and is less toxic.
88
 Ruthenium(II) ions can also be oxidised in a 
similar manner to Fe(II), allowing for electron transfer, and generation of reactive oxygen 
species.     
 
Coordination modes 
Thiosemicarbazones act as ligands by chelating to an electron-deficient metal. They can act 
as either bidentate
85,89
 or tridentate ligands (Fig. 1.17).
38-40
 Bidentate ligands chelate to a 
metal in a [N,S] fashion,
85,89























Figure 1.17: Illustration of a) monodentate, b) bidentate and c) tridentate chelation. 
 













 to name a few, have been synthesized.  
 
Cyclopalladation 
Bidentate ligands can form a single palladacycle whilst the tridentate C,N,S-chelating ligand 
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may involve two 5-membered rings
38-40
 (Fig. 1.18) or it may involve a 5- and 6-membered 
ring.
95
    
 
The palladacycle forms when the tridentate ligand chelates via the imine nitrogen, the thiolate 
sulfur and the carbon of the aryl or alkyl group, to the metal (Fig. 1.18). Palladium(II) ions 
are soft metals, and thus react easily with soft bases such as the imine nitrogen and the thione 
sulfur, in the ligand. Palladium(II) ions have a d
8
 configuration, and thus a square planar 
geometry is expected.
96
 The idea of a square planar geometry around the Pd(II) centre is 
supported by the rigid structure of the palladacycles. It is believed that for the C,N,S-
chelating ligand, the complex is stabilized due to the aromatic nature of the palladacycles 
(C=N, C=C and the filled d-orbitals of Pd).
97
  












R1 =  aryl or alkyl group 
R2 = alkyl group 
Figure 1.18: The general structure of palladacycles.    
 
The chelation of the aryl group to the metal to form palladacycles occurs via various 
mechanisms including oxidative addition, transmetallation, alkoxy- and carbopalladation of 
alkenes, halopalladation of alkynes and C-H bond activation.
98
 C-H bond activation occurs 
when a C-H bond is cleaved through electrophilic attack of Pd(II) ion to form a Pd-C bond 
between the palladium ion and the ortho-carbon on the aryl group. The palladium source is 
usually found in the form of salts such as palladium(II) chloride with a base, palladium(II) 




1.5.2. The use of thiosemicarbazone-based complexes as antimalarial agents    
Some of the first thiosemicarbazone complexes evaluated as antimalarials were synthesized 
in the 1980’s. Scovill and co-workers prepared Cu(II), Ni(II), Fe(II) and Mn(II) complexes 
with 2-acetylpyridine thio- and selenosemicarbazones.
100
 The Cu(II), Ni(II) and Fe(II) 
complexes prepared using 2-acetylpyridine thiosemicarbazone ligands were evaluated in vivo 
against P. berghei in mice. The thiosemicarbazone ligands exhibited activity at dosage levels 
of 40 to 160 mg/kg, whereby 3/5 infected mice were cured. Upon complexation, the Cu(II) 
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infected mice at a dose 160 mg/kg. The Ni(II) complexes were inactive and the Fe(II) 




In a study by Khanye et al., a variety of Au(I)-thiosemicarbazone complexes were 
synthesized.
41
 The Au(I) was coordinated to two ferrocenyl-derived thiosemicarbazones 
through the sulfur atoms to form linear complexes. The free ligands and their corresponding 
complexes were tested against P. falciparum D10 (CQS) and W2 (CQR) strains. Most of the 
complexes showed significant activity against the P. falciparum strains when compared to 
their free ligands. Compound XXXVII (Fig. 1.19) exhibited the highest activity against the 
W2 (IC50 value = 1.28 µM) strain. However, these compounds were less effective than 































It has been established that ferroquine- and thiosemicarbazone-derivatives are active against 
P. falciparum.
9,65
 The ferrocenyl moiety in ferroquine has no cytotoxic activity. However, in 
the same way as the iron in haematin produces reactive oxygen species when oxidized, so 
does the iron in ferroquine.
9
 A study carried out by Biot and co-workers aimed to utilizes the 
previously mentioned properties of ferroquine, and the chelating ability of 
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substituents on the aryl group of the thiosemicarbazone, as well as the group attached to the 
ferrocenyl moiety, were varied when the compounds were synthesize. Compound XXXVIII 
(Fig. 1.20) was one of the most active compounds synthesized by Biot et al.
42
 The compound 
had IC50 values of 0.2 and 0.8 µM against the P. falciparum strains 3D7 (CQS) and W2 

















The activity of various C,N,S-chelated thiosemicarbazone cyclopalladated complexes has 
been investigated in a study conducted by Chellan et al.
40
 The complexes were synthesized 
using P-donor ligands, such as triphenylphosphine for mononuclear complexes (XXXIX) and 
the bridging ligands, 1,1’-bis(diphenylphosphino)ferrocene (Fig. 1.21) and trans-1,2-











































R = CH3, CH2CH3 
XXXX 
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The complexes were tested against both 3D7 (CQS) and K1 (CQR) strains of P. falciparum. 
Moderate activity was exhibited by the mononuclear complexes, as well as the binuclear 1,1’-
bis(diphenylphosphino)ferrocene complexes, which was higher than the activity of the free 
ligand. However, no conclusive evidence was gained to illustrate that a relationship exists 




1.6. Multinuclear complexes  
It has been observed that in certain cases, with an increase in the number of metal centres, 
there is an enhancement of biological activity.
101-105
 One of the most noted cases, involves the 
platinum-containing complexes BBR3005 [{trans-PtCl(NH3)2}2μ-H2N-(CH2)6-NH2]
2+
 
(XXXXI) and BBR3464 [{trans-PtCl(NH3)2}2{trans-Pt(NH3)2(μ-H2N-(CH2)6-NH2)2}]
4+
 
(XXXXII) which were evaluated as anticancer agents.
102
 These complexes contain platinum 
centres linked by aliphatic diamine chains. BBR3464 shows enhanced anticancer activity 
compared to the other related binuclear compounds such as BBR3005 (XXXXI, Fig. 15) 
which has a lower nuclearity. BBR3464 has also shown activity significantly higher than 













































1.6.1. Multinuclear transition metal complexes as antimalarial agents 
Mono- and binuclear gold(III) complexes were synthesized by Gabbiani et al., using 
dipyridyl derivatives, and their activity tested against the chloroquine-sensitive 3D7 strain.
101
 
All the binuclear complexes showed higher activity when compared to the mononuclear 
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1.23) had IC50 values of 12.2 and 2.3 µM respectively.
101
 These gold(III) complexes have 



























































       
 
 
Fc =  




     R = H, Me 
 
Figure 1.23: The structure of the mononuclear (XXXXIII) and binuclear (XXXXIV) gold(III)-complexes. The 
structure of the dendritic ferrocenylthiosemicarbazone (XXXXV).
101,104 
   
 
Ferrocenylthiosemicarbazones have been incorporated onto a poly(propyleneimine) 
dendrimer scaffold (Fig. 1.23) by Khanye et al., and the antiplasmodial activity evaluated.
102
 
When comparing compounds XXXXV (R = H, Me), which contains four ferrocenyl moieties, 
to the scaffold without the ferrocenyl moiety, there is a significant increase in activity. These 
compounds were tested in vitro against the chloroquine-resistant W2 strain. Compounds 
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μM respectively, whilst the other compounds were inactive at the highest tested concentration 
(20 μM).
104
     
 
Various other multinuclear complexes such as XXXI (Section 1.4.1., Fig. 1.14) and XXXVI 
(Section 1.5.1., Fig. 1.19) have exhibited good biological activity in comparison to their free 
ligands.
41,79
 With results that suggest that multinuclear complexes are more active than their 
mononuclear complexes,
103
 it can be inferred that the same concept may apply when dealing 
with the nuclearity of thiosemicarbazone complexes, though these results must be read with 
some caution. Therefore, multinuclear platinum group metal thiosemicarbazones complexes 
may prove promising as antimalarial agents.  
 
1.7. Aims and objectives    
General aims 
The main aim of the project was to synthesize thiosemicarbazone ligands as well as their 
palladium(II) and ruthenium(II) complexes. The ligands and complexes were characterized, 
and the biological activity of selected compounds was evaluated.  
 
Specific objectives 
 To synthesize the monothiosemicarbazone ligands using 3,4-dichloroacetophenone, 
3,4-dichloropropiophenone and ferrocenecarboxaldehyde. 
 
 
 To synthesize the dithiosemicarbazone ligand by reacting dithiosemicarbazide with 
ferrocenecarboxaldehyde. 
 
 To synthesize mono- and binuclear cyclopalladated complexes containing N- and P-
donor ligands. 
  
 To synthesize ruthenium(II)-arene complexes using the mono- and dimeric 
ferrocenylthiosemicarbazones.   
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P, 2D (COSY and 
HSQC) NMR spectroscopy,  IR spectroscopy and mass spectrometry. 
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The synthesis and characterization of aryl-derived thiosemicarbazone cyclopalladated 
complexes containing N- and P-donor ligands 
 
2.1. Introduction 
As previously mentioned thiosemicarbazone ligands are well known for their ability to 
chelate to a range of metals through the use of donor atoms, such as oxygen, sulfur and 
nitrogen.
1-5
 Cyclopalladated complexes characteristically contain a palladium-carbon sigma 
bond, where an aromatic sp
2
 carbon is typically used. The additional donor atoms stabilize 
the metal when forming the cycle.
6-7
 In this chapter, the aryl-monothiosemicarbazone ligands 
chelate in a tridentate C,N,S-mode (Fig. 2.1), whereby C-H activation of the aryl proton in the 
6
th





The thiosemicarbazone systems chosen for the synthesis of C,N,S-chelated cyclopalladated 
complexes contain an alkyl group on the imine carbon. Ketones are preferred over aldehydes 
due to the steric interaction between the alkyl group and the aromatic ring, pushing the ring 





The complexes containing the P- and N-donor ligands (Section 2.2.4. and 2.2.5.) were 
derived from tetranuclear complexes, which were initially synthesized by Chellan et al.
3
 The 
complex is tetranuclear due to a core around which four cyclopalladated units are situated. 
The palladium is coordinated to the sulfur atom in the unit with which it forms a palladacycle 
as well as with the sulfur atom in the adjacent unit. Therefore, as a result of the Pd-Sbridging 


















R= H, Me 
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Various tridentate C,N,S cyclopalladated complexes containing P-donor ligands for example 
PR3 or bis(diphenylphosphino) bridging compounds have been synthesized by Lobana et al. 
and Weis et al. to name a few.
12,14
 Attempts to investigate complexes containing N-donor 
ligands are scarce due to limited reactivity when cleaving the Pd-Sbridging bond of the 
tetranuclear complex.
15
 Therefore, the preparation of complexes containing N- and P-donor 
ligands was attempted. 
 
2.2. Results and discussion  
2.2.1. The synthesis and characterization of the monothiosemicarbazone ligands (1, 2) 
The aryl monothiosemicarbazone ligands were prepared via a Schiff base condensation 
reaction between the ketones, 3,4-dichloroacetophenone or 3,4-dichloropropiophenone, and 
thiosemicarbazide in ethanol (Scheme 2.1). This reaction results in the formation of the imine 



















R = CH3, CH2CH3 1: R = CH3








Scheme 2.1: The synthesis of the monothiosemicarbazone ligands (1, 2). 
 
Physical properties 
Compounds 1 and 2 were isolated as white crystalline solids in moderate yields (Table 2.1). 
Compounds 1 and 2 have melting points comparable to literature values (Table 2.1), ranging 
between 196.0-197.9 °C and 185.6-186.4 °C respectively.
16
 The ligands are soluble in 
dichloromethane, chloroform, acetone, ethyl acetate, tetrahydrofuran and dimethyl sulfoxide.  
 
Table 2.1: The physical appearance, yield and melting point of the monothiosemicarbazone 
ligands (1, 2) 
Compound 
number 
R Yield (%) Physical Appearance 
Melting point 
(˚C) 
1  CH3 51 White crystalline solid 194.8-197.9 
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Compounds 1 and 2 are known, and thus 
1
H NMR spectroscopy and infrared spectroscopy 
were the only methods of characterization carried out. 
 
1
H NMR spectroscopy 
The NMR spectra for compounds 1 and 2 were recorded in DMSO-d6. The 
1
H NMR spectra 
of the ligands show characteristic peaks associated with thiosemicarbazones. The peak for the 
hydrazinic proton is observed at δ 10.24 and 10.36 for compounds 1 and 2 respectively. The 
aromatic proton Hb resonates as a doublet (J = 2.00 Hz) at δ 8.25 and 8.23 for 1 and 2 
respectively.  
 
The peaks associated with the aromatic protons He and Hf are observed as a doublet and a 
doublet of doublets respectively (see appendix, pg 132). The peak for He is observed at δ 7.61 
and 7.60 (
3
JHH ~ 8.60 Hz) for 1 and 2 respectively, whilst the peak for the aromatic proton Hf 
is observed at δ 7.88 and 7.86 respectively. The proton Hf couples to Hb (
4
JHH = 2.00 Hz) and 
He (
3




The amine protons of compound 1 and 2 resonate at ca. δ 8.13 and 8.31. The nitrogen of the 
terminal amine group is able to delocalize its lone pair of electrons leading to restricted 
rotation of the amine group about the C-N axis, which results in different environments and 




The alkyl substituent on the imine carbon is located upfield in the 
1
H NMR spectrum. The 
peak for the methyl protons of compound 1 is observed as a singlet at δ 2.28, whilst the CH3 
and CH2 protons of the ethyl chain of compound 2 are observed as a triplet (
3
JHH = 7.60 Hz) 
and quartet (
3
JHH = 7.60 Hz) at δ 0.99 and 2.86 respectively. The data correspond to that 




Infrared (IR) spectroscopy 
Upon synthesis of compounds 1 and 2, an absorption band is observed in the IR spectrum at 
1594 and 1596 cm
-1
 respectively, for the imine bond. Imine absorption bands are typically 
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2.2.2. The synthesis and characterization of the mono- and dimeric iminophosphine and 
aminophosphine ligands (3-6) 
The aminophosphine ligands (4 and 6) were prepared via reductive amination. The 
iminophosphine ligands were synthesized via a Schiff base condensation reaction between (2-
diphenylphosphino)benzaldehyde and n-propylamine (3) or p-phenylenediamine (5) in 
toluene or methanol (Scheme 2.2).
20-22
 Compounds 3 and 5 were reduced using sodium 
borohydride to produce the aminophosphine ligands (4 and 6).
21
 The monomeric ligand (4) 
was synthesized as a model to determine if complexation would occur (Section 2.2.4.a.), and 
if this would be a feasible system for the complexation of multimeric ligands. The dimeric 
aminophosphine ligand (6) was synthesized as a bridging ligand between two cyclopalladated 

































  h     i     j















Scheme 2.2: The synthesis of the imino (3 and 5) - and aminophosphine (4 and 6) ligands. 
 
Physical properties 
Compounds 3 and 4 were isolated as yellow oils and compounds 5 and 6 were isolated as 
yellow powders in relatively high yields (Table 2.2). Compounds 5 and 6 have high melting 
points. Compounds 3 and 6 are soluble in chlorinated solvents, dimethyl sulfoxide and 
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Table 2.2: Physical appearance and yield of the ligands (3-6) 
Compound number Yield (%) Physical Appearance Melting point (˚C) 
3 90 Yellow oil - 
4 91 Yellow oil - 
5 88 Light-yellow powder 206.4-210.4 
6 94 Yellow powder 194.8-198.5 
 
Spectroscopic and analytical techniques such as NMR spectroscopy, infrared spectroscopy 
and mass spectrometry were used to characterize compounds 3-6. 
 
1
H NMR spectroscopy 
The NMR spectra of compounds 3-5 were recorded in CDCl3, whilst the spectrum of 
compound 6 was recorded in DMSO-d6. Upon formation of the iminophosphine ligands 3 and 
5, a doublet corresponding to the imine proton is observed at ca. δ 9.00. The peak 
corresponding to the aldehyde proton of the starting material is not observed at δ 10.51 which 
confirms condensation. Coupling constants of ca. 5.00 Hz for 3 and 5 suggests a four bond 
coupling of the imine proton with phosphorus, which is comparable with that seen in 
literature (
4




Reduction of the imine bond is confirmed by the absence of the imine peak in the 
1
H NMR 
spectra of compounds 4 and 6, and the appearance of a signal for the Hg proton which 
resonates at δ 3.90 and 4.19 for 4 and 6 respectively (see appendix, pg. 132 and 133). The 
amine proton Hh is observed as a broad signal at δ 1.72 and 5.30 respectively for 4 and 6.   
 
The signals for the aromatic protons are observed in the range δ 6.76-8.19. The signal for He 
is observed as a multiplet due to coupling with Hd and phosphorus. For compounds 3, 4 and 
6, the signal for Hb is observed as a doublet of doublets, whereas for compound 5 a multiplet 
is observed. A coupling constant of ca. 7.50 Hz corresponds to coupling with the adjacent 
aromatic proton Hc, whilst a coupling constant of ca. 4.50 Hz corresponds to a three bond 
coupling with phosphorus.
21-23
 The aromatic protons Hc (4 and 6) and Hd (5 and 6) are 
observed as a triplet (J ~ 7.60 Hz) due to coupling with adjacent aromatic protons (Table 






























JHP = 4.77) 
- 
7.98 (m, He); 7.31 (m, Hc & Hd & HAr); 
6.88 (dd, JHH = 7.51, JHP = 4.48, Hb). 
4 - 3.90 (s) 
7.58 (m, He); 7.40 (m, Hd); 7.23 (m, 
HAr); 7.09 (t, 
3
JHH = 7.64, Hc); 6.83 
(dd, JHH = 7.32, JHP = 4.39, Hb). 
5 
9.06 (d,  
4
JHP = 5.10) 
- 
8.19 (m, He); 7.45 (t, 
3
JHH = 7.44, Hd) 
7.33 (m, Hc & HAr); 6.94 (m, Hb). 
6 - 4.19 (br s) 
7.60 (m, He); 7.41 (m, HAr); 7.31 (t, 
3
JHH = 7.80, Hd); 7.24 (m, HAr); 7.17 
(t, 
3
JHH = 7.60, Hc); 6.76 (dd, JHH = 
7.51, JHP = 4.76, Hb). 
 
The aromatic protons of the phenyl groups are observed as multiplets. In the 
1
H NMR 
spectrum for 3, the signal overlaps with those of Hc and Hd whereas for compound 5 the 
signal overlaps with that of Hc. The protons of the rigid aromatic spacer are observed as a 
singlet at δ 6.88 and 6.14 for compounds 5 and 6 respectively. This observation is due to the 
symmetry of the compounds about a two-fold rotation axis. 
 
For compounds 3 and 4, the protons of the propyl chain are observed upfield in the aliphatic 
region. For 3 and 4, the CH3 protons are observed as a triplet (J ~ 7.40 Hz) at δ 0.75 and 0.73 
respectively due to coupling with the adjacent CH2 protons. The -CH2- protons are observed 
as a multiplet at δ 1.51 and 1.26 for 3 and 4 respectively, whilst the remaining N-CH2- 
protons of 3 and 4 are observed as a triplet (J ~ 7.00 Hz) at δ 3.44 and 2.39 respectively 





H} NMR spectroscopy               








H} NMR spectra of 4 and 6, are observed 
as doublets due to coupling with phosphorus (Table 2.4), including the quaternary carbons 
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The PPh2 carbons are observed as doublets in the range δ 128-136. However, for compound 4 
one of the carbons is observed as a singlet at δ 128.7 (Table 2.4). The aromatic carbon Cb 
resonates as a doublet at δ 129.3 (
2
JCP = 5.20 Hz) and 131.3 (
 2
JCP = 9.46 Hz) for compounds 
4 and 6 respectively. The signals for the aromatic carbons Cc-e are observed as singlets in the 










(ppm, J = Hz) 
Quaternary carbons 




JCP = 10.1); 133.9 (d, 
2
JCP = 
20.1); 128.5 (d, 
3
JCP = 6.87); 128.7 (s). 
135.6 (d, 
1
JCP = 13.5, Ca); 
144.6 (d, 
2





JCP = 10.3); 133.5 (d, 
2
JCP = 
19.8); 128.8 (d, 
3
JCP = 6.97); 127.0 (d, 
4
JCP 
= 4.40).  
134.4 (d, 
1
JCP = 14.7, Ca); 
144.1 (d, 
2
JCP = 22.0, Cf); 
139.7 (s, Ci). 
 
The aromatic carbons of the rigid spacer in compound 6 are observed as singlets at δ 139.7 
(Ci) and 113.5 (Cj), which corroborates the statement that these compounds are symmetrical. 
For compounds 4 and 6, the carbon Cg is observed as a doublet at δ 52.7 (
3
JCP = 20.7 Hz) and 
46.1 (
3
JCP = 25.7 Hz) respectively due to the three bond coupling experienced with 
phosphorus. The signals for the carbons Ci, Cj and Ck of the propyl chain are observed in the 
aliphatic region at δ 51.4, 23.2 and 11.9 respectively for compound 4. These chemical shifts 
and coupling constants correspond to those seen in literature for the compound N-(2-





P NMR spectroscopy 
In the 
31
P NMR spectra of compounds 3 and 5 a peak is observed at δ -13.9 and -12.2 
respectively, which is upfield from δ -11.96 (2-diphenylphosphinobenzaldehyde). Upon 
reduction of 3 and 5, the peaks shifted upfield to δ -16.1 and -16.9 for compounds 4 and 6 
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Infrared (IR) spectroscopy    
The IR spectra of compounds 3 and 4 were recorded using NaCl solution cell 
(dichloromethane), whilst 5 and 6 were recorded using KBr pellets. For iminophosphine 
ligands 3 and 5, the absorption band for the imine bond is observed at 1637 and 1610 cm
-1
 
respectively. No absorption band is observed in the imine region for the aminophosphine 
ligands 4 and 6, whilst a weak absorption band is observed at 3405 and 3427 cm
-1
 
respectively; in the region for N-H stretching frequency of secondary amines.
19
 This confirms 





-mass spectra were recorded for compounds 5 and 6. The molecular ion peak for 5 and 6 
is observed at m/z 653 (40 %) and 656 (40 %) respectively. The peaks corresponding to the 
[M-H]
+
 ion are observed at m/z 652 (94 %) and 655 (100 %) respectively for 5 and 6. 
 
2.2.3. The synthesis and characterization of C,N,S-chelated thiosemicarbazone 
cyclopalladated tetranuclear complexes (7, 8) 
The synthesis of the tetranuclear palladium(II) complexes (7 and 8) involves the reaction 
between the aryl-monothiosemicarbazone ligands (1 and 2) and potassium 


















1: R = CH3 






7: R = CH3
8: R = CH2CH3
K2[PdCl4] or Na2PdCl4.nH2O
 
Scheme 2.3: The synthesis of the tetranuclear complexes (7, 8). 
 
Physical properties 
Compounds 7 and 8 were isolated as yellow powders in low yields of 44 and 25 % 
respectively (Table 2.5). The onset of decomposition without melting is observed at 322 and 
327 ˚C for 7 and 8 respectively. The compounds show solubility in ethyl acetate, 
tetrahydrofuran and dimethyl sulfoxide, whilst 7 also shows good solubility in diethyl ether 











                                                                                                                                      Chapter 2 
38 
 
Table 2.5: Physical appearance, melting point and yield of the tetranuclear complexes (7, 8) 
Compound 
number 
R Yield (%) Physical Appearance Melting point (˚C) 
7 CH3 44 Yellow powder 
Decomp. without 
melt: 327-331 
8 CH2CH3 25 Yellow powder 




H NMR spectroscopy     
The NMR spectra of compounds 7 and 8 were recorded in DMSO-d6. It is observed that upon 
complexation, the peak associated with the hydrazinic proton is absent in the 
1
H NMR 
spectra due to formation of a second C=N bond as a result of chelation of the ligand in the 
thiolate form. The aromatic proton He resonates as a singlet at δ 6.72 and 6.65 for 7 and 8, 
whilst the peak for Hb is observed as a singlet at δ 7.37 and 7.34 for 7 and 8 respectively (see 
appendix, pg. 133). Observing a singlet for Hb, and the absence of a peak for Ha, suggests that 
the Pd-C bond has formed.  
 
The amine protons for compounds 7 and 8 resonate as a singlet at δ 7.07 and 7.16 
respectively. With the formation of the Pd-S bond in the complex, there is free rotation about 
the amine bond, which results in one signal for the amine protons.
3,8
 The peak for the methyl 
protons in compound 7 is observed as a singlet at δ 2.00, while vicinal coupling with two 
protons results in the observation of a triplet (
3
JHH = 7.00 Hz) at δ 1.06 for the CH3 protons of 
compound 8. The CH2 protons for compound 8 are observed as two quartets at δ 1.79 (
3
JHH = 
7.32 Hz) and 2.86 (
3
JHH = 7.71 Hz), where one quartet corresponds to one proton. The data 




Infrared (IR) spectroscopy 
When the ligand chelates to the palladium in a C,N,S tridentate fashion, electron density is 
donated onto the metal. In order to stabilize the metal, electron density is donated from the 
metal to empty π*-orbitals of the nitrogen, which results in a change in the length of the 
imine bond.
11,19
 However, due to the distribution of electron density across the compound, the 
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For compounds 7 and 8, the imine absorption band shifted from 1594 and 1596 cm
-1
 in the 
ligand (1 and 2), to 1600 and 1595 cm
-1
 respectively (Table 2.6).
19
 These absorption bands 




Molecular structure of complex 7    
Single crystals, crystallized with three molecules of tetrahydrofuran, were obtained from the 
slow evaporation of a solution of compound 7 dissolved in tetrahydrofuran/hexane. The 
molecular structure of 7 was determined by single-crystal X-ray diffraction, and is shown in 
Fig. 2.2. Table 2.7 list the crystallographic data, while selected bond lengths and angles are 
given in Table 2.8. 
 
Figure 2.2: The molecular structure of compound 7. 
 
Compound 7 crystallizes in a monoclinic system with space group P21/n (Table 2.7). The 
formation of the expected two 5-membered rings are seen as the thiosemicarbazone ligand 
chelates to the palladium(II) ion in a tridentate C,N,S-mode.
3,14
 The Pd4S4 core reported in 
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Table 2.8: Crystal data and structure refinement data for compound 7 
Empirical formula C36H28Cl8N12Pd4S4.3C4H8O 
Formula weight 1682.46 
Temperature (K) 173(2)  
Wavelength (Å) 0.71073  
Crystal system Monoclinic 
Space group P21/n 
a (Å) 16.4634(9) 
b (Å) 9.1883(5) 
c (Å) 38.962(2) 
α (˚) 90 
β (˚) 93.4590(10) 














) 0.18 x 0.17 x 0.16 
θ Range for data collection (˚) 2.06 to 28.40 
Index range -22 ≤ h ≤ 19; -10 ≤ k ≤ 12; -52 ≤ l ≤ 52  
Reflections collected 67481 
Independent reflections [R(int)] 14734 [0.0604] 
Data / restraints / parameters     14734 / 0 / 723 
Goodness-of-fit on F
2
             1.011 
Transmission         0.7658, 0.7422 
Final R indices [I>2σ(I)]      R1 = 0.0365, wR2 = 0.0681 
R indices (all data)               R1 = 0.0598, wR2 = 0.0758 
Largest difference in peak and hole (e. Å 
-3
)  0.722 and -0.520 
 
Upon formation of compound 7, the bonds N(1)-C(7) and N(2)-C(9)  have equal bond lengths 
of 1.303(4) Å, which confirms the formation of the second imine bond (Table 2.8). The S(1)-
C(9) bond has a length of 1.787(4) Å, which is longer than that of the imine bond suggesting 
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complex, the thiosemicarbazone chelates to the palladium in the thiolate form. For a perfect 
four-coordinate planar geometry, the sum of the acute and obtuse angles around the 
palladium(II) centre would be equal to 720˚. Compound 7 has a slightly distorted square-
planar geometry around the metal centre, where the sum of the aforementioned angles 
deviates from 720˚ by approximately 20˚ (Table 2.8).    
 
Table 2.8: Selected bond lengths (Å) and angles (˚) for compound 7. 
Pd(1)-N(1)                     2.002(3)  N(1)-Pd(1)-C(1) 81.24(13) 
Pd(1)-C(1) 1.998(3) N(1)-Pd(1)-S(1) 83.15(8) 
Pd(1)-S(1) 2.3637(9) N(1)-Pd(1)-S(4) 175.63(8) 
Pd(1)-S(4) 2.3194(9) S(4)-Pd(1)-S(1) 100.56(3) 
S(1)-C(9) 1.787(4)  C(1)-Pd(1)-S(4) 94.91(10) 
N(1)-C(7) 1.303(4) C(1)-Pd(1)-S(1) 164.06(11) 
N(2)-C(9) 1.303(4) Pd(1)-S(4)-Pd(4) 110.11(4) 
 
2.2.4. The synthesis and characterization of C,N,S-chelated thiosemicarbazone 
cyclopalladated complexes containing P-donor ligands  
a. Mononuclear C,N,S–chelated thiosemicarbazone cyclopalladated complexes (9-11) 
The mononuclear cyclopalladated complexes (9-11) were synthesized by reacting the 
tetranuclear complexes (7 or 8) with the P-donor ligands, PTA or aminophosphine (4) 
(Scheme 2.4). According to the HSAB (Hard Soft Acid Base) principle, the Pd(II) ion is a 
soft acid, whilst sulfur and phosphorus donor ligands are soft bases.
26
 In addition to it being 
more likely that a stronger bond would form via the softer phosphorus atom than the 
borderline amine nitrogen, there is a greater chance of coordination occurring via phosphorus 
as it is a stronger base. Due to the basicity of the phosphorus donor ligands, there is 
competition between the phosphorus and the sulfur, which leads to the cleavage of the Pd-
Sbridging bond in the tetranuclear complex and the insertion of the phosphorus ligand into the 
fourth coordination site on the metal. 
 
The essential structural feature of cell membranes is the phospholipid bilayer, and thus if a 
compound enters the cell via membrane crossing, factors such as lipophilicity becomes 
important. A compound should ideally be lipophilic enough to interact and cross the 
membrane into the cell, but not too lipophilic that it is retained at the membrane. Therefore, 
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compound. As seen in Section 2.2.2., aminophosphine ligands have also been synthesized. 
However, when the complex [Pd(3,4-dichloroacetophenone thiosemicarbazone)(N-(2-
(diphenylphosphino)benzylidene)propan-1-amine)] was synthesized, and attempts were made 
to purify by column chromatography (silica gel),  the imine bond in the complex was 
hydrolysed and the aldehyde starting material remained coordinated to palladium. Therefore, 









7: R = CH3, 
















9:   R = CH3










































Compounds 9-11 were isolated as yellow powders in varying yields between 40-94 % (Table 
2.9). Compounds 9-11 melt in ranges noted in Table 2.9. The compounds are soluble in 
chloroform, tetrahydrofuran and dimethyl sulfoxide. Compounds 10 and 11 are also soluble 
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Table 2.9: Melting points and yields of the mononuclear complexes (9-11) 
Compound 
number 
R Yield (%) Melting point (˚C) 
9 CH3 94 243.0-248.4 
10 CH2CH3 74 235.9-239.4 
11 CH3 40 179.7-184.1 
 
The NMR spectra were recorded using DMSO-d6.  
1
H NMR spectroscopy 
As the Pd-Sbridging bond is cleaved, the mononuclear complex is formed. The peak associated 
with the aromatic proton Hb of compounds 9 and 11 is observed as a doublet (J ~ 3.50 Hz) at 
δ 7.10 and 6.13 which is due to a four bond coupling with the phosphorus of the P-donor 
ligand (see appendix, pg 134). The peak associated with Hb of compound 10 is observed as a 
broad signal at δ 7.11. A doublet is expected for compound 10, and perhaps further resolving 
of the broad signal would reveal a doublet, with a coupling constant comparable to that seen 
for compounds 9 and 11. 
 
The peak corresponding to the aromatic proton He is shifted downfield when compared to 
that seen for 7 and 8, to ca. δ 7.25. With the formation of the mononuclear complex, Hb 
became more shielded whilst He became more deshielded. The electron density donated by 
the ligand may have shielded Hb when compared to the tetranuclear complex whilst when the 








(ppm, J = Hz) 
Aromatic protons 




9 4.27 (s) 
4.59 (d, JHP = 12.4) 
4.44 (d, JHP = 13.2) 
7.27 (s, He); 7.10 (d, 
4
JHP = 3.42, Hb). 
10 4.26 (s)  
4.58 (d, JHP = 12.8) 
4.44 (d, JHP = 12.8) 
7.27 (br s, He); 7.11 (br s, Hb). 
11 - - 
7.74 (m, Hn); 7.49 (m, Hk & HAr); 7.32 
(t, 
3
JHH = 7.70, Hl); 7.23 (s, He); 7.00 
(m, Hm); 6.13 (d, 
4
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The signal for the amine protons of the thiosemicarbazone unit shifted slightly upfield to ca. 
δ 7.00 for compounds 9-11. For compounds 9 and 10, a singlet associated with the PCH2N 
protons of PTA is observed at ca. δ 4.27. The NCH2N protons are in an AB spin system 
resulting in two doublets corresponding to the different environments experienced by the 
axial and equatorial NCH2N. The doublet associated with the protons in the axial and 





For compound 11, a multiplet observed at δ 7.49 is associated with the overlapping signals of 
the phenyl protons as well as the aromatic Hk proton. The multiplets observed at δ 7.74 and 
7.00 correspond to the protons Hn and Hm, due to coupling with adjacent protons, as well as 
phosphorus. A triplet observed at δ 7.32 (
3
JHH = 7.70 Hz) corresponds to Hl, which is due to 
coupling with Hk and Hm (Table 2.10).  
 
For compound 11, the signal for the proton Hp is observed as a singlet at δ 4.12. The CH3 (Ht) 
protons of the propyl chain are observed as a triplet (J   7.28 Hz) at δ 0.71, due to coupling 
with the adjacent CH2 protons. The signal for the -CH2- protons is observed as a multiplet at 
δ 2.26 due to coupling with adjacent Ht and Hr protons of the propyl chain. The peak 
corresponding to the Hr protons overlaps with the DMSO-d6 peak, which was confirmed 
using 2D (HSQC) NMR spectroscopy.  
 
For compound 9, the singlet corresponding to the methyl protons shifted downfield to δ 2.21 
from δ 2.00 for compound 7. For compound 10, a triplet (
3
JHH = 7.60 Hz) is observed at δ 
1.02 which corresponds to the methyl protons. One quartet (
3
JHH = 7.60 Hz) is observed at δ 
2.70 for the -CH2- protons as opposed to the two quartets observed for compound 8. For 





H} NMR spectroscopy  
For compounds 9-11, the signal for the thiolate carbon shifted downfield to ca. δ 177.0 when 
compared to that observed for the tetranuclear complexes (Table 2.11).
3
 For compound 11, a 
doublet (J = 9.43 Hz) is observed due to three bond coupling with phosphorus. The imine 
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For compounds 9 and 10, the aromatic carbons Ca-f are observed as singlets at ca. δ 164.0, 
127.2, 136.0, 130.6, 127.0 and 152.5 respectively. For 11, the aromatic carbons Ca, Cf, Cc-e 
are observed as singlets at δ 163.7, 153.2, 131.3, 130.8 and 126.7. The aromatic carbons Cb as 
well as the remaining aromatic carbons are observed as doublets in the range δ 127.2-163.6 
due to coupling with phosphorus (Table 2.11). 
 
The carbons of PTA, NCH2N and PCH2N, are observed as doublets at δ 72.4 (
3
JCP = 7.40 Hz) 
and 51.5 (
1
JCP = 15.5 Hz) for 9 and 10. The carbons of the alkyl chains are observed in the 
aliphatic region of the spectra. The methyl carbon of the thiosemicarbazone unit is observed 
at δ 13.6, 11.5 and 13.7 for compounds 9, 10 and 11 respectively. The CH2 group of 
compound 10 is observed at δ 20.0. In the 
13
C NMR spectrum of 11, the Ct, Cs and Cr carbons 
resonate as singlets at δ 12.0, 51.5 and 56.2 whilst Cp is observed as a doublet at δ 52.8 (
3
JCP 











(ppm, J = Hz) 
C-S 
(ppm,  




(ppm, J = Hz) 
9 
51.5 
(d, JCP = 15.5); 
72.4 
(d, JCP = 7.40) 
177.2 (s) 163.7 (s) 
163.6 (s, Ca); 153.2 (s, Cf); 
136.4 (s, Cc); 130.6 (s, Cd); 
127.2 (s, Cb); 127.1(s, Ce).  
10 
51.5 
(d, JCP = 15.5); 
72.4 
(d, JCP = 7.40) 
177.4 (s) 168.3 (s) 
164.2 (s, Ca); 151.9 (s, Cf); 
136.6 (s, Cc); 130.6 (s, Cd); 









JCP = 4.70, Co); 
145.2 (d, 
3
JCP = 11.4, Cn); 
135.9 (d, 
1
JCP = 8.10, Cj); 
135.0 (d, 
1
JCP = 12.8, CPh); 
130.7 (d, 
2
JCP = 8.10, CPh); 
130.1 (d, 
4
JCP = 3.40, CPh); 
129.3 (d, 
2
JCP = 10.1, Cb); 
127.2 (d, 
3















P NMR spectroscopy 
A singlet is observed at δ -49.5, -49.6 and 29.5 in the 
31
P NMR spectra for compounds 9-11 
respectively. This testifies to the presence of only one phosphorus species and no unreacted 




Infrared (IR) spectroscopy   
Upon displacement of the Pd-Sbridging bond by the PTA or aminophosphine ligand, the 
absorption band for the imine bond chelated to the metal is found at a lower wavenumber for 
9-11 when compared to the tetranuclear complexes 7 and 8 (Table 2.6).  
 
For compounds 9-11, the second C=N absorption band is observed at a higher wavenumber 
when compared to compounds 7 and 8 (Table 2.12). The P-donor ligand donates electron 
density onto the metal. When back-donation occurs, more electron density is donated to the 
P-donor ligand when compared to the atoms of the thiosemicarbazone. Therefore, less 




Table 2.12: The absorption bands of the imine bond in the IR spectra (9-11) 
Compound number C=N ν (cm
-1
) 
9 1624, 1574 
10 1641, 1559 
11 1618, 1582 
 
Mass spectrometry 
For compounds 9 and 10, the EI
+
-mass spectra were recorded, whilst the ESI
+
-mass spectrum 
was recorded for 11. The molecular ion peak for compounds 9-11 is observed at m/z 524 (4 
%), 538 (2.4 %) and 700 (45 %) respectively. The base peak for compound 11 is observed at 




Molecular structure of complex 10 and 11    
Single crystals of compound 10 were obtained by the slow diffusion of hexane into a minimal 
amount of tetrahydrofuran, which the compound had been dissolved in. The slow evaporation 
of a solution of compound 11 dissolved in chloroform/hexane allowed for the formation of 










                                                                                                                                      Chapter 2 
47 
 
determined by single-crystal X-ray diffraction, and are shown in Fig. 2.3. Table 2.13 lists 








Figure 2.3: The molecular structure of compound 10 (a) and 11 (b). 
 
Table 2.13: Selected bond lengths (Å) and angles (˚) for compounds 10 and 11. 
10 11 
Bond lengths 
Pd(1)-N(1) 2.022(2) Pd(1)-N(1) 2.033(5) 
Pd(1)-C(1) 2.024(3) Pd(1)-C(5) 2.029(4) 
Pd(1)-P(1) 2.2412(7) Pd(1)-P(1) 2.2571(14) 
Pd(1)-S(1) 2.3397(7) Pd(1)-S(1) 2.3181(15) 
S(1)-C(10) 1.768(3) S(1)-C(1) 1.755(6) 
N(2)-C(10) 1.310(3) N(2)-C(1) 1.331(8) 
N(1)-C(7) 1.302(3) N(1)-C(2) 1.298(7) 
Bond angles 
N(1)-Pd(1)-C(1) 80.71(10) N(1)-Pd(1)-C(5) 81.34(18) 
N(1)-Pd(1)-S(1) 83.19(6) N(1)-Pd(1)-S(1) 83.24(13) 
C(1)-Pd(1)-P(1) 101.45(8) C(5)-Pd(1)-P(1) 96.42(14) 
P(1)-Pd(1)-S(1) 95.16(2) P(1)-Pd(1)-S(1) 99.11(5) 
C(1)-Pd(1)-S(1) 163.28(8) C(5)-Pd(1)-S(1) 164.47(14) 
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Table 2.14: Crystal data and structure refinement data for compound 10 and 11 
 10 11 
Empirical formula C16H21Cl2N6PPdS C31H31Cl2N4PPdS.2CHCl3 
Formula weight 537.72 938.66 
Temperature (K) 173(2)  173(2) 
Wavelength (Å) 0.71073  0.71073   
Crystal system Monoclinic Triclinic 
Space group C2/c P-1       
a (Å) 35.7802(19) 11.7431(9)   
b (Å) 6.9559(4) 12.8847(11)   
c (Å) 16.2229(9) 14.7987(11)   
α (˚) 90 69.656(2)     
β (˚) 92.3610(10) 84.069(2)     
γ (˚) 90 72.202(2)   
V (Å
3
) 4034.2(4) 1999.0(3)   
Z 8 2 
Dcalc (Mg.m
-3
) 1.771 1.542   
Absorption coefficient (mm
-1
) 1.383 1.120   
F(000) 2160 924 
Crystal size (mm
3
) 0.09 x 0.08 x 0.07 0.07 x 0.08 x 0.12   
θ Range for data collection (˚) 2.28 - 28.44 1.8 - 28.3   
Index range -47 ≤ h ≤ 47;  -9 ≤ k ≤ 9;  
-21 ≤ l ≤ 21 
-15 ≤ h ≤ 14; -17 ≤ k ≤ 17;  
-11 ≤ l ≤ 19   
Reflections collected 35350 21501 
Independent reflections [R(int)] 5077 [0.0666] 9946 [0.041]   
Data / restraints / parameters     5077 / 0 / 244 9946 / 21 / 414 
Goodness-of-fit on F
2
             1.009 1.042 
Transmission         0.9094, 0.8857 0.9256, 0.8772 
Final R indices [I>2σ(I)]      R1 = 0.0291, wR2 = 0.0586 R1 = 0.0664, wR2 = 0.1719 
R indices (all data)               R1 = 0.0443, wR2 = 0.0644 R1 = 0.0928, wR2 = 0.1909 
Largest difference in peak and 
hole (e. Å 
-3
)  
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Compound 10 crystallizes in a monoclinic system and space group C2/c. The formation of 
the expected two 5-membered rings are observed as the thiosemicarbazone ligand bonds to 
the palladium(II) ion in a tridentate C,N,S-mode.
3,14
 The fourth coordination site on the metal 
is occupied by the PTA ligand. Compound 11 crystallizes in a triclinic system with a P-1 
space group. For compound 11, the propyl chain was disordered and carbons 29 and 30 were 
refined with equal site occupancy factors of one-third each. As seen with 10, the 
thiosemicarbazone chelates to the palladium(II) ion in a tridentate mode with the 
aminophosphine occupying the fourth coordination site. 
  
Upon formation of compounds 10 and 11, the imine bond containing the nitrogen coordinated 
to palladium is slightly shorter than that observed for compound 7, while the second C=N 
bond is slightly longer (Tables 2.8 and 2.13). The S(1)-C(10) (10) and S(1)-C(1) (11) bonds 
have lengths of ca. 1.76 Å, which is slightly shorter than that observed for 7 (Table 2.8).  
 
Compounds 10 and 11 have slightly distorted square-planar geometries around the palladium 
centre. For compounds 10 and 11, the bond angles formed between the ligands and the 
palladium centre deviates from that expected for square-planar complexes, where as seen 
with compound 7, the sum of the acute and obtuse angles deviate from 720˚ (Table 2.13). 
This observed geometry corresponds to that seen with other similar cyclopalladated 




b. Binuclear C,N,S-chelated thiosemicarbazone cyclopalladated complexes (12) 
The binuclear complex (12) was synthesized by reacting the tetranuclear complex (7) with 
the aminophosphine ligand (6) in acetone. The aminophosphine ligand occupies the fourth 
coordination site on palladium via phosphorus (Scheme 2.5) where it is used as a bridging 




































































Scheme 2.5: The reaction between the tetranuclear complex (7) and the aminophosphine ligand (6) 
 
Physical properties 
Compound 12 was isolated as a bright yellow powder in moderate yield of 58 %, and melted 
in the range 246.5-249.3 ˚C. Compound 12 is soluble in dichloromethane, chloroform and 
dimethyl sulfoxide.   
 
The NMR spectra were recorded using DMSO-d6.  
 
1
H NMR spectroscopy 
Upon formation of compound 12, a doublet is observed at δ 6.18 (
4
JHP = 3.70 Hz), which 
corresponds to the aromatic proton Hb, due to coupling with the phosphorus of the 
aminophosphine ligand. A multiplet observed at δ 7.50 corresponds to the overlapping 
signals for the aromatic protons Hk, Hn and the phenyl groups. The multiplet observed at δ 
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The proton Hl is observed as a triplet (J = 7.50 Hz) at δ 7.35 due to coupling with adjacent 
aromatic protons Hk and Hn. A singlet is observed for both the aromatic protons He and Hs at 
δ 7.21 and 5.87 respectively. As seen with compound 6, the protons of the aromatic spacer 
resonate as a singlet due to the symmetrical nature of the compound. The amine protons of 
the thiosemicarbazone unit and aminophosphine ligand are observed as broad signals at δ 
6.91 and 5.32 respectively. The -CH2-N protons are observed as a broad signal at δ 4.65 





H} NMR spectroscopy  
In the 
13
C NMR spectrum for compound 12, the signal for the thiolate carbon is observed at δ 
177.1 (J = 10.1 Hz) due to three bond coupling with phosphorus. The imine carbon resonates 
as a singlet at δ 164.0. The carbons of the phenyl groups are observed as doublets in the 






H} NMR chemical shifts for selected carbons of compound 12 
Phenyl carbons 
(ppm, J = Hz) 
Aromatic carbons 
(ppm, J = Hz) 
135.0 (d, 
1
JCP = 12.1, CPh); 130.1 (d, 
4
JCP = 
3.89, CPh); 129.3 (d, 
2
JCP = 10.4, CPh); 
127.0 (d, 
3
JCP = 10.8, CPh).  
163.5 (d, 
2
JCP = 4.71, Co); 144.6 (d, 
3
JCP = 10.1, 
Cn); 135.7 (d, 
3
JCP = 7.40, Cj); 133.0 (d, 
2
JCP = 
3.40, Ck); 128.6 (d, 
3
JCP = 8.17, Cb). 
 
The signals for the aromatic carbons Ca, Cc-f and Cl-m are observed as singlets at δ 163.3, 
130.3, 130.8, 153.3, 126.8 and 131.8 respectively. The quaternary carbon Cr as well as the 
remaining aromatic carbons (Cs) of the rigid spacer resonates as singlets at δ 140.0 and 114.0 
respectively. The aromatic carbons Cb, Cj-k and Cn-o are observed as doublets in the region δ 
128.6-163.5 due to coupling with phosphorus (Table 2.15). A doublet observed at δ 47.9 (
3
JCP 
= 14.8 Hz) corresponds to Cp whilst the methyl carbon is observed as a singlet at δ 13.8.    
 
31
P NMR spectroscopy 
A single peak is observed at δ 29.0, which is upfield from δ -16.9. This is comparable with 
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Infrared (IR) spectroscopy 
Compound 12 contains two imine bonds, and thus two absorption bands are observed in the 
IR spectrum at 1597 and 1574 cm
-1
. Upon moving from the tetranuclear complex to the 
binuclear complex, the absorption band for both imine bonds shifts to a lower wavenumber. 
The absorption band associated with the imine bond not directly coordinated to the metal is 
expected to shift to a higher wavenumber as seen with 11 (Section 2.2.4.a.).     
 
Mass spectrometry      
In the ESI
+
 mass spectrum of compound 12, the molecular ion peak and the [M+H]
+
 ion are 
observed at m/z 1390 (10 %) and 1391 (12 %) respectively. 
  
2.2.5. The synthesis and characterization of C,N,S-chelated thiosemicarbazone 
cyclopalladated complexes containing N-donor ligands (13-15) 
Mono- (13) and binuclear (14 and 15) complexes containing pyridyl ligands were synthesized 
by reacting the tetranuclear complex 7 with N-donor ligands 4-picoline, 4,4’-dipyridyl and 
1,2-bis(4-pyridyl)ethylene (Scheme 2.6). According to the HSAB (Hard Soft Acid Base) 
principle, Pd(II) and sulfur are soft acids and bases respectively, while pyridyl ligands are 
borderline bases and not as basic as sulfur.
26
 Therefore, the cleavage of Pd-Sbridging bonds by a 
borderline base will not occur as readily as when a softer base is used. These reactions 
occurred sluggishly in comparison to those in Section 2.2.4, and harsh conditions (e.g. high 
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Scheme 2.6: The reaction of the tetranuclear complex (7) with the N-donor ligands, 4-picoline (13), 4,4’-
dipyridyl (14) and 1,2-bis(4-pyridyl)ethylene (15) . 
 
Physical properties 
The compounds were isolated as yellow (13 and 15) and brown (14) powder in low to 
moderate yields (Table 2.16). The compounds exhibit high thermal stability and decompose 
without melting (Table 2.16). The compounds are soluble in dimethyl sulfoxide and 
tetrahydrofuran. Compound 13 is also soluble in ethyl acetate, dichloromethane and acetone, 
while compound 15 is also soluble in diethyl ether and ethyl acetate.  
 
  Table 2.16: Physical appearance, melting point and yield of the complexes 13-15 
Compound number Yield (%) Physical Appearance Melting point (˚C) 
13 69 Yellow powder 
Decomp. w/o melting 
311.0 
14 34 Brown powder 
Decomp. w/o melting 
287.8 
15 15 Yellow powder 















The NMR spectra were recorded using DMSO-d6.  
 
1
H NMR spectroscopy  
The NMR spectra of compounds 13-15 were recorded using DMSO-d6. The Hb and He 
protons are observed as singlets at ca. δ 7.38 and 6.73 respectively. The amine protons are 
observed as broad signals at δ 7.08 for compounds 13 and 15, while a peak is observed at δ 
7.19 for compound 14.  
 
The pyridyl protons Hj resonate as a doublet (
3
JHH = 5.86 Hz) at δ 8.41 and 8.59 for 
compounds 13 and 15 respectively, and a broad signal is observed for compound 14 at δ 8.73. 
A doublet is observed at δ 7.20 (
3
JHH = 4.90 Hz) and 7.59 (
3
JHH = 5.86 Hz) for the Hk protons 
of compounds 13 and 15 respectively. The Hk protons of compound 14 resonate as a broad 
signal at δ 7.83. 
 
A singlet observed at δ 7.50 corresponds to the Hm protons of the ethylene bridge in 
compound 15. The methyl protons of the thiosemicarbazone unit are observed as a singlet at 
δ 2.00 for the compounds whilst the methyl group on the 4-picoline ligand is observed at δ 
2.31 for compound 13. 
 
No change in the chemical shift is observed for the complexes when compared to the starting 
material. This suggests that either the complex dissociates in solution, or that the bond 
between the palladium and the nitrogen is so weak that the effect on the shifts is minimal. 
However, when stoichiometric amounts of the tetranuclear complex and the ligand are used 
to synthesize the binuclear complexes, it has been observed that in certain cases the 
integration of peaks associated with the thiosemicarbazone protons account for only one unit. 






H} NMR spectroscopy  
The thiolate carbon resonates as a singlet at ca. δ 167.0, with the imine carbon being 
observed as a singlet at ca. δ 165.5. The aromatic carbons of the thiosemicarbazone unit are 
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singlets at ca. δ 150.0 for the carbons Cj and Ck. For compound 13 the Cl carbon is observed 
at δ 146.5, while Cl is observed at δ 133.6 for compounds 14 and 15.   
The carbon of the ethylene bridge, Cm, of compound 15 is observed as a singlet at δ 131.1. 
The methyl group of the thiosemicarbazone unit is observed at ca. δ 14.0 for compounds 13-













13 149.6 (s, Cj & Ck); 146.5 (s, Cl). 
164.0 (s, Ca); 149.1 (s, Cf); 132.8 (s, 
Cc); 125.8 (s, Cd); 126.6 (s, Ce); 
124.4 (s, Cb). 
14 151.1 (s, Cj & Ck); 133.6 (s, Cl).  
164.8 (s, Ca); 150.4 (s, Cf); 129.7 (s, 
Cc); 126.5 (s, Cd); 126.4 (s, Ce); 
121.8 (s, Cb). 
15 
150.7 (s, Cj & Ck); 133.6 (s, Cl); 
131.1 (s, Cm). 
164.8 (s, Ca); 150.4 (s, Cf); 129.7 (s, 
Cc); 126.5 (s, Cd); 126.4 (s, Ce); 
121.8 (s, Cb). 
  
Infrared (IR) spectroscopy 
The absorption band for the imine bonds in the tetranuclear complex is observed at 1600 cm
-1
 
(Table 2.6). As the nitrogen of the 4-picoline binds to palladium, the absorption band 
associated with the pyridyl imine bond shifts to higher wavenumbers. For compound 13, the 
absorption bands shifted to 1568 and 1617 cm
-1
 while the C=N bond in 4-picoline is observed 
at 1559 cm
-1
. The absorption band associated with the imine bond, whose nitrogen chelated to 
the palladium, is observed at the lower wavenumber (1568 cm
-1
).   
 






13 1617, 1568, 1559 
14 1643, 1624, 1594 
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When the pyridyl nitrogen binds to the metal, there is delocalisation of electron density 
throughout the complex. Therefore less electron density is situated on the imine bonds in the 
cyclopalladated unit. For compounds 14 and 15, the absorption band for the imine bond 
directly attached to the metal shift to lower wavenumber (1594 and 1596 cm
-1
 respectively). 
On the other hand the absorption band for the second C=N bond as well as the pyridyl imine 
bond shifts to higher wavenumbers (Table 2.18).  
 
Mass Spectrometry        
The EI
+
-mass spectrum was generated for compound 13, whist the ESI
+
-mass spectra were 
recorded for 14 and 15. 
 
A peak in the mass spectrum of compound 13 is observed at m/z 459 (2.2 %), which 
corresponds to the [M]
+
 ion. In the mass spectrum of compound 14, a peak is observed at m/z 
409 (100 %) which corresponds to the [M-2Cl]
2+
 ion. For compound 15, the peak which 
corresponds to the molecular ion and the [M+H]
+
 ion is observed at m/z 915 (4 %) and 916 (5 
%) respectively.   
 
2.3. Summary    
Monothiosemicarbazone (1 and 2), iminophosphine (3 and 5) and aminophosphine (4 and 6) 
ligands have been synthesized and characterized. The monothiosemicarbazone ligands were 
reacted with palladium salts (K2[PdCl4] or Na2[PdCl4]) to form the cyclopalladated 
tetranuclear complexes (7 and 8), where the thiosemicarbazones (1-2) chelate in a C,N,S-
mode. In turn, these tetranuclear complexes were reacted with P-donor ligands, which 
includes the aminophosphine ligands (4 and 6), and N-donor ligands to yield homometallic 
mono- (9-11, 13) and binuclear (12, 14 and 15) cyclopalladated complexes. The complexes 
containing the P-donor ligands were synthesized more readily than those containing the N-
donor ligands, where reactions occurred more sluggishly and required harsher conditions. 
Molecular structures of compounds 7 and 10 and 11 were determined, and found to have a 
slightly distorted square planar geometry. The molecular structures confirmed that the P-
donor ligands PTA and the aminophosphine ligand 4 are positioned in the fourth site of the 
metal, and coordinates via the phosphorus atom.  Therefore, cyclopalladated complexes with 
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The synthesis and characterization of ferrocenyl-derived N,S-chelated 
thiosemicarbazone  ruthenium(II) and palladium(II) complexes 
 
3.1. Introduction          
Ferroquine, an analogue of chloroquine which has a ferrocenyl moiety incorporated into the 
side chain, has exhibited better activity than chloroquine and against chloroquine-resistant 
strains of malaria.
1
 Therefore, with the medicinal success of ferroquine, a variety of 
compounds containing the ferrocenyl moiety have been synthesized.
1-6
 Organic antimalarial 
drugs such as mefloquine have also been modified with the incorporation of a ferrocenyl 
moiety to determine if this will also result in an enhancement of activity.
6-9
 However, despite 
activity displayed by these compounds, none have shown better activity than ferroquine.   
 
Structure-activity relationship studies have been carried out on ferroquine to determine the 
significance of the various components.
10
 The hydrophobic nature of the ferrocenyl moiety is 
believed to assist with the lipophilicity of the compound while iron is able to undergo 
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As stated above and seen in Chapter 1, a variety of compounds containing a ferrocenyl 
moiety have been synthesized. The ferrocenyl moiety was coupled with other active moieties 
such as trioxanes, chalcones and thiosemicarbazones.
1,12-16
 In this chapter, ferrocenyl-derived 
complexes were synthesized and chelated in a N,S bidentate mode in an effort to utilize the 
properties of the ferrocenyl moiety.  
 
3.2. Results and discussion     
3.2.1. The synthesis and characterization of ferrocenyl-derived thiosemicarbazones (16, 
18) 
The monomeric ferrocenylthiosemicarbazone 16 was synthesized via a Schiff base 
condensation reaction between ferrocenecarboxaldehyde and thiosemicarbazide in either 
water or ethanol (Scheme 3.1).
17-18
 The dithiosemicarbazide (17) was synthesized from the 
reaction of hydrazine hydrate with 1,4-phenyldiisothiocyanate.
12
 The dithiosemicarbazide 
was reacted with two equivalents of ferrocenecarboxaldehyde in a Schiff base condensation 




























































Scheme 3.1: The synthesis of the monomeric ferrocenylthiosemicarbazone (16) and the dimeric 
ferrocenyldithiosemicarbazone (18).  
 
Physical properties 
Compounds 16-18 were isolated as powders in relatively high yields (Table 3.1). Compound 
17 melts between 197.2-198.6 ˚C and compounds 16 and 18 decompose without melting 
(Table 3.1). Compound 16 is soluble in organic solvents such as dichloromethane, ethanol, 
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organic solvents, with the exception of dimethyl sulfoxide. Compound 18 is soluble in 
dimethyl sulfoxide, and is partially soluble in organic solvents such as tetrahydrofuran, 
chloroform, acetone and ethyl acetate.    
 
Table 3.1: Physical appearance, melting point and yield of compounds 16-18 
Compound 
number 
Yield (%) Physical Appearance Melting point (˚C) 
16 85 Orange powder 
Decomp. w/o melting 
150.4 
17 84 White powder 197.2-198.6 
18 86 Reddish-brown powder 
Decomp. w/o melting 
208.1 
 
The NMR spectra were recorded using DMSO-d6.  
 
1
H NMR spectroscopy 
Formation of the ferrocenyl-derived compounds 16 and 18 is confirmed by the presence of a 
singlet at ca. δ 7.95, which corresponds to the imine proton He. The protons of the ferrocenyl 
moiety resonate in the range δ 4.18-4.84 (Table 3.2). For compound 16, the adjacent Hc and 
Hd protons resonate as triplets (J = 1.60 Hz, see appendix, pg. 134) due to three bond 






H NMR spectrum of 18, the singlet at δ 7.59 corresponds to the aromatic spacer which 
is observed slightly downfield from δ 7.54 for compound 17.  
 
For compounds 16 and 18, the hydrazinic proton is observed as a singlet at ca. δ 11.3 whilst 
two singlets are observed at δ 7.55 and 7.96 for the primary amine protons of compound 16. 
The observation of two singlets, accounting for one proton each, has been reported for similar 
compounds.
13,19-21
 The restricted rotation of the amino group about the C-N axis results in the 





The peak for the secondary amine protons of 18, which are located adjacent to the aromatic 
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whereby the ferrocenyl moiety has a deshielding effect on the rest of the compound. The 










(ppm,  J = Hz) 
16 7.88 (s) 4.18 (s, Ha); 4.39 (t, J = 1.60, Hd); 4.71 (t, J = 1.60, Hc). 
17 - 7.54 (s, Hf).  










H} NMR spectra of compounds 16 and 18, the imine carbo  resonates at ca. δ 
143.6 (Table 3.3). The thiolate carbon of compound 16 resonates at δ 176.9 whereas the peak 
in the spectrum of 18 shifted upfield from δ 179.4 (17) to 174.4 upon formation of the 
dithiosemicarbazone. The carbons of the ferrocenyl moiety resonate in the range δ 67.5-69.9 
with the quaternary carbon (Cb) of the ferrocenyl moiety observed at ca. δ 78.6 (Table 3.3).  
 
The carbons of the aromatic spacer in compounds 17 and 18 are observed as a singlet due to a 
two-fold symmetry axis. The quaternary carbon is observed at ca. δ 135.5 for 17 and 18, 
whilst the peak for the remaining aromatic carbons (Cj) shifts slightly downfield in the 
13
C 















16 176.9 (s) 143.3 (s) 
67.5 (s, Cc); 68.8 (s, Ca); 69.9 (s, Cd); 
78.8 (s, Cb). 
17 179.4 (s) - 123.2 (s, Cf); 135.4 (s, Ce). 
18 174.4 (s) 143.9 (s) 
67.6 (s, Cc); 68.7 (s, Ca); 69.9 (s, Cd); 
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Infrared (IR) spectroscopy    
In the IR spectra of compounds 16-18, absorption bands observed in the range 3154 - 3440 
cm
-1
 correspond to the stretching vibrations of both the primary (16 and 17) and secondary 
amine (16-18) functionalities.    
 
Table 3.4: The absorption bands observed in the IR spectra of compounds 16-18 
Compound number C=N ν (cm
-1
) C=S ν (cm
-1
) 
16 1599 818 
17 - 821 
18 1600 831 
 
Compounds 16 and 18 contain imine bonds whose absorption bands are observed at 1599 and 
1600 cm
-1
 respectively. The C=N stretchings are typically observed in this region.
22
 
Compounds 16-18 contain C=S bonds whose absorption bands are observed between 818-
831 cm
-1
 (Table 3.4). As compound 18 is formed from 17, the C=S absorption band shifts to 
a higher wavenumber. Due to the deshielding effect of the ferrocenyl moiety, electron density 
is drawn from the C=S bond resulting in a longer bond.  
 
Mass spectrometry 
The molecular ion peaks for compounds 16 and 17 were observed at m/z 287 (100 %) and 
256 (23 %) respectively. A peak corresponding to the [M+H]
+
 ion is observed at m/z 649 
(100 %) for 18.  
 
3.2.2. The synthesis and characterization of N,S-chelating thiosemicarbazone  
ruthenium(II)-arene complexes  
a. Heterobimetallic binuclear N,S-chelated thiosemicarbazone ruthenium(II)-arene 
complexes (22-24) 
The ruthenium(II)-arene dimers (19-21), in which the arenes were p-cymene, benzene or 
phenoxyethanol rings, were synthesized following literature methods.
23-25
 The ruthenium(II)-
arene dimers (19-21) were subsequently reacted with two equivalents of the 
ferrocenylthiosemicarbazone (16) in either dichloromethane or methanol (Scheme 3.2). The 
Ru-Clbridging bond is displaced upon chelation of compound 16 to form the desired cationic 
Ru(II)-arene complexes (22-24). Compounds 22 and 23 were stable as the chloride salts. 
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stability of a compound becomes problematic, increasing the size of the counter-ion enhances 
stability of the compound.
26
 Therefore, in the case of compound 24 an anion metathesis using 
sodium hexafluorophosphate, resulting in the chloride counter-ion being exchanged to 
























22 (Ar = 19), X = Cl
23 (Ar = 20), X = Cl

















Scheme 3.2: The synthesis of binuclear ruthenium(II)-arene complexes (22-24) 
 
Physical properties 
Compounds 22-24 were isolated as powders in moderate to high yields. The compounds 
decompose without melting (Table 3.5). Compounds 22-24 are soluble in methanol and 
dimethyl sulfoxide. Compound 22 is also soluble in most organic solvents. The compounds 
are partially soluble in water. 
 
Table 3.5: Physical appearance, melting point and yield of complexes 22-24 
Compound 
number 
Yield (%) Physical Appearance Melting point (˚C) 
22 92 Reddish-brown powder 
Decomp. w/o melting 
162.1 
23 67 Orange powder 
Decomp. w/o melting 
155.1 
24 69 Orange powder 
Decomp. w/o melting 
173.8 
 






P NMR, 2D (COSY, 
HSQC) NMR, IR spectroscopy and mass spectrometry.  
 
1
H NMR spectroscopy  
The 
1
H NMR spectrum of 22 was recorded in acetone-d6 and the spectra of 23 and 24 were 
recorded in methanol-d4. Upon coordination of ruthenium to compound 16, the expected 
downfield shift of the peak associated with the imine proton is observed at ca. δ 8.60 in the 
1
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A singlet corresponding to the Ha protons is observed at ca. δ 4.25 for 22-24. In the 
1
H NMR 
spectra, one proton in the c-position of the ferrocenyl moiety is observed at ca. δ 6.04, which 
is significantly downfield from the other ferrocenyl protons, particularly the remaining Hc 
proton (see appendix, pg. 135). Due to the orientation of the ferrocenyl moiety with respect to 
the rest of the complex, one proton in the c-position experiences through space coupling with 
the imine proton resulting in the proton being more deshielded. For compound 22, the Hd 
protons and the remaining Hc proton, resonates at δ 4.64 and 4.84 respectively. However, for 
23 and 24 the Hc and Hd protons overlapped with the water peak, which was confirmed using 
2D (COSY) NMR. 
 
The amine protons of compounds 23 and 24 and the hydrazinic protons of compound 22 are 
not observed due to exchange with the deuterated solvent. However, the primary amine 











(ppm,  J = Hz) 
Arene protons 
(ppm,  J = Hz) 
22 8.74 (br s) 
4.21 (s, Ha); 
4.64 (m, Hd); 
4.84, 6.02 (br s, 
Hc). 
1.01 (d, J = 6.80, Hg); 1.06 (d, J = 
6.96, Hk); 1.99 (s, Hh); 2.57 (m, HAr); 
5.14 (d, J = 5.84, HAr); 5.25 (d, J = 
5.60, HAr); 5.31 (d, J = 5.60, HAr); 
5.60 (d, J = 5.84, HAr). 
23 8.48 (s) 
4.30 (s, Ha); 
6.06 (br s, Hc). 
3.87 (m, Hg); 4.15 (m, Hh); 5.11 (t, J = 
5.31, Hl); 5.26 (d, J = 6.41, Hj); 5.30 
(d, J = 6.04, Hn); 5.72 (t, J = 5.95, Hk); 
5.82 (t, J = 5.68, Hm). 
24 8.50 (s) 
4.34 (s, Ha); 
6.08 (s, Hc). 
5.69 (s, Hbenzene). 
 
Another approach to confirming chelation of compound 16 to yield 22 and 23 lies in the 
splitting of the aromatic protons of the arene ring. Due to the stereogenic nature of the 
ruthenium centre, which has four different substituents coordinated to itself, these complexes 















PrC6H4CH3 ring is considered). However, upon formation of 22, the characteristic 
four doublets are observed between δ 5.14-5.60, which accounts for each proton.
27
 As seen 
with 22, upon formation of compound 23 the three triplets observed in the 
1
H NMR spectrum 
of 20 split further into triplets for Hk-m, and doublets for Hj and Hn (Table 3.6). This splitting 
is due to three bond coupling with adjacent aromatic protons. However, for compound 24, the 
aromatic protons of the benzene arene are equivalent, and thus a singlet is observed at δ 5.69.  
 
For 22, the isopropyl methyl groups (Hg) are observed as two doublets at δ 1.01 and 1.06 with 
a coupling constant of δ 6.80 and 6.96 Hz respectively. The singlet observed at δ 1.99 
corresponds to the other methyl group (Hk).
27
 This is indicative of the diastereotopic character 










H} NMR spectra of compounds 22-24 were recorded using MeOD-d4. 
In the 
13
C NMR spectra of 22-24, the thione carbon is observed at ca. δ 178.7, whilst the 
imine carbon resonates at ca. δ 163.6. The arene quaternary carbons Ci and Cj are observed at 















22 178.7 (s) 163.1 (s) 
18.7 (s, Ck); 21.8, 22.9 (s, Cg); 32.1 (s, 
Ch); 83.9 (s, CAr); 85.5 (s, CAr); 89.2 (s, 
CAr); 90.1 (s, CAr). 
23 178.8 (s) 163.6 (s) 
61.0 (s, Cg); 66.1 (s, Cj); 70.0 (s, Cn); 
72.8 (s, Ch); 76.7 (s, Cl); 93.2 (s, Ck); 
93.4 (s, Cm).  
24 178.7 (s) 164.0 (s) 88.6 (s, CAr). 
 
The carbons corresponding to the ferrocenyl moiety are observed in the range δ 71.0-77.8. In 
the 
1
H NMR spectroscopy section above, it was mentioned that one of the Hc protons is 
shifted significantly downfield when compared to the other. This is also observed in the 
13
C 
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The quaternary Cb carbon is the most deshielded and is observed as a singlet at ca. δ 77.4. 




C NMR spectra of 22-24, the aromatic carbons of the arene ring resonate as singlets 
in the range δ 66.1-93.4 (Table 3.7). Only one signal is observed at δ 88.6 for the benzene 
arene of compound 24. For 22, the carbons of the methyl and isopropyl group resonate as 
singlets in the aliphatic region δ 18.7-32.1. The observation that the two methyl groups of the 
isopropyl group are different is once again confirmed as two peaks are seen in the 
13
C NMR 
spectrum.        
 
31
P NMR spectroscopy 
A septet is observed at δ -144.6 in the 
31
P NMR spectrum of 24 which corresponds to the 
hexafluorophosphate counter-ion. This confirms that an exchange of the counter-ion 
occurred.  
 
Infrared (IR) spectroscopy    
In the IR spectra, the absorption bands corresponding to the amine (N-H) stretchings (22-24) 
and the hydroxyl (O-H) stretching (23) are observed between 3435-3064 cm
-1
. As seen in the 
IR spectra of similar cationic complexes upon chelation of 16, there is a shift of both the C=N 
and the C=S absorption bands to higher wavenumbers (Table 3.8).
27
 This is as a result of less 
electron-density being localized on the C=N and C=S bonds due to a more electron-deficient 
metal centre. 
 
Table 3.8: The absorption bands observed in the IR spectra for compounds 22-24 
Compound number C=N ν (cm
-1
) C=S ν (cm
-1
) 
22 1615 824 
23 1615 833 
24 1617 843 
 
Mass spectrometry 
In the case of these complexes, M refers to the cationic portion (excluding the counter-ion). 
The ESI
+
-mass spectra for compounds 22-24  displayed a base peak at m/z 522, 526 and 466 
respectively, which corresponds to the [M-Cl]
+
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b. Heterobimetallic tetranuclear N,S-chelated thiosemicarbazone ruthenium(II)-arene 
complexes (25, 26) 
The tetranuclear ruthenium(II)-arene complexes (25 and 26) were synthesized by reacting the 
ferrocenyldithiosemicarbazone (18) with the ruthenium(II)-dimers (19 and 20) in a methanol: 
dichloromethane mixture (Scheme 3.3). Attempts were made to synthesize the complex 
containing the benzene ring, but efforts to fully characterize this complex were unsuccessful, 
as the complex was not air-stable. These complexes were synthesized as higher nuclearity 
versions of complexes 22-24. However, over a short period of time these complexes 




















































25 (Ar = 19) 











Scheme 3.3: The synthesis of tetranuclear Ru(II)-arene thiosemicarbazone complexes (25, 26). 
  






P NMR, 2D (COSY, 




Physical properties  
Compounds 25 and 26 were isolated as powders in moderate to high yields (Table 3.9). 
Compound 25 is soluble in acetone whereas 25 and 26 is partially soluble in organic solvents 
such as chloroform, tetrahydrofuran and ethanol. 
 
Table 3.9: Physical appearance and yields for complexes 25 and 26 
Compound 
number 
Yield (%) Physical Appearance Melting point (˚C) 
25 64 Dark red powder Decomp. w/o melt 
167.1 
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H NMR spectroscopy  
For compounds 25 and 26 the imine proton resonates at ca. δ 8.76, which is downfield 
relative to the free compound (ca. δ 8.60). In the 
1
H NMR spectrum of 25, the hydrazinic and 
secondary amine protons are observed as broad signals at δ 10.4 and 9.14 respectively. These 
protons are not observed for 26 due to solvent exchange in deuterated methanol. The 
aromatic protons of the rigid aromatic spacer are observed as a broad signal at ca. δ 7.54 for 










(ppm,  J = Hz) 
Arene protons 
(ppm,  J = Hz) 
25 
8.81 (br s) 4.33 (m, Ha); 4.77 (d, J = 
7.69, Hd); 4.86 (br s, Hc); 
6.16 (d, J = 8.06, Hc). 
1.14 (m, Hk); 1.20 (m, Hk); 1.99 (s, 
Ho); 2.70 (m, Hl); 5.31 (br s, HAr); 
5.44 (m, HAr); 5.78 (d, J = 6.23, HAr). 
26 
8.71 (s) 4.36 (m, Ha); 6.12 (br s, 
Hc). 
3.87 (m, Hk); 4.15 (m, Hl); 5.18 (t, J 
= 5.70, Hp); 5.31 (d, J = 6.00, Hn); 
5.35 (d, J = 6.22, Hr); 5.78 (t, J = 
6.00, Ho); 5.88 (t, J = 6.00, Hq). 
 
As mentioned in Section 3.2.2.a., these complexes are chiral with ruthenium being a 
stereogenic centre. Due to the presence of two stereogenic centres, the product could result in 
a compound with four (2
2
) different orientations. As a result of this, there is a loss of the two-




H NMR spectra of 25 and 26, a multiplet is observed around δ 4.34 for the Ha protons. 
As observed for 22-24, one proton in the c-position of the ferrocenyl moiety is observed at 
ca. δ 6.14 whilst the remaining Hc and Hd protons of compound 25 are observed at δ 4.86 and 
4.77 respectively. The Hc and Hd protons of 26 overlap with the water peak, and their 
positions are confirmed using 2D (COSY) NMR. The isopropyl methyl groups (Hk) of 25 are 
observed as multiplets at δ 1.14 and 1.20, whilst the other methyl group (Ho) is observed as a 
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For compound 26, the aromatic protons of the arene ring are observed as triplets for Ho-q, and 
doublets for Hn and Hr (Table 3.10). The coupling constant of ca. 5.96 Hz suggests that the 






H} NMR spectroscopy              
Due to the poor solubility of compound 26, even in dimethyl sulfoxide, the compound could 
not be characterized using 
13
C NMR. In the 
13
C NMR spectrum of 25, the imine and thione 
carbons resonate at δ 164.2 and 176.6 respectively. As observed for compound 22, the 
aliphatic carbons of the p-cymene ring resonate in the aliphatic region of the 
13
C NMR 
spectrum in the range δ 18.8-31.7 (Table 3.11).  
 
The quaternary carbons Ci, Cm and Cn resonate as singlets at δ 136.9, 104.3 and 103.7, and 
the aromatic carbons of the p-cymene ring are observed in the range δ 84.1-89.9. However, 
upon formation of 25, the carbons of the aromatic spacer are observed in the range δ 126.4-
126.6, suggesting a loss of the two-fold symmetry seen for 18. The ferrocenyl carbons 
resonate as singlets in the range δ 71.2-78.0 where the quaternary Cb carbon is observed as 















25 176.6 (s) 164.2 (s) 
18.8 (s, Co); 22.1, 23.1 (s, Ck); 31.7 (s, 
Cl); 84.1 (s, CAr); 85.4 (s, CAr); 89.2 (s, 




P NMR spectroscopy 
The observation of a septet at δ -144.2 and -144.6 in the 
31
P NMR spectra of compounds 25 
and 26 which correspond to the hexafluorophosphate counter-ion, confirms counter-ion 
exchange.   
 
Infrared (IR) spectroscopy    
Upon complexation, the C=N stretching bands of 25 and 26 are observed at 1611 cm
-1
, whilst 
the C=S stretching bands are observed at 841 cm
-1
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found at higher wavenumbers when compared to 18 (Table 3.4). This is an expected 
observation when considering cationic complexes. A more electron-deficient metal centre 
leads to less electron-density localized on the C=N and C=S bonds resulting in the 
absorptions bands shifting to a higher wavenumber. The absorption bands corresponding to 




Table 3.12: The absorption bands observed in the IR spectra of compounds 25 and 26 
Compound number C=N ν (cm
-1
) C=S ν (cm
-1
) 
25 1611 841 





-mass spectra of compounds 25 and 26, the [M-Cl]
2+
 peaks are observed at m/z 
559 (100 %) and 563 (70 %) respectively. 
 
There is evidence for the complex containing the benzene arene in the ESI
+
-mass spectrum of 




 ions are observed at m/z 1041 (3 %) and 503 
(100 %) respectively.     
 
3.2.3. The synthesis and characterization of N,S-chelated thiosemicarbazone 
palladium(II) complexes containing P-donor ligands 
a. Heterobimetallic binuclear N,S-chelated thiosemicarbazone palladium(II) complexes 
(28, 29) 
Attempts were made to synthesize the [Pd(ferrocenylthiosemicarbazone)]4 complex described 
by Mariño et al., in which compound 16 was reacted with potassium tetrachloropalladate in a 
water-ethanol mixture.
17
 However, analysis of the solid suggests the synthesis of a chloro-
bridged complex, [Pd(ferrocenylthiosemicarbazone)(μ-Cl)]2 (27). As explained in Chapter 2 
section 2.1., C-H activation is more likely to occur if an alkyl substituent is present on the 
imine carbon, forcing the compound into a geometry which allows cyclometalation to take 
place.
8
 Attempts to prepare compound 27 using Na2[PdCl4] under the same conditions were 
unsuccessful as only a decomposed solid was collected. Binuclear palladium(II) complexes 
(28 and 29) were prepared by reacting 27 with P-donor ligands PTA and triphenylphosphine 



















28: L = PTA
29: L = PPh3
2 L




























Scheme 3.4: The synthesis of binuclear ferrocenylthiosemicarbazone palladium(II) complexes containing P-
donor ligands (28, 29).   
 
Physical properties  
Compound 27 was isolated as a reddish-brown powder with a yield of 47 %. Compounds 28 
and 29 were isolated in moderate yields as reddish-orange and red powders respectively 
(Table 3.13). Compound 27 is only soluble in dimethyl sulfoxide. Compounds 28 and 29 are 
soluble in dimethyl sulfoxide, chloroform and tetrahydrofuran. The onset of decomposition 
for compounds 28 and 29 occurs at 241.3 and 164.7 ˚C respectively.  
 
Table 3.13: Physical appearance, melting point and yield of the compounds (27-29) 
Compound number Yield (%) Physical Appearance Melting point (˚C) 
27 47 Reddish-brown powder - 
28 54 Reddish-orange powder 
Decomp. w/o melting 
241.3 
29 75 Red powder 
Decomp. with melting 
164.7 
 
The NMR spectra of compounds 27-29 were recorded using DMSO-d6. 
 
1
H NMR spectroscopy          
In the 
1
H NMR spectra for compound 27, the peak observed at δ 7.44 corresponds to the 
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corresponding to the imine proton is observed as a doublet at δ 7.87 (see appendix, pg. 136), 
and for 29 the peak is observed at δ 8.14. The proton experiences a four bond coupling (J = 
ca. 4.00 Hz) with the phosphorus of the P-donor ligand. The terminal amine protons are 
observed as a broad signal at δ 6.91 in the 
1
H NMR spectrum of 27 whilst a broad signal is 
observed at ca. δ 6.80 for 28 and 29.  
 
The ferrocenyl protons Ha are observed at ca. δ 4.20 whereas the Hd protons (27 and 29) are 
observed as a triplet (
3
JHH = 1.60 Hz) at ca. δ 4.54. For 27-29, the Hc protons are observed as 
a triplet (
3









(ppm,   
J = Hz) 
PCH2N 




(ppm,  J = Hz) 
Aromatic protons 





4.22 (s, Ha); 4.56 (t, 
3
JHH = 
1.60 Hz, Hd); 5.04 (t, 
3
JHH = 
1.60 Hz, Hc). 
28 
7.87 (d,  




J = 13.0); 
4.54 (m), overlap 
with Hd.  
4.17 (s, Ha); 5.07 (t, J = 
1.60, Hc). 
29 
8.14 (d,  
J = 4.00) 
- - 
4.22 (s, Ha); 4.53 (t, J = 
1.60, Hd); 5.08 (t, J = 1.60, 




H NMR spectrum of compound 28, a similar splitting is observed as seen with other 
palladium complexes containing PTA.
28
 The PCH2N protons are observed as a singlet at δ 
4.32 whilst the NCH2N protons split into an AB spin system. Two doublets are observed due 
to the different environments experienced by the axial and equatorial NCH2N protons (Table 
3.14). The doublet observed at δ 4.38 corresponds to the NCH2(ax)N protons, whilst the peak 
observed at δ 4.54 corresponds to the NCH2(eq)N as well as the Hd protons. For compound 29, 
the phenyl protons of the triphenylphosphine ligand are observed as a multiplet between δ 



















H} NMR spectroscopy                
In the 
13
C NMR spectrum of 27, the thiolate carbon resonates at δ 169.9. For compounds 28 
and 29, a doublet is observed in the 
13
C NMR spectra at ca. δ 171.9, which corresponds to the 
thiolate carbon as a result of three bond coupling with phosphorus. The imine carbon of 27 
resonates at δ 155.2 and shifts slightly upfield to δ 151.6 and 152.7 for 28 and 29 
respectively.  
 
The quaternary carbon Cb resonates as a singlet at δ 73.2 for 27. For the ferrocenyl carbons of 
28 and 29, the quaternary Cb carbon resonates as a doublet (J ~ 4.72 Hz) at ca. δ 73.7, and 
experiences four bond coupling with phosphorus. The remaining ferrocenyl carbons of 27-29 










(ppm,   
J = Hz) 
C=N 
(ppm,   
J = Hz) 
NCH2N 
(ppm,   
J = Hz) 
PCH2N 
(ppm,   
J = Hz) 
Aromatic carbons 
(ppm, J = Hz)  
27 169.9 (s) 155.2 (s) - - 73.2 (s, Cb) 
28 




J = 8.08) 
51.6 (d, 
J = 17.5) 
73.8 (d, J = 4.71, 
Cb) 
29 
171.6 (d, J 
= 11.5) 
152.7 (s) - - 
73.7 (d, J = 4.73, 
Cb) 
 
As observed with other PTA containing complexes, the PTA carbons of 28 resonate as 
doublets due to coupling with phosphorus. The NCH2N carbons are observed at δ 71.8, while 
the PCH2N carbons are observed at δ 51.6 (Table 3.15). For compound 29, the phenyl 
carbons are observed in the range δ 128.2-133.9.   
 
31
P NMR spectroscopy 
A peak for free PTA and triphenylphosphine is observed at δ -104.0 and -6.60 respectively.  
However, upon formation of the complex a peak is observed downfield at δ -33.5 and 27.6 
for 28 and 29 respectively.  
 
Infrared (IR) spectroscopy    
In the IR spectrum of compound 27, the strong and broad absorption band observed at 1602 
cm
-1
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are observed in the range 1592-1614 cm
-1
, which corresponds to the two imine bonds. As 
observed with other palladium complexes (Chapter 2, Section 2.2.4.a.), upon coordination of 
the P-donor ligand, the absorption band corresponding to the imine bond directly coordinated 
to the metal shifts to a lower wavenumber, while the second absorption band is observed at a 
higher wavenumber. 
 
Table 3.16: The absorption bands observed in the IR spectra of compounds 27-29 




28 1614, 1598 
29 1607, 1592 
 
Mass spectrometry    
The mass spectra of 27 and 29 were recorded using electrospray ionisation, whilst the EI
+
-
mass spectrum of 28 was recorded.  
   
For compound 27, the peak observed at m/z 854 (5 %) refers to the molecular ion peak [M]
+
 





observed at m/z 585 (6.7 %) and 654 (100 %) respectively.   
 
Molecular structure of complex 28 
Single crystals of compound 28 were obtained by the slow evaporation of a solution of 28 
dissolved in ethyl acetate/hexane and the molecular structure was determined by single-
crystal X-ray diffraction. The molecular structure of 28 is shown in Fig. 3.2 and Table 3.17 
lists selected bond lengths and angles. The crystallographic data is given in Table 3.18. 
Compound 28 crystallizes in a monoclinic system with space group P21/n. The 
ferrocenylthiosemicarbazone compound chelates to the palladium(II) ion in a bidentate N,S- 
mode to form the observed 5-membered ring (Fig. 3.2).
29-30
 The fourth coordination site on 














Figure 3.2: The molecular structure of compound 28. 
 
Palladium(II) complexes are generally square planar complexes, and therefore due to the 
environment around the palladium centre where the sum of the acute and obtuse bond angles 
deviates from 720˚ by approximately 12˚, compound 28 has a slightly distorted square planar 





Table 3.17: Selected bond lengths (Å) and angles (˚) for compound 28. 
Bond lengths Bond angles 
Pd(1)-N(1) 2.090(2) N(1)-Pd(1)-Cl(1) 96.69(8) 
Pd(1)-Cl(1) 2.3489(9) N(1)-Pd(1)-S(1) 83.68(8) 
Pd(1)-P(1) 2.2213(8) Cl(1)-Pd(1)-P(1) 89.41(3) 
Pd(1)-S(1) 2.2466(8) P(1)-Pd(1)-S(1) 89.93(3) 
S(1)-C(1) 1.752(3) Cl(1)-Pd(1)-S(1) 176.41(3) 
N(2)-C(1) 1.306(4) N(1)-Pd(1)-P(1) 172.20(8) 
N(1)-C(8) 1.296(4)   
 
As observed with compounds 10 and 11 (Chapter 2, Section 2.2.4.a.), the lengths of the two 
imine bonds are different, with the imine coordinated to the metal being slightly shorter than 
the other. The S(1)-C(1) bond has a length of 1.752(3) Å, which is equivalent to a single 
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Table 3.18: Crystal data and structure refinement data for compound 28 
Empirical formula C18H24ClFeN6PPdS   
Formula weight 585.16 
Temperature (K) 173(2)  
Wavelength (Å) 0.71073  
Crystal system Monoclinic 
Space group P21/n 
a (Å) 7.0423(3)  
b (Å) 25.1284(6)    
c (Å) 12.5604(5)   
α (˚) 90                
β (˚) 90.041(2) 
γ (˚) 90 
V (Å
3











) 0.04 x 0.10 x 0.11 
θ Range for data collection (˚) 3.2- 26.4   
Index range -8 ≤ h ≤ 8; -31 ≤ k ≤ 31; -15 ≤ l ≤ 15  
Reflections collected 48765 
Independent reflections [R(int)] 4527 [0.055] 
Data / restraints / parameters     4527 / 2 / 270 
Goodness-of-fit on F
2
             1.051 
Transmission         0.9094, 0.8857 
Final R indices [I>2σ(I)]      R1 = 0.0306, wR2 = 0.0808 
R indices (all data)               R1 = 0.0432, wR2 = 0.0850 
Largest difference in peak and hole (e. Å 
-3
)  -0.91 and 1.60 
 
b. Heterobimetallic tetra- and pentanuclear N,S-chelated thiosemicarbazone 
palladium(II) complexes containing P-donor ligands (30-32) 
Polynuclear palladium(II) complexes were synthesized by either reacting 27 with a dimeric 
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ligands. The pentanuclear complex (30) was synthesized by reacting 
[Pd(ferrocenylthiosemicarbazone)(μ-Cl)]2 (27) with 1,1'-bis(diphenylphosphino)ferrocene 
(dppf) in acetone (Scheme 3.5).
17
 With the incorporation of dppf, an additional ferrocenyl 
moiety may contribute to the antiplasmodial activity.  
 
The tetranuclear palladium(II) complexes 31 and 32 were synthesized by reacting 
ferrocenyldithiosemicarbazone (18) with two equivalents of the palladium-precursor, 
PdCl2(PTA)2 and PdCl2(PPh3)2 respectively, in an ethanol:acetone  mixture. Compounds 31 
and 32 were synthesized to allow comparison with compounds 28 and 29, which contains 
only one ferrocenyl moiety and P-donor ligand. The Pd-precursors, PdCl2(PTA)2 and 












































































31: L = PTA
32: L = PPh3
2
L = PTA or PPh3
L
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Physical properties    
Compound 30 was isolated as an orange powder whilst 31 and 32 were isolated as reddish-
orange powders in moderate to high yield (Table 3.19). Compounds 30-32 decompose 
without melting with the onset of decomposition occurring at 200.0, 218.3 and 237.2 ˚C 
respectively. Compounds 30-32 are soluble in dimethyl sulfoxide, while 30 and 32 are also 
soluble in chloroform, dichloromethane and tetrahydrofuran.       
 
Table 3.19: Physical appearance, melting point and yield of the compounds 30-32 
Compound number Yield (%) Physical Appearance Melting point (˚C) 
30 78 Orange powder 
Decomp. w/o melting 
200.0 
31 99 Reddish-orange powder 
Decomp. w/o melting 
218.3 
32 70 Reddish-orange powder 
Decomp. w/o melting 
237.2  
 
The NMR spectra of compounds 30-32 were recorded using DMSO-d6. 
 
1
H NMR spectroscopy  
In the 
1
H NMR spectra of compounds 30-32, the peak corresponding to the imine proton is 
observed as a doublet at ca. δ 8.24. The proton experiences a four bond coupling, with a 








(ppm,   
J = Hz) 
PCH2N 
(ppm,   
J = Hz) 
N-CH2(ax)-N 
N-CH2(eq)-N 
(ppm,  J = Hz) 
Aromatic protons 
(ppm,  J = Hz) 
30 8.19 (d, 
J = 4.03) 
- - 
4.14 (s, Ha); 4.51 (br s, Hi); 
4.87 (br s, Hd); 5.07 (br s, 
Hh); 5.18 (br s, Hc); 7.47-7.87 
(m, HPh).  
31 8.14 (d, 
J = 4.00) 
4.38 (s) 
4.41 (d, J = 13.4) 
4.58 (d, J = 12.8) 
4.19 (s, Ha); 4.52 (br s, Hd); 
5.01 (br s, Hc); 7.59 (s, Hi).  
32 8.39 (d, 
J = 4.00) 
- - 
4.22 (s, Ha); 4.52 (br s, Hd); 

















H NMR spectrum of compound 31, similar splitting is observed as seen with other 
palladium complexes containing PTA.
28
 The PCH2N protons are observed as a singlet at δ 
4.38 whilst the NCH2N protons are split into two doublets due to an AB spin system (Table 
3.20). The doublets corresponding to the NCH2(ax)N and NCH2(eq)N protons are observed at δ 
4.41 and 4.58 respectively. The phenyl protons of 30 are observed between δ 7.47-7.87. A 
multiplet at δ 7.47 corresponds to the phenyl protons of 32. 
 
The ferrocenyl protons Ha are observed as a singlet at ca. δ 4.18 whilst the Hc and Hd protons 
are observed as broad signals at ca. δ 5.06 and 4.64 respectively for 30-32. The remaining 
ferrocenyl protons Hh and Hi, contributed by the dppf ligand, are observed as broad signals at 
δ 5.07 and 4.51 respectively. The primary amine protons of 30 are observed as a broad signal 
at δ 6.74. Upon formation of compounds 31 and 32, the peak corresponding to the hydrazinic 
proton (18) is absent as the second imine bond forms. The secondary protons (Hg) are 





H} NMR spectroscopy           
For compound 30, a doublet is observed in the 
13
C NMR spectrum at δ 171.5, whereas for 31 
and 32 a doublet is observed at ca. δ 167.5 which corresponds to the thiolate carbon. The 
imine carbon resonates as a singlet at δ 152.5, 154.8 and 156.0 for 30-32 respectively. For the 
ferrocenyl carbons of 30 and 31, the quaternary Cb carbon resonates as a doublet (J = 4.68 
Hz) at ca. δ 73.4, whilst a singlet is observed at δ 72.3 for 32. The remaining ferrocenyl 
carbons resonate as singlets in the range δ 66.9-73.7. The Ch-i ferrocenyl carbons of dppf 
resonate as doublets (J = 9.42 and 7.41 Hz respectively) due to coupling with phosphorus 











J = Hz) 
C=N 
(ppm, 
J = Hz) 
NCH2N 
(ppm, 
J = Hz) 
PCH2N 
(ppm, 





J = 12.1) 
152.5 (s) - - 
75.8 (d, J = 7.41, Ci); 
76.2 (d, J = 9.42, Ch). 
31 167.8 (s) 154.8 (s) 
72.2 (d,  
J = 12.8) 
51.5 (d,  
J = 18.2) 
119.9 (Ci); 136.1 (Ch). 
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For 31 and 32, the quaternary carbons (Ch) of the aromatic spacer are observed as a singlet at 
ca. δ 136.0 while the remaining aromatic carbons (Ci) are observed as a singlet at ca. δ 119.8. 
As observed with other PTA containing complexes, the PTA carbons of 31 resonate as 
doublets due to coupling with phosphorus. The NCH2N carbons are observed at δ 72.2, with 
the PCH2N carbons being observed at δ 51.5 (Table 3.21). For compounds 30 and 32, the 
phenyl carbons are observed in the range δ 128.1-134.4.   
 
31
P NMR spectroscopy 
For compound 30, a peak is observed at δ 22.0, which is upfield from the signal observed at δ 
-17.8 for free dppf. For the palladium-precursors, cis-PdCl2(PTA)2 and PdCl2(PPh3)2, a peak 
is observed at δ -20.4 and δ 23.6 respectively. Upon formation of compounds 31 and 32, the 
peak in the 
31
P NMR spectra shifts upfield in the case of 31 (δ -32.0) and downfield for 32 (δ 
27.8). These values are comparable to those seen for the binuclear complexes (28 and 29) in 
Section 3.2.3.a.   
 
Infrared (IR) spectroscopy    
In the IR spectra of compounds 30-32, two absorption bands are observed in the range 1572-
1602 cm
-1
, which corresponds to the two imine bonds. The absorption band at the lower 
wavenumber corresponding to the C=N bond coordinated to the metal (Table 3.22).   
 
Table 3.22: The absorption bands observed in the IR spectra of compounds 30-32 
Compound number C=N ν (cm
-1
) 
30 1602, 1587 
31 1593, 1576 
32 1598, 1572 
 
Mass spectrometry    
The ESI
+
-mass spectra was recorded for compounds 30 and 31. For 30, the peak observed at 





respectively (see appendix, pg. 137). For compound 31, the molecular ion peak is observed at 
m/z 1244 (10 %). For compound 32, the peak observed at 1457 (3 %) and 692 (100 %) 
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3.3. Cyclic voltammetry 
Electrochemical studies were carried out as a preliminary investigation to determine the 
effect of phosphorus-containing ligands (PTA, PPh3 and dppf) on the ferrocenyl moiety 
through the palladium metal centre. These electrochemical studies were conducted in order to 
possibly compare the electronic effects with the antiplasmodial activity of the compounds. 
There is evidence which suggests that the oxidation of the ferrocenyl moiety could produce, 
via Fenton-like reactions, reactive oxygen species (hydroxyl radicals) which disrupts lipid 
membranes.
33-35
 In principle, compounds containing more electron-donating groups would 
favour the oxidation process of the Fc/Fc
+
 couple i.e. hydroxyl radicals will form easily 
resulting in antiplasmodial activity. 
 








Fc 283 217 250 
16 384 328 356 
28 402 344 373 
29 391 326 359 
30 364, 791 297 331 
a
 Epa: Anodic potential 
b
 Epc: Cathodic potential 
c
 E1/2: Half wave potential [(Epa + Epc)/2] 
 
In this study, the effects of the thiosemicarbazone moiety, as well as palladium and the P-
donor ligand will be investigated. The synthesis of compounds 16, 28, 29 and 30 were 
described in Sections 3.2.3.a. and 3.2.3.b.
17
 The voltammograms of compounds 16, 28 and 29 





 On the other hand, from the cyclic voltammogram of compound 30 the redox 
cycle the two ferrocenyl moieties of the thiosemicarbazone unit was fully reversible, whereas 
only the oxidation peak was observed for the ferrocenyl moiety of the 1,1’-
















Figure 3.3: Cyclic voltammograms of compounds 16 and 28. 
 
The half wave potential (E1/2) could indicate the ease with which the ferrocenyl moiety is 
oxidized compared to ferrocene.
36
 Therefore, an E1/2 value larger than that observed for 
ferrocene suggests a system which is more difficult to oxidize. In comparison to free 
ferrocene (E1/2 = 250 mV), the ferrocenyl moiety of the tested compounds (16, 28-30) are 
more difficult to oxidize due the presence of the thiosemicarbazone unit, palladium and the 
phosphorus ligands (Fig. 3.3). However, compounds 16 and 29 have comparable E1/2 values 
(356 mV and 359 mV respectively), while compound 28 has an E1/2 value of 373 mV 
showing the poorest electron-donating effect (Table 3.23). Therefore, from the E1/2 values it 
can be deduced that the ferrocenyl moiety in compound 28 is more difficult to oxidize. The 
PPh3 ligand displayed a greater electron-donating effect than PTA, which resulted in a lower 
























































Figure 3.4: Cyclic voltammograms of compounds 29 and 30. 
 
As mentioned above, the Fc/Fc
+
 redox cycle of the dppf group in compound 30 was 
irreversible (Fig. 3.4). Free dppf was analysed, and the voltammogram displayed the 
oxidation signal of free dppf at 1068 mV. The cyclic voltammogram of 30 displayed an 
oxidation signal at 791 mV which suggest that the palladium thiosemicarbazone units have an 
electron-donating effect on dppf, resulting in an easily oxidized ferrocenyl moiety. However, 
an E1/2 value of 331 mV suggests that the ferrocenyl moieties of the thiosemicarbazone unit 
were easy to oxidize when compared to the compounds 28 and 29 (Table 3.23).     
 
3.4. Summary    
The ferrocenyl-derived thiosemicarbazone compounds (16 and 18) were synthesized, and 
reacted with the ruthenium-dimers 19-21 to yield heterobimetallic compounds 22-26. These 
compounds (22-26) were isolated as cationic ruthenium(II) complexes, and characterized 
using NMR spectroscopy, infrared spectroscopy and mass spectrometry (ESI
+
). The 
ruthenium(II) complexes containing the p-cymene and phenoxyethanol rings were generally 
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(24) was isolated as an air-stable hexafluorophosphate salt, while this was not the case for 
tetranuclear complex. 
 
The ferrocenyl-derived compound 16 was also reacted with potassium tetrachloropalladate to 
synthesize the chloro-bridged compound, 27. Compound 27 was used in subsequent reactions 
with P-donor ligands, PTA, PPh3 and dppf, to prepare binuclear complexes 28 and 29 and 
pentanuclear complex 30 respectively. Compound 18 was reacted with palladium-precursors 
to synthesize tetranuclear palladium(II)-complexes (31 and 32) containing P-donor ligands, 
PTA and PPh3. As opposed to the cationic ruthenium(II) complexes, the neutral palladium(II) 
complexes (28-32) were air-stable compounds. The palladium(II) complexes (27-32) were 





). The crystal structure of compound 28 was determined using single-crystal X-ray 
diffraction, and found to have a slightly distorted square planar geometry.    
 
Preliminary electrochemical studies were carried out on selected ferrocenyl-derived 
palladium complexes to determine which ferrocenyl moiety is more easily oxidized. The 
cyclic voltammograms revealed that compound 28 was the most difficult to oxidize, whereas 
compound 30 was oxidized more easily. Compound 30 displayed a greater electron-donating 
effect compared to compounds 28 and 29, while the PTA ligand displayed a weaker electron-
donating effect when compared to the PPh3 ligand. 
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Thiosemicarbazones have been evaluated for antiplasmodial activity against P. falciparum 
strains.
1-3
 Several mechanisms have been proposed to explain the activity of 
thiosemicarbazones against P. falciparum. An important process for parasite survival 
involves the degradation of host haemoglobin in the food vacuole of the parasite to derive 
amino acids.
4
 It is believed that thiosemicarbazones may either inhibit cysteine proteases 
which are involved in haemoglobin degradation, or chelate to endogenous metals such as 




A variety of organometallic compounds have been evaluated as antimalarial agents.
6-9
 As 
previously mentioned thiosemicarbazones are favourable ligands for coordination compounds 
due to the supply of electron-donating atoms such as oxygen, nitrogen and sulfur which are 
able to chelate to a range of metals. As part of this MSc study, the metals of interest are 
palladium and ruthenium. It has been stated in Chapter 1 that ruthenium was chosen due to 
its’ ability to mimic iron as well as the low toxicity generally observed for ruthenium(II) 
complexes.
10 
On the other hand, platinum and palladium resemble each other in a given 
oxidation state, and toxicity problems have been reported for platinum complexes.
11
 
Therefore, palladium complexes were synthesized to determine if they were more 
biologically active and a suitable alternative. 
 
Reports of complexes so far studied include metals such as palladium(II), platinum(II), 
gold(I), gold(III), copper(II), nickel(II) and iron(II) ions.
12-17
 The biological activity of 
thiosemicarbazone complexes is believed to be attributed to either the generation of reactive 
oxygen species or a synergistic effect whereby the thiosemicarbazone ligand dissociates from 
the metal upon entering the cell to allow chelation of endogenous metals.
1,18
 In earlier studies, 
an enhancement of activity has been observed upon complexation as opposed to the free 
ligand, as well as an enhancement with an increase in metal centres.
19-20 
Therefore, in this 
study the antiplasmodial activity of the free ligands synthesized as well as the polynuclear 
complexes will be evaluated to determine if the presence of a metal and/or several metals 
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4.2. The antiplasmodial activity of aryl-derived thiosemicarbazone cyclopalladated 
complexes containing N- and P-donor ligands 
A biological evaluation of selected aryl-derived thiosemicarbazones (1 and 2) and their 
corresponding palladium(II) complexes (7-15) described in Chapter 2 was undertaken. These 
compounds were evaluated for antiplasmodial activity against the P. falciparum strains, 
NF54 (chloroquine-sensitive) and Dd2 (chloroquine-resistant). The control drug used in the 
experiment was chloroquine diphosphate (CQDP) for both the NF54 and the Dd2 strains.  
 
Compounds 1 and 2 (Fig. 4.1) exhibited better activity against the Dd2 strain than the NF54 
strain, with the lowest IC50 value of  4.46 ± 0.74 μM being observed for compound 2 (Table 
4.1). The observation that the compound containing an ethyl group (on the imine carbon) has 
better activity over those containing methyl groups have been reported in literature.
21
 For the 
tetranuclear complexes 7 and 8 (Fig. 4.1), both complexes were inactive against the NF54 
and Dd2 strains, which may be attributed to poor solubility at the highest tested 
concentrations (100 000 ng/mL).   
 
The thiosemicarbazone ligands (1 and 2) and complexes (7 and 8) have previously been 
tested against different strains, namely the CQS (3D7) and CQR (K1) strains.
12
 In these 
strains, the ligands exhibited moderate activity against 3D7, but were inactive (> 20 μM) 
against the K1 strain.
12
 When tested against the 3D7 and K1 strains, complex 7 exhibited 
moderate activity while 8 was inactive at the tested concentration.
12
 Perhaps different 





















































































Figure 4.1: The cyclopalladated complexes evaluated for antiplasmodial activity. 
 
The mononuclear complexes containing P-donor ligands exhibited activity against the NF54 
and Dd2 strains. A comparison between compounds 9 and 10 (Fig. 4.1, containing the P-
donor ligand PTA), shows that compound 10 (containing the ethyl chain on the imine carbon) 
exhibits better inhibitory activity against the Dd2 strain (IC50 = 1.73 ± 0.16 μM) than 9 (IC50 
= 2.69 ± 0.22 μM).
21
 However, it appears that incorporation of an aminophosphine ligand 
may contribute more to the lipophilic properties of the compound. Compound 11 (Fig. 4.1) is 
slightly more active than compounds 9 and 10, with the best inhibitory effect displayed 
against the Dd2 strains (IC50 = 1.59 ± 0.053 μM). Compounds 9-11 exhibit comparable 
inhibitory activity against the NF54 strain with IC50 values of 1.93 ± 0.04 μM, 1.81 ± 0.11 
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for the mononuclear complexes (9-11) compared to the free monothiosemicarbazone ligands 




 values for compounds 1-15 against the P. falciparum strains NF54 (CQS) 
and Dd2 (CQR).  
Compound NF54 (μM) Dd2 (μM) RI
b
 
1 14.1 ± 0.34 9.82 ± 0.78 0.70 
2 19.0 ± 2.18 4.46 ± 0.74 0.23 
7 Inactive Inactive ND
c
 
8 Inactive Inactive ND 
9 1.93 ± 0.04 2.69 ± 0.22 1.39 
10 1.81 ± 0.11 1.73 ± 0.16 0.96 
11 1.76 ± 0.074 1.59 ± 0.053 0.90 
12 Inactive 54.56 ± 3.83 ND 
13 86.8 ± 9.99 7.11 ± 0.068 0.082 
14 ND 0.191 ± 0.0013 ND 
15 63.71 ± 6.49 Inactive ND 
CQDP 0.031 ± 0.006 0.22 ± 0.016 7.10 
a
 IC50: Compound concentration causing 50 % inhibition of parasitaemia in vitro 
b
 RI : Resistance index = [IC50 (Dd2)]/[IC50 (NF54)] 
c
 ND : Not determined 
 
As previously stated, the rationale behind the synthesis of polynuclear complexes is to 
determine if an enhancement of activity will be observed for an increased number of metal 
centres. However, compound 12 (Fig. 4.1) which contains a dimeric aminophosphine ligand, 
allowing for the synthesis of a binuclear complex, exhibits only moderate activity (IC50 = 
54.56 ± 3.83 μM) against the Dd2 strain in comparison to the mononuclear complexes 9-11 
(IC50 = ca. 1.83 μM). Against the NF54 strain, compound 12 is inactive at the tested 
concentration (>100 000 ng/mL, Table 4.1), which may be due to poor solubility in the assay. 
However, based on the data available for the Dd2 strain, the proposed enhancement of 
activity is not observed moving from the mononuclear complexes (9-11) to the binuclear 
complex (12).   
 
An RI value <1 or as small as possible would suggest that there is no evidence of cross-
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and do not display cross-resistance with chloroquine.
22
 The RI values of the tested 
compounds are determined relative to chloroquine, and are calculated by dividing the IC50 
values for the CQR strain (Dd2) by that of the CQS strain (NF54). The RI values were 
calculated for the aryl-derived compounds, and found to be lower than the value for 
chloroquine diphosphate. Comparing the RI values of compounds 1-12, only compound 9 is 







































Figure 4.2: The cyclopalladated complexes evaluated for antiplasmodial activity. 
 
Cyclopalladated complexes containing N-donor ligands have also been evaluated for 
antiplasmodial activity. Against the Dd2 strain, compounds 13 and 14 (Fig. 4.2) exhibited 
moderate activity with IC50 values of 7.11 ± 0.068 μM and 0.191 ± 0.0013 μM respectively. 
Compound 15 (Fig. 4.2) was inactive at the tested concentration (>10 000 ng/mL). However, 
against the NF54 strain compounds 13 and 15 exhibits moderate activity, whilst compound 
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increase in activity against the Dd2 in comparison to the NF54 strain. Compound 14 
exhibited the highest activity with an IC50 value of 0.191 ± 0.0013 μM against the Dd2 strain 
(Table 4.1).  
 
There is no obvious trend observed for the complexes containing N-donor ligands (13-15) 
when comparing their activity to the free ligand, as well as the activity between the mono- 
and binuclear complexes. Against the Dd2 strain, the mononuclear complex 13 exhibited a 
slight enhancement of activity compared to the free ligand (1). Moving from the mononuclear 
complex to the binuclear complex (14) there is a significant enhancement of activity 
compared to both the free ligand and the mononuclear complex. It appears that a trend is 
evident when considering the Dd2 strain. However, for the NF54 strain there is a loss of 
activity for 13 (IC50 = 86.8 ± 9.9 μM) compared to the free ligand (IC50 = 14.1 ± 0.34 μM), 
and a slight enhancement of activity moving from 13 to the binuclear complex 15 (IC50 = 
63.71 ± 6.49 μM). 
 
The calculated RI value for the aryl-derived complex 13 (RI = 0.082) was lower than the 
value for chloroquine diphosphate, suggesting that 13 is more active against the Dd2 strain 
and is less likely to be susceptible to cross-resistance. A comparison of the RI values of 
compounds 1-13, shows that compound 13 is the least susceptible (Table 4.1).       
 
4.3. The antiplasmodial activity of N,S-chelated ferrocenylthiosemicarbazone 
ruthenium(II)-arene complexes 
The ferrocenyl-derived thiosemicarbazone (16) and related ruthenium(II) complexes (22-24) 
described in Chapter 3 were screened for antiplasmodial activity against the P. falciparum 
strains, NF54 and Dd2. The control drug used in the experiment was once again 





































22 (Ar = 19), X = Cl 
23 (Ar = 20), X = Cl 
  24 (Ar = 21), X = PF6 
Figure 4.3: The ferrocenylthiosemicarbazone ruthenium complexes evaluated for antiplasmodial activity. 
 
Compound 16 (Fig. 4.3) exhibited moderate activity against the NF54 and Dd2 strains with 
IC50 values of 3.43 ± 0.36 μM and 6.40 ± 0.088 μM respectively. When evaluated against the 
Dd2 strain, the ruthenium(II) complexes 22 and 23 (Fig. 4.3) exhibited activity (IC50 = 6.59 ± 
0.31 and 6.61 ± 0.29 μM respectively) comparable to that of the free ligand (16, IC50 = 6.40 ± 
0.088 μM), whereas compound 24 was 2-fold less active (IC50 = 14.1 ± 0.88 μM) than both 
the free ligand and compounds 22 and 23 (Table 4.2). While compound 16 appears to exhibit 
higher activity against the NF54 strain, the same cannot be said for the complexes. There was 
a decrease in activity when the ruthenium(II)-arene complexes 22-24 were tested against the 
NF54 strain, exhibiting only moderate activity. Once again compounds 22 and 23 exhibited 
comparable activity (IC50 = 8.63 ± 0.60 and 9.71 ± 1.97 μM respectively) to each other, 
whilst compound 24 was significantly less active (IC50 = 16.5 ± 1.02 μM, Table 4.2). The 
arene ring is present in order to stabilize the metal, as well as possibly altering the 
lipophilicity of the complex, either to assist with membrane crossing or retaining the complex 
within the active site.
23
 Perhaps the complexes containing the p-cymene and phenoxyethanol 
rings are more favourable than the benzene (24), due to the lipophilic properties contributed 
to whichever mode of action is being followed. 
 
The calculated RI values for the free ligand (16) as well as the ruthenium(II) complexes (22-
24) are significantly lower than chloroquine diphosphate (RI = 7.10). However, it is apparent 
that only the free ligand is prone to cross-resistance, whereas compounds 22-24 have RI 
















 values for compounds 16 and 22-24 against the P. falciparum strains NF54 
(CQS) and Dd2 (CQR).  
Compound NF54 (μM) Dd2 (μM) RI
b
 
16 3.43 ± 0.36 6.40 ± 0.088 1.87 
22 8.63 ± 0.60 6.59 ± 0.31 0.76 
23 9.71 ± 1.97 6.61 ± 0.29 0.68 
24 16.5 ± 1.02 14.1 ± 0.88 0.85 
CQDP 0.031 ± 0.006 0.22 ± 0.016 7.10 
a
 IC50: Compound concentration causing 50 % inhibition of parasitaemia in vitro 
b
 RI : Resistance index = [IC50 (Dd2)]/[IC50 (NF54)] 
 
4.4. The antiplasmodial activity of N,S-chelated ferrocenylthiosemicarbazone 
palladium(II) complexes containing P-donor ligands  
The synthesis of palladium(II) complexes containing ferrocenyl-derived thiosemicarbazones 
were described in Chapter 3. The ferrocenyl-derived thiosemicarbazones (16 and 18) and the 
corresponding palladium(II) complexes (28-31) were screened for antiplasmodial activity 
against the NF54 and Dd2 strains, with chloroquine diphosphate (CQDP) as the control drug 
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The heterobimetallic binuclear complexes (28 and 29) exhibited moderate activity against 
both strains, whilst the heterobimetallic pentanuclear complex (30) exhibited moderate 
activity (IC50 = 5.56 ± 0.26 μM) against the NF54 strain but was inactive (>10 000 ng/mL) 
against the Dd2 strain. Compound 29 (Fig. 4.4), which contains the triphenylphosphine 
ligand, is more active than compound 28 (PTA, Fig. 4.4) against both the NF54 and Dd2 
strains with IC50 values of 3.89 ± 0.53 μM and 4.94 ± 0.41 μM respectively. When compared 
to the free ligand, the activity of compound 29 (IC50 = 3.89 ± 0.53 μM) is similar against the 
NF54 strain and more active (IC50 = 4.94 ± 0.41 μM) than compound 16 against the CQR 
(Dd2) strain (Table 4.3).  
 
Compound 28 (IC50 = 9.29 ± 0.51 μM) was more active against the Dd2 strain than the NF54, 
but no enhancement of activity is observed compared to the free ligand (IC50 = 6.40 ± 0.088 
μM). As mentioned before, compound 30 (Fig.4.4) was inactive against the Dd2 strain at the 
tested concentration. An IC50 value of 5.56 ± 0.26 μM was obtained when 30 was tested 
against the NF54 strain. The pentanuclear complex (30), containing three ferrocenyl moieties 
and two palladium centres, exhibited good activity. However, this activity was not higher 




 values for compounds 16, 18 and 28-31 against the P. falciparum strains 
NF54 (CQS) and Dd2 (CQR). 
Compound NF54 (μM) Dd2 (μM) RI
b
 
16 3.43 ± 0.36 6.40 ± 0.088 1.86 
28 14.98 ± 0.32 9.29 ± 0.51 0.62 
29 3.89 ± 0.53 4.94 ± 0.41 1.27 
30 5.56 ± 0.26 Inactive ND
c
 
18 Inactive Inactive ND 
31 Inactive Inactive ND 
CQDP 0.031 ± 0.006 0.22 ± 0.016 7.10 
a
 IC50: Compound concentration causing 50 % inhibition of parasitaemia in vitro 
b
 RI : Resistance index = [IC50 (Dd2)]/[IC50 (NF54)] 
c
 ND : Not determined 
 
The observation that a complex containing PPh3 is more active than one containing PTA (Fig. 
4.5) has previously been reported in the literature by Chellan et al.
14
 The complexes were 
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ligand exhibited higher activity than those containing PTA, with IC50 values of 19.93 ± 3.74 
μM and 14.47 ± 1.98 μM for D10 and Dd2 respectively.
14
 The complexes containing PTA 










L = PTA, PPh3 




Both the ferrocenyldithiosemicarbazone (18) and the palladium(II) complex (31) were 
inactive at the tested concentration against the CQS (NF54) and CQR (Dd2) strains. The 
resistance index values were calculated for compounds 28-29 (Table 4.3). A comparison of 
the RI values suggests that compound 28, which is the least active against both strains, has 
the lowest RI value.   
 
As seen in Chapter 3 (Section 3.3), preliminary cyclic voltammetry studies were carried out to 
determine if the activity of the compounds could be related to the generation of reactive 
oxygen species. There is evidence which suggests that the oxidation of the ferrocenyl moiety 





From the electrochemical studies, it was found that compounds 16 and 29 had comparable 
E1/2 values of 356 mV and 359 mV, respectively. Compound 28 had an E1/2 value of 373 mV, 
whereas compound 30 had a value of 331 mV. If it is easier to oxidise the iron in the 
ferrocenyl moiety (lower E1/2 value) then more electrons would be available for radical 
generation. Therefore, examining the E1/2 values it is expected that compounds 16 and 29 
would have similar activity. As stated before compounds 16 and 29 have comparable IC50 
values against the NF54 strain, whilst compound 28 is the least active (Table 4.3). It is 
expected that compound 30 would have the best activity, whereas compound 28 would be the 
least active. The proposal that compound 30 has the best activity is not observed in this study, 















Selected aryl- and ferrocenyl derived ligands, as well as palladium and ruthenium compounds 
were evaluated for antiplasmodial activity against the chloroquine-sensitive (NF54) and the 
chloroquine-resistant (Dd2) strains of P. falciparum. For the aryl-derived series (1-15) it was 
found that of the palladium(II) complexes containing P-donor ligands, the mononuclear 
complex 11 containing the aminophosphine ligand, was the most active against both strains. 
For the compounds containing the N-donor ligands the binuclear complex 14 was the most 
active against the Dd2 strain. Overall, the mononuclear complexes containing P-donor 
ligands (9-11) exhibited an enhancement of activity compared to the free ligands (1 and 2). 
However, this trend was not observed moving to the binuclear complex (12), which was less 
active than the ligands as well as the mononuclear complexes.  
 
There was no clear overall correlation between the ligand, the number of metal centres and 
the biological activity observed. Against the Dd2 strain, the trend appears to hold as an 
enhancement of activity is observed moving from the free ligand (1) to the mononuclear 
complex (13) to the binuclear complex (14). Considering the activity exhibited against the 
NF54 strain, a slight enhancement of activity moving from 13 to the binuclear complex 15, 
whereas both are significantly less active than the free ligand. 
 
In the second series, which focuses on ferrocenyl-derived ruthenium(II) complexes, the free 
ligand 16 and the heterobimetallic binuclear complexes (22-24) were tested. There was no 
obvious beneficiary effect observed due to the incorporation of a ruthenium(II) ion as the IC50 
values were either similar to that of the free ligand or exhibited lower activity.  
 
The third series of compounds synthesized centred around ferrocenyl-derived palladium(II) 
complexes (28-31) which contain P-donor ligands. Compounds 28-30 exhibited activity 
against both strains, with compound 29 which contains the triphenylphosphine ligand, 
exhibiting the best activity. The free ferrocenyldithiosemicarbazone (18) and the 
corresponding palladium(II) complex (31) which contains PTA were both inactive against the 
NF54 and Dd2 strains at the tested concentrations.  
 
Against the NF54 strain, the activity observed for the free ligand and the binuclear complex 
(29) is comparable whereas the binuclear complex 28 is less active. The pentanuclear 
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Therefore, the expected enhancement of activity cannot ultimately be ruled out for this series 
of compounds. The preliminary data from electrochemical studies for certain compounds 
suggest a correlation between the ease of oxidation and the IC50 values.     
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Overall conclusion and future outlook 
 
5.1. Overall conclusion 
The first series focuses on aryl-derived cyclopalladated thiosemicarbazone complexes. Aryl-
derived monothiosemicarbazone ligands were prepared and characterized using spectroscopic 
techniques such as NMR and infrared (IR) spectroscopy. When the thiosemicarbazone 
ligands were reacted with K2[PdCl4]/Na2[PdCl4], the thiosemicarbazone chelated in a 
tridentate C,N,S-donor fashion to afford the tetranuclear complexes. The tetranuclear 
complexes were characterized using NMR and infrared (IR) spectroscopy, and used in 
subsequent reactions with P- and N-donor ligands.  
 
Monomeric and dimeric imino- and aminophosphine ligands were prepared by reacting the 
aldehyde with the appropriate amine, and the further reduction of the iminophosphine using 
sodium borohydride to synthesize the aminophosphine ligands. The ligands were 
characterized using various spectroscopic and analytical techniques such as NMR and IR 
spectroscopies, and mass spectrometry. 
 
P-donor ligands, including the aforementioned aminophosphine ligands, were used to prepare 
three mononuclear complexes and one binuclear complex. One mononuclear and two 
binuclear complexes were prepared as additional set of cyclopalladated complexes which 
contain N-donor ligands. These complexes were characterized using NMR and IR 
spectroscopies, and mass spectrometry. In addition to their spectroscopic and analytical 
characterization, the molecular structures of two mononuclear cyclopalladated complexes (10 
and 11) have been determined using single-crystal X-ray diffraction, and found to have a 
slightly distorted square-planar geometry around the palladium(II) centre. 
 
Ferrocenyl-derived thiosemicarbazones have been prepared and characterized using NMR, 
infrared (IR) spectroscopy and mass spectrometry. The ferrocenyl-derived 
thiosemicarbazones were used in the preparation of a second and third series of compounds. 
 
Heterobimetallic ruthenium(II) complexes make up the second series, wherein the ferrocenyl-
derived thiosemicarbazones chelate in a N,S-chelated mode. Three ruthenium dimers 
[Ru(Ar)(μ-Cl)Cl]2 (Ar = p-
i
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ferrocenyl-derived thiosemicarbazones to prepare three binuclear and two tetranuclear 
ruthenium(II)-arene complexes. These complexes were characterized using NMR and IR 
spectroscopies, and mass spectrometry.   
 
The third series focuses on the synthesis of N,S-chelated ferrocenyl-derived palladium(II) 
complexes. A binuclear chloro-bridged complex, prepared by reacting the monomeric 
ferrocenyl-derived thiosemicarbazone with K2[PdCl4], is used in subsequent reactions with P-
donor ligands. Two binuclear complexes, two tetranuclear complexes and one pentanuclear 
complex were synthesized and characterized using NMR and IR spectroscopies, and mass 
spectrometry. The molecular structure of a binuclear complex, containing the water-soluble 
P-donor ligand 1,3,5-triaza-7-phosphaadamantane, was elucidated using single-crystal X-ray 
diffraction.  
 
Selected ligands and metal complexes were evaluated for antiplasmodial activity against 
Plasmodium falciparum strains, NF54 (chloroquine-sensitive) and Dd2 (chloroquine-
resistant). The ligands and complexes exhibited moderate inhibitory effects in the low 
micromolar range, with the first series of compounds containing the cyclopalladated 
complexes exhibiting better inhibitory effects than series two and three.  
 
5.2. Future outlook 
This project has revealed that there is merit in the use of these thiosemicarbazone palladium 
and ruthenium complexes as biological agents. Better inhibitory effects may be observed if 
changes are made to the structures presented in this study. Perhaps varying the aryl rings of 
the thiosemicarbazone ligand, the terminal amine group or even the metal centre will 
favourably change the properties of the compounds, allowing for an enhancement of 
biological activity.      
 
β-hematin studies carried out by Chellan et al. with cycloplatinated complexes revealed that 
there was no interaction between the β-hematin and the thiosemicarbazone complexes.
1
 It is 
believed that the interaction between thiosemicarbazone ligands and cysteine proteases leads 
to the observed biological activity.
2
 However the mode of action for the complexes is 
believed to be via synergistic effects. Therefore, additional studies would need to be carried 
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Further ROS studies would need to be conducted on the ferrocenyl-derived palladium 
complexes to determine if there is a connection between the cyclic voltammetry data and the 
biological data.  
 
5.3. References 
1. P. Chellan, K. M. Land, A. Shokar, A. Au, S. H. An, C. M. Clavel, P. J. Dyson, C. de 
Kock, P. J. Smith, K. Chibale and G. S. Smith, Organometallics, 2012, 31, 5791.  
2. D. C. Greenbaum, Z. Mackey, E. Hansell, P. Doyle, J. Gut, C. R. Caffrey, J. Lehrman, 








































6.1. General remarks 
All reagents and solvents were purchased from commercial suppliers. All reagents were 
purchased from Aldrich and used without further purification. PdCl2 and Na2PdCl4.nH2O and 
RuCl3.nH2O were received as a generous donation from the Anglo American South Africa. 
K2[PdCl4], PdCl2(PPh3)2 and PdCl2(PTA)2 was prepared according to published literature 
procedures.
1-2
 Nuclear magnetic resonance (NMR) spectra were recorded on either a Varian 
Mercury XR300 MHz (
1
H: 300.08 MHz, 
13
C: 75.46 MHz, 
31
P: 121.47 MHz), Varian Mercury 
XR400 MHz (
1
H: 399.95 MHz) or Bruker Biospin GmbH (
1












chemical shifts are referenced to the deuterated solvent. Infrared (IR) spectra were 
determined using a Perkin–Elmer Spectrum 100 FT-IR spectrometer, and were recorded 
using KBr pellets or NaCl solution cell (dichloromethane). Elemental analyses (C, H, S and 
N) were recorded on a Thermo Flash 1112 Series CHNS-O Analyser. Mass spectrometry was 
carried out at the University of Cape Town on a JEOL GCmateII and data were recorded 
using Electron Impact (EI) mode. Mass spectrometry was carried out at the University of 
Stellenbosch on a Waters API Quattro Micro triple quadrupole mass spectrometer and 
samples injected into a stream of 50% acetonitrile and 0.1% formic acid. Data were recorded 
using Electrospray Ionisation (ESI) mass spectrometry in the positive mode. Melting points 
were determined on the Büchi Melting Point apparatus B-540. Single-crystal X-ray 
diffraction data were collected on a Bruker KAPPA APEX II DUO diffractometer using 
graphite-monochromated Mo-K radiation ( = 0.71073 Å). 
 
6.2. Aryl-derived cyclopalladated thiosemicarbazone complexes  
6.2.1. Synthesis of monothiosemicarbazone, imino- and aminophosphine ligands (1-6) 
Synthesis of 3,4-dichloroacetophenone thiosemicarbazone (1)
3
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3,4-Dichloroacetophenone (0.708 g, 3.75 mmol) and thiosemicarbazide (0.342 g, 3.75 mmol) 
was added to ethanol (30.0 mL). While stirring, excess acetic acid (~ 2 mL) was added to the 
reaction. The reaction mixture was refluxed in air at 85 ˚C for 3 hrs, which produced a white 
solid upon cooling. The white crystalline solid, 1 (0.504 g, 51 %), was collected by suction 
filtration, washed with ethanol (20.0 mL) and diethyl ether (20.0 mL), and dried in vacuo. 
Melting point: 194.8-197.9 ˚C (lit. m.p. 196.0-197.9 ˚C). 
1
H NMR (400.22 MHz, DMSO-d6): 
δ (ppm) = 10.24 (s, 1H, CNNH); 8.31 (br s, 1H, NH2); 8.25 (d, 
4
JHH = 2.00 Hz, 1H, Hb); 8.14 
(br s, 1H, NH2); 7.88 (dd,
 4
JHH = 2.00, 
3
JHH = 8.40 Hz, 1H, Hf); 7.61 (d, 
3
JHH = 8.40 Hz, 1H, 
He); 2.28 (s, 3H, CH3). Elemental analysis for C9H9Cl2N3S: Found C 41.3, H 3.54, N 15.7, S 
12.3 %; Calculated C 41.2, H 3.46, N 16.0, S 12.2 %. FT-IR (KBr, cm
-1
): ν = 3422 (s, N-H); 
3187 (w, N-H); 3141 (w, N-H); 1594 (s, C=N); 817 (m, C=S).  
 
















3,4-Dichloropropiophenone (0.515 g, 2.54 mmol) and thiosemicarbazide (0.232 g, 2.54 
mmol) was added to ethanol (30.0 mL). While stirring, excess acetic acid (~ 3 mL) was 
added to the reaction. The reaction mixture was refluxed in air at 85 ˚C for 2 days and stirred 
overnight, which produced a white solid. The white crystalline solid, 2 (0.379 g, 54 %), was 
collected by suction filtration, and washed with ethanol (20.0 mL) and diethyl ether (10.0 
mL), and dried in vacuo. Melting point: 186.6-188.1 ˚C (lit. m.p. 185.6-186.4 ˚C). 
1
H NMR 
(400.22 MHz, DMSO-d6) : δ (ppm) = 10.36 (s, 1H, CNNH); 8.31 (br s, 1H, NH2); 8.23 (d, 
4
JHH = 2.00 Hz,
 




JHH = 8.80 Hz, 1H, Hf); 
7.60 (d, 
3
JHH = 8.80 Hz, 1H, He); 2.86 (q,
 3
JHH = 7.60 Hz, 2H, CH2); 0.99 (t, 
3
JHH = 7.60 Hz, 
3H, CH3). Elemental analysis for C10H11Cl2N3S: Found C 44.1, H 4.04, N 15.4, S 11.6 %; 
Calculated C 43.5, H 4.01, N 15.2, S 11.6 %. FT-IR (KBr, cm
-1
): ν = 3387 (m, N-H); 3261 
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2-(Diphenylphosphino)benzaldehyde (0.147 g, 0.507 mmol) was dissolved in dry toluene 
(30.0 mL), followed by the addition of n-propylamine (0.0500 mL, 0.609 mmol). The 
reaction mixture was stirred over anhydrous MgSO4, at ambient temperature for 24 hrs. The 
anhydrous MgSO4 was filtered by gravity, and the solvent removed to yield an oil. The oil 
was redissolved in chloroform (20.0 mL) and extracted with water (40.0 mL x 6), after which 
the organic layer was collected. The organic layer was dried over anhydrous MgSO4, the 
anhydrous MgSO4 filtered, and the solvent removed. An orange oil, 3 (0.149 g, 90 %), was 
isolated and dried in vacuo. 
1
H NMR (300.08 MHz, CDCl3): δ (ppm) = 8.87 (d, 
4
JHP = 4.77 
Hz, 1H, Hg); 7.98 (m, 1H, He); 7.31 (m, 12H, Hc & Hd & PPh2); 6.88 (dd, JHH = 7.51, 4.48 Hz, 
1H, Hb); 3.44 (t, 
3
JHH = 6.83 Hz, 2H, Hh); 1.51 (m, 2H, Hi); 0.75 (t, 
3
JHH = 7.38 Hz, 3H, Hj). 
31
P NMR (121.47 MHz, CDCl3): δ (ppm) = -13.9. FT-IR (solution, CH2Cl2, cm
-1
): ν = 1637 
(s, C=N). 
 
















Compound 3 (0.0635 g, 0.192 mmol) was dissolved in dry methanol (20.0 mL), followed by 
the slow addition of sodium borohydride (0.0127 g, 0.336 mmol). The reaction mixture was 
stirred at ambient temperature for 3 hrs. The solvent was removed, the contents of the flask 
quenched with water (20.0 mL), and extracted with dichloromethane (3 x 20.0 mL). The 
organic layer was collected, washed with water (2 x 15.0 mL), and dried over anhydrous 















H NMR (399.95 MHz, CDCl3): δ (ppm) = 7.58 (m, 1H, He); 7.40 (m, 1H, Hd); 7.23 
(m, 10H, PPh2); 7.09 (t,
 3
JHH = 7.64 Hz, 1H, Hc); 6.83 (dd, JHH = 7.32, 4.39 Hz, 1H, Hb); 3.90 
(s, 2H, Hg); 2.39 (t, 
3
JHH = 7.40 Hz, 2H, Hi); 1.72 (br s, 1H, Hh); 1.26 (m, 2H, Hj); 0.73 (t, 
3
JHH = 7.44 Hz, 3H, Hk). 
13
C NMR (75.46 MHz, CDCl3): δ (ppm) = 144.6 (d, 
2
JCP = 24.1 Hz, 
Cf); 136.6 (d, 
1
JCP = 10.1 Hz, CPh); 135.6 (d, 
1
JCP = 13.5 Hz, Ca); 133.9 (d, 
2
JCP = 20.1 Hz, 
CPh); 133.6 (Ce); 129.3 (d,
 2
JCP = 5.20 Hz, Cb); 128.8 (Cd); 128.7 (CPh); 128.5 (d, 
3
JCP = 6.87 
Hz, CPh); 127.1 (Cc); 52.7 (d, 
3
JCP = 20.7 Hz, Cg); 51.4 (Ci); 23.2 (Cj); 11.9 (Ck). 
31
P NMR 
(121.47 MHz, CDCl3): δ (ppm) = -16.1. FT-IR (solution, CH2Cl2, cm
-1




















2-(Diphenylphosphino)benzaldehyde (0.101 g, 0.346 mmol) was added to methanol (15.0 
mL), followed by the addition of p-phenylenediamine (0.0186 g, 0.172 mmol). The reaction 
mixture was refluxed at 68 ˚C for 6 hrs, and stirred overnight at ambient temperature to yield 
a yellow suspension. A light yellow powder, 5 (0.0985 g, 88 %), was collected by suction 
filtration, washed with hexane (5.00 mL), and dried in vacuo. Melting point: 206.4-210.4 ˚C. 
1
H NMR (399.95 MHz, CDCl3): δ (ppm) = 9.06 (d, 
4
JHP = 5.10 Hz, 2H, Hg); 8.19 (m, 2H, 
He); 7.45 (t, 
3
JHH = 7.80 Hz, 2H, Hd); 7.33 (m, 22H, PPh2 & Hc); 6.94 (m, 2H, Hb); 6.88 (s, 
4H, Hi). 
31
P NMR (162.00 MHz, CDCl3): δ (ppm) = -22.2. FT-IR (KBr, cm
-1
): ν = 3435 (w, 
N-H); 1610 (m, C=N). MS-EI
+
: m/z 653 ([M]
+
, 40 %); 652 ([M-H]
+











































Compound 5 (0.0572 g, 0.0876 mmol) was dissolved in dry dichloromethane:methanol 
(75:25 % V/V, 20.0 mL), followed by the slow addition of sodium borohydride (0.0157g, 
0.415 mmol). The reaction mixture was stirred at ambient temperature for 6 hrs. The solvent 
was removed, the contents redissolved in dichloromethane (25.0 mL), extracted using water 
(20.0 mL), and the organic layer was collected. The organic layer was washed with water (4 x 
20.0 mL), and once again collected, and dried over anhydrous MgSO4. The solvent was 
reduced to precipitate a yellow powder, 6 (0.0543 g, 94 %), which was collected by suction 
filtration, washed with hot hexane and dried in vacuo. Melting point: 194.8-198.5 ˚C. 
1
H 
NMR (399.95 MHz, DMSO-d6): δ (ppm) = 7.60 (m, 4H, He); 7.41 (m, 12H, PPh2); 7.31 (t, 
3
JHH = 7.80 Hz, 2H, Hd); 7.24 (m, 8H, PPh2); 7.17 (t, 
3
JHH = 7.60 Hz, 2H, Hc); 6.76 (dd, JHH = 
7.51, 4.76 Hz, 2H, Hb); 6.14 (s, 4H, Hj); 5.30 (br s, 2H, Hh); 4.19 (br s, 4H, Hg). 
13
C NMR 
(100.65 MHz, DMSO-d6): δ (ppm) = 144.1 (d, 
2
JCP = 22.0 Hz, Cf); 139.7 (Ci); 135.7 (d, 
1
JCP 
= 10.3 Hz, CPh); 134.4 (d, 
1
JCP = 14.7 Hz, Ca); 133.5 (d, 
2
JCP = 19.8 Hz, CPh); 132.2 (Ce); 
131.3 (d,
 2
JCP = 9.46 Hz, Cb); 129.0 (Cd); 128.8 (d, 
3
JCP = 6.60 Hz, CPh); 127.0 (d, 
4
JCP = 4.40 
Hz, CPh); 126.7 (Cc); 113.5 (Cj); 46.1 (d, 
3
JCP = 25.7 Hz, Cg). 
31
P NMR (162.00 MHz, 
CDCl3): δ (ppm) = - 16.9. FT-IR (KBr, cm
-1





, 40 %); 655 ([M-H]
+
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6.2.2. Synthesis of C,N,S-chelated thiosemicarbazone tetranuclear cyclopalladated 
complexes (7, 8) 
Synthesis of [Pd(3,4-dichloroacetophenone thiosemicarbazone)]4 (7)
5















Potassium tetrachloropalladate (0.629 g, 1.93 mmol) was dissolved in water (5.00 mL). 
Ethanol (25.0 mL) was added to the solution, followed by the addition of compound 1 (0.502 
g, 1.93 mmol), while stirring. The reaction mixture was stirred in air, at ambient temperature, 
for 2 days to produce a yellow solid. The solid was purified using diethyl ether and hexane. 
The yellow powder, 7 (0.945 g, 34 %), was collected by suction filtration, washed with 
ethanol (30.0 mL), and dried in vacuo.  
 
The reaction with sodium tetrachloropalladate was carried out using a similar method to the 
reaction with potassium tetrachloropalladate.  Sodium tetrachloropalladate (0.701 g, 2.01 
mmol) was dissolved in water (5.00 mL). Ethanol (30.0 mL) was added to the solution, 
followed by the addition of compound 1 (0.622 g, 2.37 mmol), while stirring. The reaction 
mixture was stirred at ambient temperature for 3 days to produce a brown solid. The brown 
solid was recrystallised using diethyl ether and hexane. The yellow powder, 7 (0.383 g, 44 
%), was collected by suction filtration, washed with hexane (30.0 mL), and dried in vacuo. 
Melting point: 313.2-318.3 ˚C (Decomposition without melting). 
1
H NMR (399.95 MHz, 
DMSO-d6): δ (ppm) = 7.37 (s, 1H, Hb); 7.07 (s, 2H, NH2); 6.72 (s, 1H, He); 2.00 (s, 3H, 
CH3). Elemental analysis for C36H28Cl8N12Pd4S4: Found C 29.3, H 2.20, N 10.62, S 8.28 %; 
Calculated C 29.5, H 1.92, N 11.5, S 8.75 %. FT-IR (KBr, cm
-1
): ν = 3473 (w, N-H); 3352 
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Synthesis of [Pd(3,4-dichloropropiophenone thiosemicarbazone)]4 (8)
5















Potassium tetrachloropalladate (0.352 g, 1.08 mmol) was dissolved in water (5.00 mL), 
followed by the addition of ethanol (20.0 mL). Compound 2 (0.296 g, 1.07 mmol) was added 
to the flask while stirring. The reaction mixture was stirred at ambient temperature for 2 days 
to produce a yellow solid. The yellow powder, 8 (0.408 g, 25 %), was collected by suction 
filtration, washed with ethanol (20.0 mL) and diethyl ether (10.0 mL), and dried in vacuo. 
Melting point: 322-327 ˚C (Decomposition without melting). 
1
H NMR (400.22 MHz, 
DMSO-d6): δ (ppm) = 7.34 (s, 1H, Hb); 7.16 (s, 2H, NH2); 6.65 (s, 1H, He); 2.86 (q,
 3
JHH = 
7.68, 12.7 Hz, 1H, CH2); 1.79 (q,
 3
JHH = 7.44, 12.5 Hz, 1H, CH2); 1.06 (t, 
3
JHH = 7.00 Hz, 3H, 
CH3). Elemental analysis for C40H36Cl8N12Pd4S4: Found C 31.9, H 2.64, N 10.4, S 8.10 %; 
Calculated C 31.6, H 2.38, N 11.0, S 8.42 %. FT-IR (KBr, cm
-1
): ν = 3472 (w, N-H); 3376 
(w, N-H); 1595 (s, C=N); 1562 (m, C=C).  
 
6.2.3. Synthesis of C,N,S-chelated thiosemicarbazone cyclopalladated complexes 
containing P-donor ligands  
a. Mononuclear C,N,S-chelated thiosemicarbazone cyclopalladated complexes (9-11) 
















Compound 7 (0.300 g, 0.205 mmol) was suspended in acetone (30.0 mL), followed by the 
addition of 1,3,5-triaza-7-phosphaadamantane (0.123 g, 0.781 mmol) to the reaction flask. 
The reaction mixture was refluxed at 60 ˚C for 3 hrs, and cooled to ambient temperature. The 
yellow powder, 9 (0.383 g, 94 %), was collected by suction filtration, washed with acetone 














H NMR (399.95 MHz, DMSO-d6): δ (ppm) = 7.27 (s, 1H, He); 7.10 (d, 
4
JHP = 3.42 Hz, 1H, 
Hb); 7.02 (s, 2H, NH2); 4.59 (d, JHP = 12.4 Hz, 3H, N-CH2(eq)-N); 4.44 (d, JHP = 13.2 Hz, 3H, 
N-CH2(ax)-N); 4.27 (s, 6H, PCH2N); 2.21 (s, 3H, CH3). 
13
C NMR (100.65 MHz, DMSO-d6): δ 
(ppm) = 177.2 (C-S); 163.7 (C=N); 163.6 (Ca); 153.2 (Cf); 136.4 (Cc); 130.6 (Cd); 127.2 (Cb); 
127.1 (Ce); 72.4 (d, 
3
JCP = 7.40 Hz, NCH2N); 51.5 (d, 
1
JCP = 15.5 Hz, PCH2N); 13.6 (CH3). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = -49.5. Elemental analysis for 
C15H19Cl2N6PdPS: Found C 35.0, H 3.46, N 16.4, S 5.91%; Calculated C 34.4, H 3.66, N 
16.0, S 6.12 %. FT-IR (KBr, cm
-1
): ν = 3414 (m, N-H); 1624 (m, C=N); 1574 (w, C=N); 
1488 (w, C=C aromatics). MS-EI
+
: m/z 524 ([M]
+
, 4 %).  
 
















Compound 8 (0.253 g, 0.166 mmol) was suspended in acetone (30.0 mL). PTA (0.109 g, 
0.693 mmol) was then added to the reaction flask while stirring. The reaction mixture was 
refluxed at 60 ˚C for 3 hrs, and cooled to ambient temperature. The yellow powder, 10 (0.265 
g, 74 %), was collected by suction filtration, washed with acetone (15.0 mL) and diethyl ether 
(10.0 mL), and dried in vacuo. Melting Point: 235.9-239.4 °C. 
1
H NMR (399.95 MHz, 
DMSO-d6): δ (ppm) = 7.27 (br s, 1H, He); 7.11 (br s, 1H, Hb); 7.05 (s, 2H, NH2); 4.58 (d, JHP 
= 12.8 Hz, 3H, N-CH2(eq)-N); 4.44 (d, JHP = 12.8 Hz, 3H, N-CH2(ax)-N); 4.26 (s, 6H, PCH2N); 
2.70 (q, 
3
JHH = 7.60 Hz, 2H, CH2); 1.02 (t, 
3
JHH = 7.60 Hz, 3H, CH3). 
13
C NMR (100.65 
MHz, DMSO-d6): δ (ppm) = 177.4 (C-S); 168.3 (C=N); 164.2 (Ca); 151.9 (Cf); 136.6 (Cc); 
130.6 (Cd); 127.2 (Cb); 127.0 (Ce); 72.4 (d, 
3
JCP = 7.40 Hz, NCH2N); 51.5 (d, 
1
JCP = 15.5 Hz, 
PCH2N); 20.0 (CH2); 11.5 (CH3). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = -49.6. 
Elemental analysis for C16H22Cl2N6PdPS: Found C 35.8, H 4.14, N 16.1, S 5.48 %; 
Calculated C 35.7, H 4.12, N 15.6, S 5.95 %. FT-IR (KBr, cm
-1
): ν = 3440 (br, N-H); 1641 
(w, C=N); 1559 (w, C=N); 1497 (w, C=C aromatics). MS-EI
+
: m/z 538 ([M]
+
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Compound 4 (0.131 g, 0.393 mmol) was dissolved in dry acetone (20.0 mL), followed by the 
addition of compound 7 (0.143 g, 0.0973 mmol). The reaction mixture was stirred at ambient 
temperature for 3 hrs. The volume of the solution was reduced, and the solid precipitated with 
the addition of hexane. The solid was purified using column chromatography (silica, Ethyl 
acetate: hexane, 1:1). The yellow powder, 11 (0.108 g, 40 %) was collected by suction 
filtration, and washed with diethyl ether (10.0 mL). Melting point: 179.7-184.1 ˚C. 
1
H NMR 
(399.95 MHz, DMSO-d6): δ (ppm) = 7.74 (m, 1H, Hn); 7.49 (m, 11H, Hk & PPh2); 7.32 (t, 
3
JHH = 7.70 Hz, 1H, Hl); 7.23 (s, 1H, He); 7.00 (m, 1H, Hm); 6.90 (br s, 2H, NH2); 6.13 (d, 
4
JHP = 3.85 Hz, Hb); 4.13 (s, 2H, Hp); 2.28 (m, 2H, Hs); 2.26 (s, 3H, Hh); 0.71 (t, 
3
JHH = 7.28 
Hz, 3H, Ht). 
13
C NMR (100.65 MHz, DMSO-d6): δ (ppm) = 177.2 (d, 
3
JCP = 9.43 Hz, C-S); 
172.4 (C=N); 163.7 (Ca); 163.6 (d, 
2
JCP = 4.70 Hz, Co); 153.2 (Cf); 145.2 (d, 
3
JCP = 11.4 Hz, 
Cn); 135.9 (d, 
1
JCP = 8.10 Hz, Cj); 135.0 (d, 
1
JCP = 12.8 Hz, i-C); 132.6 (Ck); 131.7 (Cm); 
131.3 (Cd); 130.8 (Cc); 130.7 (d, 
2
JCP = 8.10 Hz, PPh2); 130.1 (d, 
4
JCP = 3.40 Hz, PPh2); 129.3 
(d, 
2
JCP = 10.1 Hz, Cb); 127.2 (d, 
3
JCP = 8.10 Hz, PPh2); 127.0 (Cl); 126.7 (Ce); 56.2 (Cr); 52.8 
(d, 
3
JCP = 12.8 Hz, Cp); 51.5 (Cs); 13.7 (Ch); 12.0 (Ct). 
31
P NMR (162.00 MHz, DMSO-d6): δ 
(ppm) = 29.5. Elemental analysis for C31H31Cl2N4PdPS·H2O·2C3H6O·½n-C6H14: Found C 
50.8, H 5.17, N 5.92, S 3.59 %; Calculated C 50.7, H 4.94, N 6.39, S 3.66 %. FT-IR (KBr, 
cm
-1





, 45 %); 701 ([M+H]
+
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b. Binuclear C,N,S-chelated thiosemicarbazone cyclopalladated complex (12) 











































Compound 6 (0.0413 g, 0.0629 mmol) was suspended in an acetone: dichloromethane (80:20 
% V/V, 10.0 mL) mixture, followed by the addition of compound 7 (0.0459 g, 0.0313 mmol). 
The reaction mixture was stirred at ambient temperature for 5 hrs. The yellow powder, 12 
(0.0507 g, 58 %), was collected by suction filtration, washed with hexane (10.0 mL) and 
diethyl ether, and dried in vacuo. Melting point: 246.5-249.3 ˚C. 
1
H NMR (399.95 MHz, 
DMSO-d6): δ (ppm) = 7.50 (m, 24H, Hk & Hn & PPh2); 7.35 (t, 
3
JHH = 7.50 Hz, 1H, Hl); 7.21 
(s, 1H, He); 7.08 (m, 1H, Hm); 6.91 (br s, 2H, NH2); 6.18 (d, 
4
JHP = 3.70 Hz, Hb); 5.87 (s, 4H, 
Hs); 5.32 (br s, 2H, Hq); 4.65 (br s, 2H, Hp); 2.24 (s, 3H, Hh). 
13
C NMR (100.65 MHz, 
DMSO-d6): δ (ppm) = 177.1 (d, 
3
JCP = 10.1 Hz, C-S); 164.0 (C=N); 163.5 (d, 
2
JCP = 4.71 Hz, 
Co); 163.3 (Ca); 153.3 (Cf); 144.6 (d, 
3
JCP = 11.4 Hz, Cn); 140.0 (Cr); 135.7 (d, 
1
JCP = 7.40 Hz, 
Cj); 135.0 (d, 
1
JCP = 12.1 Hz, CPh); 133.0 (d, 
2
JCP = 3.40 Hz, Ck); 131.8 (Cm); 130.8 (Cd); 
130.3 (Cc); 130.1 (d, 
4
JCP = 3.89 Hz, CPh); 129.3 (d, 
2
JCP = 10.4 Hz, CPh); 128.6 (d, 
3
JCP = 
8.17 Hz, Cb); 127.0 (d, 
3
JCP = 10.8 Hz, CPh); 126.8 (Cl); 126.5 (Ce); 114.0 (Cs); 47.9 (d, 
3
JCP = 
14.8 Hz, Cp); 13.8 (Ch). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = 29.0. Elemental 
analysis for C62H52Cl4N8Pd2P2S2·½H2O: Found C 53.6, H 4.13, N 7.52, S 3.92 %; Calculated 
C 53.2, H 3.75, N 8.01, S 4.58 %. FT-IR (KBr, cm
-1
): ν = 3483 (w, N-H); 3380 (w, N-H); 
1597 (m, C=N); 1574 (w, C=N). MS-ESI
+
: m/z 1391 ([M+H]
+
, 12 %); 1390 ([M]
+
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6.2.4. Synthesis of C,N,S-chelated thiosemicarbazone cyclopalladated complexes 
containing N-donor ligands (13-15) 




















Compound 7 (0.100 g, 0.0682 mmol) was suspended in toluene (30.0 mL), followed by the 
addition of excess 4-picoline (~ 2 mL). The reaction mixture was refluxed in air at 135 ˚C for 
9 days. The solvent was removed in order to precipitate an orange solid. The orange powder, 
13 (0.0546 g, 43 %), was collected by suction filtration, washed with ethanol (20.0 mL) and 
dried in vacuo.  
 
Compound 13 was synthesized via another method. Compound 8 (0.303 g, 0.207 mmol) was 
suspended in acetone (20.0 mL), followed by the addition of excess 4-picoline (~ 1 mL). The 
reaction mixture was refluxed in air at 70 ˚C for 5 days. The yellow powder, 13 (0.263 g, 69 
%), was collected by suction filtration, washed with diethyl ether (20.0 mL) and dried in 
vacuo.  
Melting point: 311.0 ˚C (Decomposition without melting). 
1
H NMR (300.08 MHz, DMSO-
d6): δ (ppm) = 8.41 (d, 
3
JHH = 5.86 Hz, 2H, Hj); 7.38 (s, 1H, Hb); 7.20 (d, 
3
JHH = 4.90 Hz, 2H, 
Hk); 7.08 (br s, 2H, NH2); 6.73 (s, 1H, He); 2.31 (s, 3H, Hm); 2.00 (s, 3H, Hh). 
13
C NMR 
(100.65 MHz, DMSO-d6): δ (ppm) = 166.8 (C-S); 165.1 (C=N); 164.0 (Ca); 149.6 (Cj, Ck); 
149.1 (Cf); 146.5 (Cl); 132.8 (Cc); 125.8 (Cd); 125.6 (Ce); 124.4 (Cb); 20.2 (Cm); 13.3 (CH3). 
FT-IR (KBr, cm
-1
): ν = 3427 (w, N-H); 3289 (m, N-H); 1617 (s, C=N); 1568 (w, C=N); 1559 
(w, C=N); 1493 (s, C=C aromatics). MS-EI
+
: m/z 459 ([M]
+
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Compound 7 (0.184 g, 0.126 mmol) was suspended in dry toluene (30.0 mL), followed by the 
addition of 4,4’-dipyridyl (0.0390 g, 0.251 mmol). The reaction mixture was refluxed at 140 
˚C for 2 days, and stirred overnight. The brown powder, 14 (0.0761 g, 34 %), was collected 
by suction filtration, washed with dichloromethane (20.0 mL) and diethyl ether (10.0 mL), 
and dried in vacuo. Melting point: 287.8 ˚C (Decomposition without melting). 
1
H NMR 
(399.95 MHz, DMSO-d6): δ (ppm) = 8.73 (br s, 4H, Hj); 7.83 (br s, 4H, Hk); 7.37 (s, 2H, Hb); 
7.18 (br s, 4H, NH2); 6.72 (s, 2H, He); 2.00 (s, 3H, CH3). 
13
C NMR (100.65 MHz, DMSO-
d6): δ (ppm) = 167.5 (C-S); 165.8 (C=N); 164.8 (Ca); 151.1 (Cj, Ck); 150.4 (Cf); 133.6 (Cl); 
129.7 (Cc); 126.5 (Cd); 126.4 (Ce); 121.8 (Cb); 14.1 (CH3). Elemental analysis for 
C28H22Cl4N8Pd2S2.H2O: Found C 36.8, H 2.45, N 11.8, S 7.07 %; Calculated C 37.1, H 2.44, 
N 12.4, S 7.07 %. FT-IR (KBr, cm
-1
): ν = 3456 (w, N-H); 3384 (w, N-H); 1643 (m, C=N); 
1624 (w, C=N); 1593 (m, C=N); 1522 (s, C=C aromatics). MS-ESI
+
: m/z 838 ([M+2H-ClN]
+
, 
5 %); 409 ([M-2Cl]
2+
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Compound 7 (0.201 g, 0.136 mmol) was suspended in acetone (20.0 mL). 1,2-Bis(4-
pyridyl)ethylene (0.0502 g, 0.275 mmol) was added to the suspension while stirring. The 
reaction mixture was refluxed in air at 80˚C for 3 days. The yellow powder, 15 (0.0387 g, 15 
%), was collected by suction filtration, washed with acetone (15.0 mL) and dried in vacuo. 
Melting point: 274.6 ˚C (Decomposition without melting). 
1
H NMR (300.08 MHz, DMSO-
d6): δ (ppm) = 8.59 (d, 
3
JHH = 5.86 Hz, 4H, Hj); 7.59 (d, 
3
JHH = 5.86 Hz, 4H, Hk); 7.50 (s, 2H, 
Hd); 7.38 (s, 2H, Hb); 7.08 (br s, 4H, NH2); 6.72 (s, 2H, He); 2.00 (s, 3H, CH3). 
13
C NMR 
(100.65 MHz, DMSO-d6): δ (ppm) = 167.5 (C-S); 165.8 (C=N); 164.8 (Ca); 150.7 (Cj, Ck); 
150.4 (Cf); 133.6 (Cl); 131.1 (Cm); 129.7 (Cc); 126.5 (Cd); 126.4 (Ce); 121.8 (Cb); 14.1 (CH3). 
Elemental analysis for C30H24Cl4N8Pd2S2: Found C 39.1, H 2.76, N 10.8, S 6.18 %; 
Calculated C 39.4, H 2.64, N 12.2, S 7.01%. IR (KBr, cm
-1
): ν = 3453 (br, N-H); 1628 (w, 
C=N); 1611 (w, C=N); 1596 (w, C=N). MS-ESI
+
: m/z 916 ([M+H]
+
, 5 %); 915 ([M]
+
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6.3. Ferrocenyl-Derived Ruthenium(II) and Palladium(II) Thiosemicarbazone 
Complexes 
6.3.1. Synthesis of mono- and dimeric ferrocenylthiosemicarbazones (16, 18) 
Synthesis of ferrocenylthiosemicarbazone (16)
6















Thiosemicarbazide (0.204 g, 2.24 mmol) was suspended in water (40.0 mL), to which HCl (5 
drops) was added. Ferrocenecarboxaldehyde (0.481 g, 2.25 mmol) was added to the 
suspension, and the reaction mixture was stirred at ambient temperature for 4.5 hrs. The solid 
was purified using dichloromethane and hexane. The orange powder, 16 (0.533 g, 83 %), was 
collected by suction filtration, washed with hexane, and dried in vacuo.  
 
Compound 16 was also synthesized using a method similar to that of the ligands synthesized 
in section 5.2.1.  
Thiosemicarbazide (0.216 g, 2.37 mmol) was suspended in ethanol (30.0 mL), to which 
ferrocenecarboxaldehyde (0.509 g, 2.38 mmol) was added. The suspension was refluxed at 
81˚C for 5 hrs, and stirred overnight. The solid was purified using dichloromethane/hexane to 
yield an orange powder, 16 (0.582 g, 85 %), which was collected by suction filtration, and 
dried in vacuo.  
Melting point: 150.4 ˚C (Decomposition without melting). 
1
H NMR (399.95 MHz, DMSO-
d6): δ (ppm) = 11.12 (s, 1H, Hf); 7.96 (s, 1H, Hh); 7.88 (s, 1H, He); 7.55 (s,
 
1H, Hh); 4.71 (t, 
3
JHH = 1.60 Hz, 2H, Hc); 4.39 (t, 
3
JHH = 1.60 Hz, 2H, Hd); 4.18 (s, 5H, Ha). 
13
C NMR (100.65 
MHz, DMSO-d6): δ (ppm) = 176.9 (C=S); 143.3 (C=N); 78.8 (Cb); 69.9 (Cd); 68.8 (Cc); 67.5 
(Ca). Elemental analysis for C12H13FeN3S: Found C 50.1, H 4.66, N 15.0, 8.71 %; Calculated 
C 50.2, H 4.56, N 14.6, S 11.2 %. FT-IR (KBr, cm
-1
): ν = 3419 (m, N-H); 3246 (m, N-H); 
3154 (m, N-H); 1599 (s, C=N); 818 (m, C=S). MS-EI
+
: m/z 287 ([M]
+
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Hydrazine hydrate (0.720 mL, 25.0 mmol) dissolved in water (0.500 mL) was added 
dropwise to a suspension of 1,4-phenyldiisothiocyanate (0.240 g, 1.23 mmol) in ethanol (20.0 
mL). The reaction mixture was refluxed at 81 ˚C for 1 hr, and the white suspension was 
collected by suction filtration. The white powder, 17 (0.270 g, 84 %), was washed with cold 
water (15.0 mL), cold ethanol (10.0 mL) and cold diethyl ether (10.0 mL). Melting point: 
198.6-199.3 ˚C. 
1
H NMR (300.08 MHz, DMSO-d6): δ (ppm) = 8.94 (s, 2H, Hd); 7.54 (s, 4H, 
Hf); 4.79 (br s, 4H, Ha). 
13
C NMR (100.64 MHz, DMSO-d6): δ (ppm) = 179.4 (C=S); 135.4 
(Ce); 123.2 (Cf). FT-IR (KBr, cm
-1
): ν = 3333 (m, N-H); 3297 (m, N-H); 3237 (s, N-H); 3190 
(s, N-H); 821 (m, C=S). MS-EI
+
: m/z 256 ([M]
+
, 23 %). 
 
























Compound 17 (0.199 g, 0.777 mmol) was suspended in ethanol (30.0 mL), followed by the 
addition of ferrocenecarboxaldehyde (0.332 g, 1.55 mmol). The reaction mixture was 
refluxed at 81 ˚C for 20 hr. The reddish-brown powder, 18 (0.434 g, 86 %), was collected by 
suction filtration, and washed with ethanol (10.0 mL) and diethyl ether (5.00 mL). Melting 
point: 208.1 ˚C (Decomposition without melting). 
1
H NMR (399.95 MHz, DMSO-d6): δ 
(ppm) = 11.55 (s, 2H, NHf); 9.76 (s, 2H, NHh); 8.02 (s, 2H, He); 7.59 (s,
 
4H, Hi); 4.84 (s, 4H, 
Hc); 4.46 (s, 4H, Hd); 4.25 (s, 10H, Ha). 
13
C NMR (75.46 MHz, DMSO-d6): δ (ppm) = 174.4 
(C=S); 143.9 (C=N); 135.5 (Ci); 124.2 (Cj); 78.4 (Cb); 69.9 (Cd); 68.7 (Ca); 67.6 (Cc). 
Elemental analysis for C30H28Fe2N6S2·½H2O: Found C 54.4, H 4.38, N 13.3, S 6.74 %; 
Calculated C 54.8, H 4.29, N 12.8, S 9.76 %. FT-IR (KBr, cm
-1
): ν = 3440 (w, N-H); 3303 
(w, N-H); 3154 (w, N-H); 1600 (s, C=N); 831 (m, C=S). MS-ESI
+
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6.3.2. Synthesis of heterometallic N,S-chelated ferrocenylthiosemicarbazone 

















RuCl3·3H2O (1.00 g, 3.84 mmol) was dissolved in ethanol (30.0 mL), to which an excess of 
α-phellandrene (3.60 mL, 22.3 mL) was added. The reaction mixture was refluxed at 81 ˚C 
for 24 hrs. Half the solvent was removed, and diethyl ether was added to precipitate a red 
solid. The red solid, 19 (0.977 g, 83 %), was collected by suction filtration, and washed with 
cold ethanol (15.0 mL) and diethyl ether (10.0 mL). 
1
H NMR (399.95 MHz, CDCl3): δ (ppm) 






















RuCl3·3H2O (0.999 g, 3.82 mmol) was dissolved in 1,2-ethanediol (15.0 mL), followed by 
the addition of an excess of 1-methoxy-1,4-cyclohexadiene (4.50 mL, 38.0 mmol). The 
reaction mixture was heated at 80 ˚C for 6 hrs, and left standing at ambient temperature to 
allow precipitation of a solid. The reddish-orange solid, 20 (0.469 g, 40 %), was collected by 
suction filtration and washed with methanol. Melting point: 153.1 ˚C (onset of decomposition 
without melting). 
1
H NMR (399.95 MHz, DMSO-d6): δ (ppm) = 6.14 (t, 
3
JHH = 5.60 Hz, 4H, 
Hc), 5.54 (d, 
3
JHH = 5.54 Hz, 4H, Hd), 5.38 (t,
 3
JHH = 5.20 Hz, 2H, He), 4.22 (t, 
3
JHH = 4.80 
Hz, 4H, Hb), 3.73 (t, 
3





























RuCl3·3H2O (0.975 g, 3.73 mmol) was dissolved in 90 % aqueous ethanol (50.0 mL), to 
which an excess of 1,3-cyclohexadiene (1.32 mL, 13.8 mmol) was added. The reaction 
mixture was heated at 45 ˚C for 5 hrs, and stirred overnight. The reddish-brown solid (0.877 
g, 94 %) was collected by suction filtration, and washed with ethanol and diethyl ether. 
1
H 
NMR (399.95 MHz, DMSO-d6): δ (ppm) = 5.97 (br s, 12H, Ar-H).    
 























Ruthenium-dimer 19 (0.150 g, 0.245 mmol) was dissolved in dichloromethane (30.0 mL), 
followed by the addition of compound 16 (0.140 g, 0.490 mmol). The reaction mixture was 
stirred at ambient temperature for 24 hrs. The solution was filtered by gravity, and reduced to 
approximately 2 mL. The contents were added to a large volume (~ 70 mL) of stirring diethyl 
ether to precipitate an orange solid. The orange powder, 22 (0.268 g, 92 %), was collected by 
suction filtration, and washed with diethyl ether. Melting point: 162.1˚C (Decomposition 
without melting). 
1
H NMR (399.95 MHz, Acetone-d6): δ (ppm) = 8.74 (br s, 1H, He); 7.92 (s, 
2H, NH2); 6.02 (br s, 1H, Hc); 5.60 (d, 
3
JHH = 5.84 Hz, 1H, p-cym); 5.31 (d, 
3
JHH = 5.60 Hz, 
1H, p-cym); 5.25 (d, 
3
JHH = 5.60 Hz, 1H, p-cym); 5.14 (d, 
3
JHH = 5.84 Hz, 1H, p-cym); 4.84 
(br s, 1H, Hc); 4.64 (m,
 
2H, Hd); 4.21 (s, 5H, Ha); 2.57 (m, 1H, Hh); 1.99 (s, 3H, Hk); 1.06 (d, 
3
JHH = 6.96 Hz, 3H, Hg); 1.01 (d, 
3
JHH = 6.80 Hz, 3H, Hg). 
13
C NMR (100.65 MHz, MeOD-
d4): δ (ppm) = 178.7 (C=S); 163.1 (C=N); 104.2 (Ci); 103.8 (Cj); 90.1 (p-cym); 89.2 (p-cym); 
85.5 (p-cym);  83.9 (p-cym); 77.8 (Cb); 75.9 (Cc); 75.2 (Cd); 73.9 (Cd); 71.6 (Ca); 71.0 (Cc); 
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Found C 43.1, H 4.49, N 6.70, S 3.10 %; Calculated C 43.5, H 4.48, N 6.92, S 5.28 %. FT-IR 
(KBr, cm
-1
): ν = 3435 (br, N-H); 3259 (w, N-H); 3093 (m, N-H); 1615 (w, C=N); 824 (w, 
C=S). MS-ESI
+
: m/z 522 ([M-Cl]
+





























Ruthenium-dimer 20 (0.127 g, 0.205 mmol) was suspended in dichloromethane (20.0 mL), 
followed by the addition of compound 16 (0.121 g, 0.411 mmol). The reaction mixture was 
stirred at ambient temperature for 24 hrs. The solution was filtered by gravity to remove any 
unreacted 20, and washed with methanol. The volume was reduced to approximately 2 mL, 
and added to a large volume of stirring diethyl ether, to precipitate a solid. The orange 
powder, 23 (0.164 g, 67 %), was collected by suction filtration, and washed with diethyl 
ether. Melting point: 155.1 ˚C (Decomposition without melting). 
1
H NMR (400.22 MHz, 
MeOD-d4): δ (ppm) = 8.48 (s, 1H, He); 6.06 (br s, 1H, Hc); 5.82 (t, 
3
JHH = 5.68 Hz, 1H, Hm); 
5.72 (t, 
3
JHH = 5.95 Hz, 1H, Hk); 5.30 (d, 
3
JHH = 6.04 Hz, 1H, Hn); 5.26 (d, 
3
JHH = 6.41 Hz, 
1H, Hj); 5.11 (t, 
3
JHH = 5.31 Hz, 1H, Hl); 4.30 (s, 5H, Ha); 4.15 (m, 2H, Hh); 3.87 (m, 2H, Hg). 
13
C NMR (100.65 MHz, MeOD-d4): δ (ppm) = 178.8 (C=S); 163.6 (C=N); 139.2 (Ci); 93.4 
(Cm); 93.2 (Ck); 77.6 (Cb); 76.7 (Cl); 76.0 (Cc); 75.1 (Cd); 73.7 (Cd); 72.8 (Ch); 71.6 (Ca); 71.1 
(Cc); 70.0 (Cn); 66.1 (Cj); 61.0 (Cg). Elemental analysis for C20H23Cl2FeN3O2RuS·¼H2O: 
Found C 39.5, H 4.13, N 7.36, S 4.31 %; Calculated C 39.9, H 3.85, N 6.98, S 5.33 %. FT-IR 
(KBr, cm
-1
): ν = 3401 (br, NH, OH); 3086 (w, N-H); 1615 (m, C=N); 833 (w, C=S). MS-
ESI
+
: m/z 526 ([M-Cl]
+







































Ruthenium-dimer 19 (0.0520 g, 0.1039 mmol) was suspended in methanol (15.0 mL), 
followed by the addition of compound 16 (0.0598 g, 0.208 mmol). The reaction mixture was 
stirred at ambient temperature for 24 hrs in a flask covered in foil. The solution was filtered 
by gravity, sodium hexafluorophosphate (0.0446 g, 0.266 mmol) was added, and the soution 
was stirred at ambient temperature for 2 hrs. The resulting solution was added to a large 
volume of stirring diethyl ether, to precipitate a solid. The orange po der, 24, (0.0933 g, 69 
%) was collected by suction filtration, and washed with diethyl ether. Melting point: 173.8 °C 
(Decomposition without melting). 
1
H NMR (399.95 MHz, MeOD-d4): δ (ppm) = 8.50 (s, 1H, 
He); 6.08 (s, 1H, Hc); 5.69 (s, 6H, Hbenzene); 4.34 (s, 5H, Ha). 
13
C NMR (100.65 MHz, MeOD-
d4): δ (ppm) = 178.7 (C=S); 164.0 (C=N); 88.6 (Cbenzene); 77.6 (Cb); 76.2 (Cc); 75.3 (Cd); 74.1 
(Cd); 71.6 (Ca); 71.0 (Cc). 
31
P NMR (162.00 MHz, MeOD-d4): δ (ppm) = -144.6 (septet). 
Elemental analysis for C18H19ClF6FeN3PRuS: Found C 33.7, H 3.55, N 6.52, S 4.17 %; 
Calculated C 33.4, H 2.96, N 6.50, S 4.96 %. FT-IR (KBr, cm
-1
): ν = 3405 (m, N-H); 3064 
(m, N-H); 1617 (m, C=N); 843 (m, C=S). MS-ESI
+
: m/z 466 ([M-Cl]
+
, 100 %). 
 
b. Heterobimetallic tetranuclear N,S-chelated ferrocenyl-derived ruthenium(II)-arene 






































Compound 19 (0.0755 g, 0.123 mmol) and compound 18 (0.0801 g, 0.124 mmol) were 
suspended in a methanol: dichloromethane (75:25 % V/V, 20.0 mL) mixture. The red 
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was filtered by gravity and the volume reduced. Sodium hexafluorophosphate (0.0427 g, 
0.254 mmol) was added to the solution, and stirred at ambient temperature for 1 hr. The dark 
red powder, 25 (0.116 g, 64 %), was collected by suction filtration, washed with diethyl 
ether, and dried in vacuo. The solid was purified using ethanol/hexane. Melting point: 167.1 
˚C (Decomposition without melting).
 1
H NMR (399.95 MHz, Acetone-d6): δ (ppm) = 10.4 (br 
s, 2H, Hf); 9.14 (br s, 2H, Hh); 8.81 (br s, 2H, He); 7.53 (br s, 4H, Hj); 6.16 (d, 
3
JHH = 8.06 
Hz, 2H, Hc); 5.78 (d, 
3
JHH = 6.23 Hz, 2H, p-cym); 5.44 (m, 4H, p-cym); 5.31 (br s, 2H, p-
cym); 4.86 (br s, 2H, Hc); 4.77 (d,
 3
JHH = 7.69 Hz, 4H, Hd); 4.33 (s, 10H, Ha); 2.70 (m, 2H, 
Hl); 1.99 (s, 6H, Ho); 1.20 (m, 6H, Hk); 1.14 (m, 6H, Hk). 
13
C NMR (100.65 MHz, Acetone-
d6): δ (ppm) = 176.6 (C=S); 164.2 (C=N); 136.9 (Ci); 126.4-126.6 (Cj); 104.3 (Cm); 103.7 
(Cn); 89.9 (p-cym); 89.2 (p-cym); 85.4 (p-cym); 84.1 (p-cym); 78.0 (Cb); 75.8 (Cc); 74.9 (Cd); 
73.7 (Cd); 71.4 (Ca); 71.2 (Cc); 31.7 (Ch); 23.1 (Ck); 22.1 (Ck); 18.8 (Co). 
31
P NMR (162.00 
MHz, Acetone-d6): δ (ppm) = -144.2 (septet). Elemental analysis for 
C50H56Cl2F12Fe2N6P2Ru2S2: Found C 38.1, H 4.10, N 5.17, S 3.95 %; Calculated C 40.6, H 
3.81, N 5.68, S 4.33 %. FT-IR (KBr, cm
-1
): ν = 3435 (br, N-H); 3091 (w, N-H); 1611 (w, 
C=N); 841 (s, C=S). MS-ESI
+
: m/z 559 ([M-2Cl]
2+
, 100 %); 1153 ([M-HCl]
+














































Compound 20 (0.0747 g, 0.120 mmol) and compound 18 (0.0779 g, 0.120 mmol) were 
suspended in a methanol: dichloromethane (75:25 % V/V, 20.0 mL) mixture. The red 
suspension was stirred at ambient temperature for 24 hrs in a foil-covered flask. The solvent 
was filtered by gravity and the volume reduced. Sodium hexafluorophosphate (0.0425 g, 
0.253 mmol) was added to the solution, and stirred at ambient temperature for 2.5 hrs. The 
red-brown powder, 26 (0.160 g, 90 %), was collected by suction filtration, washed with 
diethyl ether, and dried in vacuo. Melting point: 120.6 ˚C (Decomposition without melting). 
1
H NMR (300.07 MHz, MeOD-d4): δ (ppm) = 8.71 (s, 2H, He); 7.56 (br s, 4H, Hj); 6.12 (br s, 
2H, Hc); 5.88 (t, 
3
JHH = 6.00 Hz, 2H, Hq); 5.72 (t, 
3
JHH = 6.00 Hz, 2H, Ho); 5.35 (d, 
3
JHH = 
6.22 Hz, 2H, Hr); 5.31 (d, 
3
JHH = 6.00 Hz, 2H, Hn); 5.18 (t, 
3
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10H, Ha); 4.15 (m, 4H, Hl); 3.87 (m, 4H, Hk). 
31
P NMR (162.00 MHz, MeOD-d4): δ (ppm) = 
-144.6 (septet). Elemental analysis for C46H48Cl2F12Fe2N6O4P2Ru2S2: Found C 36.6, H 3.81, 
N 5.28, S 4.11 %; Calculated C 37.1, H 3.25, N 5.65, S 4.31 %. FT-IR (KBr, cm
-1
): ν = 3418 
(br, N-H); 3086 (w, N-H); 1611 (w, C=N); 841 (s, C=S). MS-ESI
+





, 2 %). 
 
6.3.3. The synthesis of heterometallic N,S-chelated ferrocenylthiosemicarbazone 
palladium(II)-complexes containing P-donor ligands  
Ferrocenylthiosemicarbazone palladium(II) precursor (27) 


















Potassium tetrachloropalladate (0.194 g, 0.596 mmol) was dissolved in distilled water (5.00 
mL), followed by the addition of ethanol (20.0 mL), resulting in a brown suspension. 
Compound 16 (0.171 g, 0.595 mmol) was added to the suspension, and stirred at ambient 
temperature for 24 hrs in a foil-covered flask. The reddish-brown powder (0.242 g, 47 %) 
was collected by suction filtration, washed with water (10.0 mL), methanol (10.0 mL) and 
diethyl ether (20.0 mL) and dried in vacuo. 
1
H NMR (400.22 MHz, DMSO-d6): δ (ppm) = 
7.44 (s, 2H, He); 6.91 (br s, 4H, NH2); 5.04 (t, 
3
JHH = 1.60 Hz, 4H, Hc); 4.56 (t, 
3
JHH = 1.60 
Hz, 4H, Hd); 4.22 (s, 10 H, Ha). 
13
C NMR (100.65 MHz, DMSO-d6): δ (ppm) = 169.9 (C-S); 
155.2 (C=N); 73.2 (Cb); 73.0 (Cc); 69.4 (Ca); 69.1 (Cd). Elemental analysis for 
C24H24Cl2Fe2N6Pd2S2: Found C 33.5, H 3.18, N 9.58, S 6.86 %; Calculated C 33.7, H 2.83, N 
9.82, S 7.49 %. FT-IR (KBr, cm
-1
): ν = 3431 (br, N-H); 3172 (w, N-H); 1602 (s, C=N). MS-
ESI
+
: m/z 854 ([M]
+
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a. Heterobimetallic binuclear N,S-chelated ferrocenylthiosemicarbazone palladium(II)-
complexes (28, 29) 















Compound 27 (0.108 g, 0.126 mmol) and PTA (0.0412 g, 0.262 mmol) was suspended in 
acetone (10.0 mL) and refluxed at 58 ˚C for 3 hrs. The red solid was purified by column 
chromatography (silica, ethyl acetate and eluted product with acetone), and purified using 
chloroform/hexane. The reddish-orange powder, 28 (0.0794 g, 52 %), was collected and dried 
in vacuo. Melting point: 241.3 ˚C (onset of decomposition without melting). 
1
H NMR 
(399.95 MHz, DMSO-d6): δ (ppm) = 7.87 (d, 
4
JHP = 3.66 Hz, 1H, He); 6.88 (br s, 2H, NH2); 
5.07 (t, 
3
JHH = 1.60 Hz, 2H, Hc); 4.54 (m, 5H, Hd & NCH2(eq)N); 4.38 (d,
 3
JHP = 13.0 Hz, 3H, 
NCH2(ax)N); 4.32 (s, 6H, PCH2N); 4.17 (s, 5H, Ha). 
13
C NMR (100.65 MHz, DMSO-d6): δ 
(ppm) = 172.1 (d, 
3
JCP = 11.4 Hz, C-S); 151.6 (C=N); 73.8 (d, 
4
JCP = 4.71 Hz, Cb); 72.7 (Cc); 
71.8 (d, 
3
JCP = 8.08 Hz, NCH2N); 71.4 (Cd); 69.2 (Ca); 51.6 (d, 
1
JCP = 17.5 Hz, PCH2N). 
31
P 
NMR (162.00 MHz, DMSO-d6): δ (ppm) = -33.5. Elemental analysis for C18H24ClFeN6PdPS: 
Found C 36.6, H 4.26, N 14.0, S 5.46 %; Calculated C 36.9, H 4.13, N 14.3, S 5.48 %. FT-IR 
(KBr, cm
-1





, 6.7 %). 
 
















Compound 27 (0.0997 g, 0.116 mmol) and triphenylphoshine (0.0611 g, 0.233 mmol) was 
suspended in acetone (10.0 mL) and refluxed at 58 ˚C for 3 hrs. The solution was filtered by 
gravity, washed with acetone and the solvent reduced. Hexane was added to precipitate a red 
powder, 29 (0.121 g, 75 %), which was collected by suction filtration, washed with hexane 
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(399.95 MHz, DMSO-d6): δ (ppm) = 8.14 (d, 
4
JHP = 4.00 Hz, 1H, He); 7.49-7.68 (m, 15H, 
PPh3); 6.72 (br s, 2H, NH2); 5.08 (t, 
3
JHH = 1.60 Hz, 2H, Hc); 4.53 (t, 
3
JHH = 1.60 Hz, 2H, 
Hd); 4.22 (s, 5H, Ha). 
13
C NMR (100.65 MHz, DMSO-d6): δ (ppm) = 171.6 (d, 
3
JCP = 11.5 
Hz, C-S); 152.7 (C=N); 133.9 (d, JCP = 10.8 Hz, CPh); 131.0 (CPh); 130.2 (CPh); 129.6 (CPh); 
128.2 (d, JCP = 10.8 Hz, CPh); 73.7 (d, 
4
JCP = 4.73 Hz, Cb); 72.7 (Cc); 71.4 (Cd); 69.2 (Ca). 
31
P 
NMR (162.00 MHz, DMSO-d6): δ (ppm) = 27.6. Elemental analysis for C30H27ClFeN3PdPS: 
Found C 51.9, H 4.07, N 5.76, S 4.16 %; Calculated C 52.2, H 3.94, N 6.09, S 4.65 %. FT-IR 
(KBr, cm
-1





, 100 %). 
 
b. Heterobimetallic tetra- and pentanuclear N,S-chelated ferrocenylthiosemicarbazone 
palladium(II)-complexes (30-32) 
























Compound 27 (0.0755 g, 0.0882 mmol) and dppf (0.0492 g, 0.0887 mmol) was suspended in 
acetone (10.0 mL) and refluxed at 58 ˚C for 3 hrs. The solution was filtered by gravity, the 
filtrate reduced and cold hexane added to yield a solid. The orange powder, 30 (0.0972 g, 78 
%), was collected by suction filtration and dried in vacuo. Melting point:  200.0 ˚C (onset of 
decomposition without melting). 
1
H NMR (399.95 MHz, DMSO-d6): δ (ppm) = 8.19 (d, 
4
JHP 
= 4.03 Hz, 2H, He); 7.47-7.87 (m, 20H, PPh3); 6.74 (br s, 4H, NH2); 5.18 (br s, 4H, Hc); 5.07 
(br s, 4H, Hh); 4.87 (br s, 4H, Hd); 4.51 (br s, 4H, Hi); 4.14 (s, 10H, Ha). 
13
C NMR (100.65 
MHz, DMSO-d6): δ (ppm) = 171.5 (d, 
3
JCP = 12.1 Hz, C-S); 152.5 (C=N); 134.4 (CPh); 132.8 
(d, JCP = 10.8 Hz, CPh); 131.5 (CPh); 131.2 (CPh); 131.0 (Cg); 128.1 (d, JCP = 10.8 Hz, CPh); 
76.2 (d, JCP = 9.42 Hz, Ch); 75.8 (d,
 
JCP = 7.41 Hz, Ci); 73.7 (d, 
4
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71.4 (Cd); 69.2 (Ca). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = 22.2. Elemental analysis 
for C58H52Cl2Fe3N6Pd2P2S2: Found C 49.8, H 4.03, N 5.29, S 4.38 %; Calculated C 49.4, H 
3.72, N 5.96, S 4.55 %. FT-IR (KBr, cm
-1
): ν = 3467 (m, N-H); 1602 (w, C=N); 1587 (w, 
C=N). MS-ESI
+
: m/z 1412 ([M+H]
+
, 3 %); 1375 ([M+2H-Cl]
+

































Compound 18 (0.0520 g, 0.0802 mmol) and PdCl2(PTA)2 (0.0787 g, 0.160 mmol) was 
suspended in ethanol:acetone (50 % V/V, 15.0 mL). The brown suspension was stirred at 
ambient temperature for 24 hrs, resulting in a red suspension. The reddish-orange powder, 31, 
(0.0991 g, 99 %) was collected by suction filtration, and washed with water, ethanol and 
diethyl ether (25.0 mL). Melting point: 218.3 ˚C (Decomposition without melting). 
1
H NMR 
(399.95 MHz, DMSO-d6): δ (ppm) = 9.51 (s, 2H, Hg); 8.14 (d, 
4
JHP = 3.67 Hz, 2H, He); 7.59 
(s, 4H, Hi); 5.01 (br s, 4H, Hc); 4.58 (d, 
3
JHP = 12.8 Hz, 6H, NCH2(eq)N); 4.52 (br s, 4H, Hd); 
4.41 (d,
 3
JHP = 13.4 Hz, 6H, NCH2(ax)N); 4.38 (s, 12H, PCH2P); 4.19 (s, 10H, Ha). 
13
C NMR 
(100.65 MHz, DMSO-d6): δ (ppm) = 167.8 (C-S); 154.8 (C=N); 136.1 (Ch); 119.9 (Ci); 73.1 
(d, 
4
JHP = 4.04 Hz, Cb); 72.2 (d, 
3
JHP = 12.8 Hz, NCH2N); 71.7 (Cc); 71.6 (Cd); 69.4 (Ca); 51.5 
(d, 
1
JCP = 18.2 Hz, PCH2N). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = -32.0. Elemental 
analysis for C42H50Cl2Fe2N12Pd2P2S2·H2O: Found C 38.9, H 4.27, N 12.9, S 4.60 %; 
Calculated C 39.9, H 3.99, N 13.3, S 5.08 %. FT-IR (KBr, cm
-1
): ν = 3401 (m, N-H); 1593 
(w, C=N); 1576 (w, C=N). MS-ESI
+
: m/z 1244 ([M]
+
, 10 %); 622 ([M+2H-2Cl2]
+
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Compound 18 (0.0603 g, 0.0930 mmol) and PdCl2(PPh3)2 (0.131 g, 0.186 mmol) was 
suspended in ethanol:acetone (50 % V/V, 15.0 mL). The brown suspension was stirred at 
ambient temperature for 24 hrs, resulting in a red suspension. The solid was purified using 
CHCl3/THF/Hexane. The reddish-orange powder, 32, (0.0941 g, 70 %) was collected by 
suction filtration, washed with diethyl ether (25.0 mL), and dried in vacuo. Melting point: 
237.2 ˚C (onset of decomposition without melting). 
1
H NMR (399.95 MHz, DMSO-d6): δ 
(ppm) = 9.24 (s, 2H, Hg); 8.39 (d, 
4
JHP = 4.00 Hz, 2H, He); 7.47 (m, 34H, PPh3 & Hi); 4.99 
(br s, 4H, Hc); 4.52 (br s, 4H, Hd); 4.22 (s, 10H, Ha). 
13
C NMR (100.65 MHz, DMSO-d6): δ 
(ppm) = 167.2 (C-S); 156.0 (C=N); 136.0 (Ch); 134.0 (d, JCP = 11.4 Hz, CPh); 131.2 (CPh); 
130.2 (CPh); 129.6 (CPh); 128.4 (d, JCP = 10.8 Hz, CPh); 119.8 (Ci); 72.3 (Cb); 72.1 (Cd); 69.4 
(Ca); 66.9 (Cc). 
31
P NMR (162.00 MHz, DMSO-d6): δ (ppm) = 27.8. FT-IR (KBr, cm
-1
): ν = 
3440 (m, N-H); 1598 (m, C=N); 1572 (w, C=N). MS-ESI
+
: m/z 1457 ([M+H]
+
, 3 %); 692 
([M-2Cl]
2+
, 100 %). 
 
6.4. Single-crystal X-ray diffraction   
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data 
collection was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream 
cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using 
the program SAINT.
11
 The data were scaled and absorption correction performed using 
SADABS.
12
 The structure was solved by direct methods using SHELXS-97
12
 and refined by 




 and using the graphics 
interface program X-Seed.
13-14
 The programs X-Seed and POV-Ray
15
 were both used to 
prepare molecular graphic images. All non-hydrogen atoms were refined anisotropically. All 
hydrogen atoms were placed at calculated positions with C-H distances ranging from 0.95 Å 
to 0.99 Å and N-H distance 0.88 Å and refined as riding on their parent atoms with Uiso (H) = 
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6.5. Cyclic voltammetry 
Cyclic voltammograms were recorded at room temperature on a BAS 100W Electrochemical 
Analyzer with a one-compartment three-electrode cell system consisting of a platinum disk 
working electrode, a platinum wire auxiliary electrode and a Ag/AgNO3 reference electrode 
(0.01 M AgNO3 and 0.1 M [n-Bu4N][ClO4] in anhydrous acetonitrile). An IR compensation 
circuit was used for all measurements. A scan rate of 100 mV s
-1
 was used throughout, 
beginning from the most negative potential and initially scanning in the anodic direction. The 
half-wave potential of the ferrocene/ferrocenium couple in this cell never varied by more than 
30 mV from a mean value of E1/2 = 250 mV versus the Ag/AgNO3
 
reference electrode, with a 
peak separation falling between ΔEp
 
= 59 and ΔEp
 
= 66 mV. Solutions were purged with 
argon and voltammograms were recorded under a blanket of argon. The platinum disk 
working electrode was polished between runs. The voltammograms of samples were recorded 
in dichloromethane solutions (1.5 μM).  
 
6.6. Antiplasmodial testing 
The test samples were tested in triplicate on one occasion against chloroquine sensitive 
(CQS) NF54 and chloroquine resistant (CQR) Dd2 strain of Plasmodium falciparum. 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method of Trager and Jensen.
16
 Quantitative assessment of antiplasmodial 
activity in vitro was determined via the parasite lactate dehydrogenase assay using a modified 
method described by Makler et al.
17
 The test samples were prepared to a 20 mg/ml stock 
solution in 100% DMSO and sonicated to enhance solubility. Samples were tested as a 
suspension if not completely dissolved. Stock solutions were stored at -20ºC. Further 
dilutions were prepared on the day of the experiment. Chloroquine diphosphate (CQDP) was 
used as the reference drug in the experiment. A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% of parasite growth (IC50 value). 
The samples were tested at a starting concentration of 100 000 ng/ml, which was then serially 
diluted 2-fold in complete medium to give 10 concentrations; with the lowest concentration 
being 2 ng/ml. The same dilution technique was used for all samples. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on 
the parasite viability (data not shown). The IC50 values were obtained using a non-linear 
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H NMR spectrum of compound 1 in DMSO-d6 
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H NMR spectrum of compound 5 in CDCl3  
 
ma133-a_1h
































































































H NMR spectrum of compound 6 in DMSO-d6 
 
ma140-b_1h



















































H NMR spectrum of compound 7 in DMSO-d6 
MA62_1h































































































H NMR spectrum of compound 9 in DMSO-d6 
 
ma86-c_1h




















































H NMR spectrum of compound 16 in DMSO-d6 
ma127-b_1h







































































































H NMR spectrum of compound 22 in Acetone-d6 
 
ma119-b_1h






































































































































H NMR spectrum of compound 28 in DMSO-d6 
 
ma147-b_1h













































































































































































































MA_UCT_120607_2 19 (0.093) Cm (19:24) 1: TOF MS ES+ 
1.43e5946.0
670.0
669.0
668.5
668.0
667.5
667.0
473.5
473.0
472.5
474.5
475.5 666.5
660.0476.0
945.0
671.0
688.0
689.0
944.0
689.5
690.0
690.5
691.0
943.0
706.9
707.4 942.0
826.1
948.0
950.0
1374.9
1373.9
1372.9
1026.0
951.0 1025.0
1024.5
1024.0
1023.5
1023.0
962.0
1371.91027.5
1366.0
1028.0
1364.01028.5
1376.9
1378.9
1386.9
1411.9
Fe
N
N NH2
SPd
Cl
PPh2
Fe
N
NH2N
S Pd
Cl
Ph2P
Fe
 
[M+H]
+
 
[M+2H-Cl]
+
 
 
[M-2Cl]
2+
 
